id	sid	tid	token	lemma	pos
dpc-4021	1	1	dermatology	dermatology	NOUN
dpc-4021	1	2	:	:	PUNCT
dpc-4021	1	3	practical	practical	ADJ
dpc-4021	1	4	and	and	CCONJ
dpc-4021	1	5	conceptual	conceptual	ADJ
dpc-4021	1	6	original	original	ADJ
dpc-4021	1	7	article	article	NOUN
dpc-4021	1	8	|	|	ADV
dpc-4021	1	9	dermatol	dermatol	ADJ
dpc-4021	1	10	pract	pract	NOUN
dpc-4021	1	11	concept	concept	NOUN
dpc-4021	1	12	.	.	PUNCT
dpc-4021	2	1	2024;14(3):e2024165	2024;14(3):e2024165	NUM
dpc-4021	2	2	1	1	NUM
dpc-4021	2	3	efficacy	efficacy	NOUN
dpc-4021	2	4	of	of	ADP
dpc-4021	2	5	leflunomide	leflunomide	NOUN
dpc-4021	2	6	compared	compare	VERB
dpc-4021	2	7	to	to	PART
dpc-4021	2	8	methotrexate	methotrexate	VERB
dpc-4021	2	9	in	in	ADP
dpc-4021	2	10	the	the	DET
dpc-4021	2	11	treatment	treatment	NOUN
dpc-4021	2	12	of	of	ADP
dpc-4021	2	13	moderate	moderate	ADJ
dpc-4021	2	14	to	to	ADP
dpc-4021	2	15	severe	severe	ADJ
dpc-4021	2	16	plaques	plaque	NOUN
dpc-4021	2	17	psoriasis	psoriasis	NOUN
dpc-4021	2	18	:	:	PUNCT
dpc-4021	2	19	a	a	DET
dpc-4021	2	20	randomized	randomized	ADJ
dpc-4021	2	21	controlled	control	VERB
dpc-4021	2	22	clinical	clinical	ADJ
dpc-4021	2	23	trial	trial	NOUN
dpc-4021	2	24	hany	hany	NOUN
dpc-4021	2	25	othman	othman	PROPN
dpc-4021	2	26	aboelwafa1	aboelwafa1	PROPN
dpc-4021	2	27	,	,	PUNCT
dpc-4021	2	28	hassan	hassan	PROPN
dpc-4021	2	29	abou	abou	PROPN
dpc-4021	2	30	khodair	khodair	PROPN
dpc-4021	2	31	mohamed1	mohamed1	PROPN
dpc-4021	2	32	,	,	PUNCT
dpc-4021	2	33	doaa	doaa	VERB
dpc-4021	2	34	mamdouh	mamdouh	PROPN
dpc-4021	2	35	ibrahim2	ibrahim2	PROPN
dpc-4021	2	36	,	,	PUNCT
dpc-4021	2	37	nermeen	nermeen	NOUN
dpc-4021	2	38	ibrahim	ibrahim	PROPN
dpc-4021	2	39	bedair3	bedair3	PROPN
dpc-4021	3	1	1	1	NUM
dpc-4021	3	2	department	department	NOUN
dpc-4021	3	3	of	of	ADP
dpc-4021	3	4	dermatology	dermatology	NOUN
dpc-4021	3	5	,	,	PUNCT
dpc-4021	3	6	venereology	venereology	NOUN
dpc-4021	3	7	and	and	CCONJ
dpc-4021	3	8	andrology	andrology	NOUN
dpc-4021	3	9	,	,	PUNCT
dpc-4021	3	10	alazhar	alazhar	PROPN
dpc-4021	3	11	universitydamietta	universitydamietta	ADJ
dpc-4021	3	12	faculty	faculty	NOUN
dpc-4021	3	13	of	of	ADP
dpc-4021	3	14	medicine	medicine	NOUN
dpc-4021	3	15	,	,	PUNCT
dpc-4021	3	16	damietta	damietta	PROPN
dpc-4021	3	17	,	,	PUNCT
dpc-4021	3	18	egypt	egypt	PROPN
dpc-4021	3	19	2	2	NUM
dpc-4021	3	20	elhusseinya	elhusseinya	NOUN
dpc-4021	3	21	central	central	ADJ
dpc-4021	3	22	hospital	hospital	NOUN
dpc-4021	3	23	,	,	PUNCT
dpc-4021	3	24	ministry	ministry	PROPN
dpc-4021	3	25	of	of	ADP
dpc-4021	3	26	health	health	PROPN
dpc-4021	3	27	,	,	PUNCT
dpc-4021	3	28	egypt	egypt	PROPN
dpc-4021	3	29	3	3	NUM
dpc-4021	3	30	department	department	PROPN
dpc-4021	3	31	of	of	ADP
dpc-4021	3	32	dermatology	dermatology	NOUN
dpc-4021	3	33	,	,	PUNCT
dpc-4021	3	34	andrology	andrology	NOUN
dpc-4021	3	35	,	,	PUNCT
dpc-4021	3	36	sexual	sexual	ADJ
dpc-4021	3	37	medicine	medicine	NOUN
dpc-4021	3	38	and	and	CCONJ
dpc-4021	3	39	stds	stds	NOUN
dpc-4021	3	40	,	,	PUNCT
dpc-4021	3	41	faculty	faculty	NOUN
dpc-4021	3	42	of	of	ADP
dpc-4021	3	43	medicine	medicine	NOUN
dpc-4021	3	44	,	,	PUNCT
dpc-4021	3	45	helwan	helwan	PROPN
dpc-4021	3	46	university	university	PROPN
dpc-4021	3	47	,	,	PUNCT
dpc-4021	3	48	cairo	cairo	PROPN
dpc-4021	3	49	,	,	PUNCT
dpc-4021	3	50	egypt	egypt	PROPN
dpc-4021	3	51	key	key	PROPN
dpc-4021	3	52	words	word	NOUN
dpc-4021	3	53	:	:	PUNCT
dpc-4021	3	54	psoriasis	psoriasis	NOUN
dpc-4021	3	55	,	,	PUNCT
dpc-4021	3	56	pasi	pasi	NOUN
dpc-4021	3	57	,	,	PUNCT
dpc-4021	3	58	methotrexate	methotrexate	NOUN
dpc-4021	3	59	,	,	PUNCT
dpc-4021	3	60	leflunomide	leflunomide	ADJ
dpc-4021	3	61	citation	citation	NOUN
dpc-4021	3	62	:	:	PUNCT
dpc-4021	3	63	aboelwafa	aboelwafa	PROPN
dpc-4021	3	64	ho	ho	PROPN
dpc-4021	3	65	,	,	PUNCT
dpc-4021	3	66	abou	abou	PROPN
dpc-4021	3	67	khodair	khodair	PROPN
dpc-4021	3	68	mohamed	mohamed	PROPN
dpc-4021	3	69	h	h	PROPN
dpc-4021	3	70	,	,	PUNCT
dpc-4021	3	71	ibrahim	ibrahim	PROPN
dpc-4021	3	72	dm	dm	PROPN
dpc-4021	3	73	,	,	PUNCT
dpc-4021	3	74	bedair	bedair	VERB
dpc-4021	3	75	ni	ni	PROPN
dpc-4021	3	76	.	.	PROPN
dpc-4021	3	77	efficacy	efficacy	PROPN
dpc-4021	3	78	of	of	ADP
dpc-4021	3	79	leflunomide	leflunomide	ADV
dpc-4021	3	80	compared	compare	VERB
dpc-4021	3	81	to	to	PART
dpc-4021	3	82	methotrexate	methotrexate	VERB
dpc-4021	3	83	in	in	ADP
dpc-4021	3	84	the	the	DET
dpc-4021	3	85	treatment	treatment	NOUN
dpc-4021	3	86	of	of	ADP
dpc-4021	3	87	moderate	moderate	ADJ
dpc-4021	3	88	to	to	ADP
dpc-4021	3	89	severe	severe	ADJ
dpc-4021	3	90	plaques	plaque	NOUN
dpc-4021	3	91	psoriasis	psoriasis	NOUN
dpc-4021	3	92	:	:	PUNCT
dpc-4021	3	93	a	a	DET
dpc-4021	3	94	randomized	randomized	ADJ
dpc-4021	3	95	controlled	control	VERB
dpc-4021	3	96	clinical	clinical	ADJ
dpc-4021	3	97	trial	trial	NOUN
dpc-4021	3	98	.	.	PUNCT
dpc-4021	4	1	dermatol	dermatol	NOUN
dpc-4021	4	2	pract	pract	PROPN
dpc-4021	4	3	concept	concept	NOUN
dpc-4021	4	4	.	.	PUNCT
dpc-4021	5	1	2024;14(3):e2024165	2024;14(3):e2024165	X
dpc-4021	5	2	.	.	X
dpc-4021	5	3	doi	doi	PROPN
dpc-4021	5	4	:	:	PUNCT
dpc-4021	5	5	https://doi.org/10.5826/dpc.1403a165	https://doi.org/10.5826/dpc.1403a165	NOUN
dpc-4021	5	6	accepted	accept	VERB
dpc-4021	5	7	:	:	PUNCT
dpc-4021	5	8	february	february	PROPN
dpc-4021	5	9	25	25	NUM
dpc-4021	5	10	,	,	PUNCT
dpc-4021	5	11	2024	2024	NUM
dpc-4021	5	12	;	;	PUNCT
dpc-4021	5	13	published	publish	VERB
dpc-4021	5	14	:	:	PUNCT
dpc-4021	6	1	july	july	PROPN
dpc-4021	6	2	2024	2024	NUM
dpc-4021	6	3	copyright	copyright	NOUN
dpc-4021	6	4	:	:	PUNCT
dpc-4021	6	5	©	©	PROPN
dpc-4021	6	6	2024	2024	NUM
dpc-4021	6	7	abo	abo	NOUN
dpc-4021	6	8	elwafa	elwafa	VERB
dpc-4021	6	9	et	et	PROPN
dpc-4021	6	10	al	al	PROPN
dpc-4021	6	11	.	.	PUNCT
dpc-4021	7	1	this	this	PRON
dpc-4021	7	2	is	be	AUX
dpc-4021	7	3	an	an	DET
dpc-4021	7	4	open	open	ADJ
dpc-4021	7	5	-	-	PUNCT
dpc-4021	7	6	access	access	NOUN
dpc-4021	7	7	article	article	NOUN
dpc-4021	7	8	distributed	distribute	VERB
dpc-4021	7	9	under	under	ADP
dpc-4021	7	10	the	the	DET
dpc-4021	7	11	terms	term	NOUN
dpc-4021	7	12	of	of	ADP
dpc-4021	7	13	the	the	DET
dpc-4021	7	14	creative	creative	ADJ
dpc-4021	7	15	commons	common	NOUN
dpc-4021	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4021	7	17	license	license	NOUN
dpc-4021	7	18	(	(	PUNCT
dpc-4021	7	19	by	by	ADP
dpc-4021	7	20	-	-	PUNCT
dpc-4021	7	21	nc-4.0	nc-4.0	NOUN
dpc-4021	7	22	)	)	PUNCT
dpc-4021	7	23	,	,	PUNCT
dpc-4021	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4021	7	25	,	,	PUNCT
dpc-4021	7	26	which	which	PRON
dpc-4021	7	27	permits	permit	VERB
dpc-4021	7	28	unrestricted	unrestricted	ADJ
dpc-4021	7	29	noncommercial	noncommercial	ADJ
dpc-4021	7	30	use	use	NOUN
dpc-4021	7	31	,	,	PUNCT
dpc-4021	7	32	distribution	distribution	NOUN
dpc-4021	7	33	,	,	PUNCT
dpc-4021	7	34	and	and	CCONJ
dpc-4021	7	35	reproduction	reproduction	NOUN
dpc-4021	7	36	in	in	ADP
dpc-4021	7	37	any	any	DET
dpc-4021	7	38	medium	medium	NOUN
dpc-4021	7	39	,	,	PUNCT
dpc-4021	7	40	provided	provide	VERB
dpc-4021	7	41	the	the	DET
dpc-4021	7	42	original	original	ADJ
dpc-4021	7	43	authors	author	NOUN
dpc-4021	7	44	and	and	CCONJ
dpc-4021	7	45	source	source	NOUN
dpc-4021	7	46	are	be	AUX
dpc-4021	7	47	credited	credit	VERB
dpc-4021	7	48	.	.	PUNCT
dpc-4021	8	1	funding	funding	NOUN
dpc-4021	8	2	:	:	PUNCT
dpc-4021	8	3	none	none	NOUN
dpc-4021	8	4	.	.	PUNCT
dpc-4021	9	1	competing	compete	VERB
dpc-4021	9	2	interests	interest	NOUN
dpc-4021	9	3	:	:	PUNCT
dpc-4021	9	4	none	none	NOUN
dpc-4021	9	5	.	.	PUNCT
dpc-4021	10	1	authorship	authorship	NOUN
dpc-4021	10	2	:	:	PUNCT
dpc-4021	10	3	all	all	DET
dpc-4021	10	4	authors	author	NOUN
dpc-4021	10	5	have	have	AUX
dpc-4021	10	6	contributed	contribute	VERB
dpc-4021	10	7	significantly	significantly	ADV
dpc-4021	10	8	to	to	ADP
dpc-4021	10	9	this	this	DET
dpc-4021	10	10	publication	publication	NOUN
dpc-4021	10	11	.	.	PUNCT
dpc-4021	11	1	corresponding	correspond	VERB
dpc-4021	11	2	author	author	NOUN
dpc-4021	11	3	:	:	PUNCT
dpc-4021	11	4	hany	hany	PROPN
dpc-4021	11	5	othman	othman	PROPN
dpc-4021	11	6	abo	abo	PROPN
dpc-4021	11	7	elwafa	elwafa	NOUN
dpc-4021	11	8	,	,	PUNCT
dpc-4021	11	9	department	department	NOUN
dpc-4021	11	10	of	of	ADP
dpc-4021	11	11	dermatology	dermatology	NOUN
dpc-4021	11	12	,	,	PUNCT
dpc-4021	11	13	venereology	venereology	NOUN
dpc-4021	11	14	and	and	CCONJ
dpc-4021	11	15	andrology	andrology	NOUN
dpc-4021	11	16	,	,	PUNCT
dpc-4021	11	17	damietta	damietta	PROPN
dpc-4021	11	18	faculty	faculty	NOUN
dpc-4021	11	19	of	of	ADP
dpc-4021	11	20	 	 	SPACE
dpc-4021	11	21	medicine	medicine	NOUN
dpc-4021	11	22	,	,	PUNCT
dpc-4021	11	23	damietta	damietta	PROPN
dpc-4021	11	24	,	,	PUNCT
dpc-4021	11	25	egypt	egypt	PROPN
dpc-4021	11	26	.	.	PUNCT
dpc-4021	12	1	email	email	NOUN
dpc-4021	12	2	:	:	PUNCT
dpc-4021	13	1	drhanyaboelwafa@gmail.com	drhanyaboelwafa@gmail.com	X
dpc-4021	13	2	introduction	introduction	NOUN
dpc-4021	13	3	:	:	PUNCT
dpc-4021	13	4	psoriasis	psoriasis	NOUN
dpc-4021	13	5	is	be	AUX
dpc-4021	13	6	a	a	DET
dpc-4021	13	7	chronic	chronic	ADJ
dpc-4021	13	8	inflammatory	inflammatory	ADJ
dpc-4021	13	9	autoimmune	autoimmune	ADJ
dpc-4021	13	10	skin	skin	NOUN
dpc-4021	13	11	disease	disease	NOUN
dpc-4021	13	12	.	.	PUNCT
dpc-4021	14	1	several	several	ADJ
dpc-4021	14	2	treatment	treatment	NOUN
dpc-4021	14	3	options	option	NOUN
dpc-4021	14	4	are	be	AUX
dpc-4021	14	5	available	available	ADJ
dpc-4021	14	6	including	include	VERB
dpc-4021	14	7	topical	topical	ADJ
dpc-4021	14	8	and	and	CCONJ
dpc-4021	14	9	systemic	systemic	ADJ
dpc-4021	14	10	options	option	NOUN
dpc-4021	14	11	.	.	PUNCT
dpc-4021	15	1	methotrexate	methotrexate	PROPN
dpc-4021	15	2	was	be	AUX
dpc-4021	15	3	the	the	DET
dpc-4021	15	4	main	main	ADJ
dpc-4021	15	5	systemic	systemic	ADJ
dpc-4021	15	6	medication	medication	NOUN
dpc-4021	15	7	in	in	ADP
dpc-4021	15	8	treating	treat	VERB
dpc-4021	15	9	severe	severe	ADJ
dpc-4021	15	10	psoriasis	psoriasis	NOUN
dpc-4021	15	11	,	,	PUNCT
dpc-4021	15	12	yet	yet	CCONJ
dpc-4021	15	13	adverse	adverse	ADJ
dpc-4021	15	14	events	event	NOUN
dpc-4021	15	15	can	can	AUX
dpc-4021	15	16	limit	limit	VERB
dpc-4021	15	17	its	its	PRON
dpc-4021	15	18	use	use	NOUN
dpc-4021	15	19	.	.	PUNCT
dpc-4021	16	1	leflunomide	leflunomide	ADJ
dpc-4021	16	2	is	be	AUX
dpc-4021	16	3	an	an	DET
dpc-4021	16	4	isoxazole	isoxazole	NOUN
dpc-4021	16	5	derivative	derivative	NOUN
dpc-4021	16	6	that	that	PRON
dpc-4021	16	7	inhibits	inhibit	VERB
dpc-4021	16	8	the	the	DET
dpc-4021	16	9	synthesis	synthesis	NOUN
dpc-4021	16	10	of	of	ADP
dpc-4021	16	11	pyrimidines	pyrimidine	NOUN
dpc-4021	16	12	,	,	PUNCT
dpc-4021	16	13	and	and	CCONJ
dpc-4021	16	14	subsequently	subsequently	ADV
dpc-4021	16	15	inhibits	inhibit	VERB
dpc-4021	16	16	rna	rna	NOUN
dpc-4021	16	17	and	and	CCONJ
dpc-4021	16	18	dna	dna	PROPN
dpc-4021	16	19	synthesis	synthesis	NOUN
dpc-4021	16	20	.	.	PUNCT
dpc-4021	17	1	objectives	objective	NOUN
dpc-4021	17	2	:	:	PUNCT
dpc-4021	17	3	as	as	SCONJ
dpc-4021	17	4	available	available	ADJ
dpc-4021	17	5	data	datum	NOUN
dpc-4021	17	6	directly	directly	ADV
dpc-4021	17	7	comparing	compare	VERB
dpc-4021	17	8	mtx	mtx	NOUN
dpc-4021	17	9	to	to	PART
dpc-4021	17	10	leflunomide	leflunomide	VERB
dpc-4021	17	11	in	in	ADP
dpc-4021	17	12	psoriasis	psoriasis	NOUN
dpc-4021	17	13	are	be	AUX
dpc-4021	17	14	lacking	lack	VERB
dpc-4021	17	15	,	,	PUNCT
dpc-4021	17	16	this	this	DET
dpc-4021	17	17	double	double	ADJ
dpc-4021	17	18	blinded	blind	VERB
dpc-4021	17	19	study	study	NOUN
dpc-4021	17	20	was	be	AUX
dpc-4021	17	21	designed	design	VERB
dpc-4021	17	22	to	to	PART
dpc-4021	17	23	compare	compare	VERB
dpc-4021	17	24	the	the	DET
dpc-4021	17	25	efficacy	efficacy	NOUN
dpc-4021	17	26	of	of	ADP
dpc-4021	17	27	methotrexate	methotrexate	NOUN
dpc-4021	17	28	versus	versus	ADP
dpc-4021	17	29	leflunomide	leflunomide	ADJ
dpc-4021	17	30	in	in	ADP
dpc-4021	17	31	the	the	DET
dpc-4021	17	32	treatment	treatment	NOUN
dpc-4021	17	33	of	of	ADP
dpc-4021	17	34	moderate	moderate	ADJ
dpc-4021	17	35	to	to	ADP
dpc-4021	17	36	severe	severe	ADJ
dpc-4021	17	37	psoriasis	psoriasis	NOUN
dpc-4021	17	38	.	.	PUNCT
dpc-4021	18	1	methods	method	NOUN
dpc-4021	18	2	:	:	PUNCT
dpc-4021	18	3	the	the	DET
dpc-4021	18	4	study	study	NOUN
dpc-4021	18	5	included	include	VERB
dpc-4021	18	6	40	40	NUM
dpc-4021	18	7	patients	patient	NOUN
dpc-4021	18	8	(	(	PUNCT
dpc-4021	18	9	25	25	NUM
dpc-4021	18	10	males	male	NOUN
dpc-4021	18	11	and	and	CCONJ
dpc-4021	18	12	15	15	NUM
dpc-4021	18	13	females	female	NOUN
dpc-4021	18	14	)	)	PUNCT
dpc-4021	18	15	with	with	ADP
dpc-4021	18	16	chronic	chronic	ADJ
dpc-4021	18	17	plaque	plaque	NOUN
dpc-4021	18	18	psoriasis	psoriasis	NOUN
dpc-4021	18	19	.	.	PUNCT
dpc-4021	19	1	s.	s.	PROPN
dpc-4021	19	2	patients	patient	NOUN
dpc-4021	19	3	were	be	AUX
dpc-4021	19	4	randomly	randomly	ADV
dpc-4021	19	5	assigned	assign	VERB
dpc-4021	19	6	to	to	ADP
dpc-4021	19	7	one	one	NUM
dpc-4021	19	8	of	of	ADP
dpc-4021	19	9	two	two	NUM
dpc-4021	19	10	equal	equal	ADJ
dpc-4021	19	11	groups	group	NOUN
dpc-4021	19	12	,	,	PUNCT
dpc-4021	19	13	group	group	NOUN
dpc-4021	19	14	a	a	NOUN
dpc-4021	19	15	for	for	ADP
dpc-4021	19	16	subcutaneous	subcutaneous	ADJ
dpc-4021	19	17	methotrexate	methotrexate	NOUN
dpc-4021	19	18	injections	injection	NOUN
dpc-4021	19	19	and	and	CCONJ
dpc-4021	19	20	group	group	NOUN
dpc-4021	19	21	b	b	PROPN
dpc-4021	19	22	for	for	ADP
dpc-4021	19	23	leflunomide	leflunomide	ADJ
dpc-4021	19	24	(	(	PUNCT
dpc-4021	19	25	loading	loading	NOUN
dpc-4021	19	26	dose	dose	VERB
dpc-4021	19	27	100	100	NUM
dpc-4021	19	28	mg	mg	ADP
dpc-4021	19	29	daily	daily	ADV
dpc-4021	19	30	for	for	ADP
dpc-4021	19	31	the	the	DET
dpc-4021	19	32	first	first	ADJ
dpc-4021	19	33	3	3	NUM
dpc-4021	19	34	days	day	NOUN
dpc-4021	19	35	,	,	PUNCT
dpc-4021	19	36	then	then	ADV
dpc-4021	19	37	20	20	NUM
dpc-4021	19	38	mg	mg	NOUN
dpc-4021	19	39	daily	daily	ADV
dpc-4021	19	40	for	for	ADP
dpc-4021	19	41	3	3	NUM
dpc-4021	19	42	months	month	NOUN
dpc-4021	19	43	.	.	PUNCT
dpc-4021	20	1	disease	disease	NOUN
dpc-4021	20	2	severity	severity	NOUN
dpc-4021	20	3	was	be	AUX
dpc-4021	20	4	determined	determine	VERB
dpc-4021	20	5	by	by	ADP
dpc-4021	20	6	psoriasis	psoriasis	NOUN
dpc-4021	20	7	area	area	NOUN
dpc-4021	20	8	and	and	CCONJ
dpc-4021	20	9	severity	severity	NOUN
dpc-4021	20	10	index	index	NOUN
dpc-4021	20	11	(	(	PUNCT
dpc-4021	20	12	pasi	pasi	NOUN
dpc-4021	20	13	)	)	PUNCT
dpc-4021	20	14	score	score	NOUN
dpc-4021	20	15	before	before	ADV
dpc-4021	20	16	and	and	CCONJ
dpc-4021	20	17	at	at	ADP
dpc-4021	20	18	the	the	DET
dpc-4021	20	19	end	end	NOUN
dpc-4021	20	20	of	of	ADP
dpc-4021	20	21	treatment	treatment	NOUN
dpc-4021	20	22	the	the	DET
dpc-4021	20	23	treatment	treatment	NOUN
dpc-4021	20	24	response	response	NOUN
dpc-4021	20	25	was	be	AUX
dpc-4021	20	26	evaluated	evaluate	VERB
dpc-4021	20	27	at	at	ADP
dpc-4021	20	28	the	the	DET
dpc-4021	20	29	baseline	baseline	NOUN
dpc-4021	20	30	and	and	CCONJ
dpc-4021	20	31	weeks	week	NOUN
dpc-4021	20	32	4	4	NUM
dpc-4021	20	33	,	,	PUNCT
dpc-4021	20	34	8	8	NUM
dpc-4021	20	35	and	and	CCONJ
dpc-4021	20	36	12	12	NUM
dpc-4021	20	37	pasi	pasi	NOUN
dpc-4021	20	38	score	score	NOUN
dpc-4021	20	39	.	.	PUNCT
dpc-4021	21	1	results	result	NOUN
dpc-4021	21	2	:	:	PUNCT
dpc-4021	21	3	both	both	DET
dpc-4021	21	4	groups	group	NOUN
dpc-4021	21	5	were	be	AUX
dpc-4021	21	6	matching	match	VERB
dpc-4021	21	7	at	at	ADP
dpc-4021	21	8	the	the	DET
dpc-4021	21	9	baseline	baseline	NOUN
dpc-4021	21	10	in	in	ADP
dpc-4021	21	11	aspects	aspect	NOUN
dpc-4021	21	12	of	of	ADP
dpc-4021	21	13	gender	gender	NOUN
dpc-4021	21	14	,	,	PUNCT
dpc-4021	21	15	age	age	NOUN
dpc-4021	21	16	,	,	PUNCT
dpc-4021	21	17	disease	disease	NOUN
dpc-4021	21	18	duration	duration	NOUN
dpc-4021	21	19	and	and	CCONJ
dpc-4021	21	20	pasi	pasi	NOUN
dpc-4021	21	21	scores	score	NOUN
dpc-4021	21	22	both	both	DET
dpc-4021	21	23	medications	medication	NOUN
dpc-4021	21	24	yielded	yield	VERB
dpc-4021	21	25	comparable	comparable	ADJ
dpc-4021	21	26	results	result	NOUN
dpc-4021	21	27	with	with	ADP
dpc-4021	21	28	no	no	DET
dpc-4021	21	29	significant	significant	ADJ
dpc-4021	21	30	difference	difference	NOUN
dpc-4021	21	31	between	between	ADP
dpc-4021	21	32	both	both	DET
dpc-4021	21	33	groups	group	NOUN
dpc-4021	21	34	in	in	ADP
dpc-4021	21	35	pasi	pasi	NOUN
dpc-4021	21	36	score	score	VERB
dpc-4021	21	37	neither	neither	CCONJ
dpc-4021	21	38	in	in	ADP
dpc-4021	21	39	side	side	NOUN
dpc-4021	21	40	effects	effect	NOUN
dpc-4021	21	41	.	.	PUNCT
dpc-4021	22	1	conclusions	conclusion	NOUN
dpc-4021	22	2	:	:	PUNCT
dpc-4021	22	3	leflunomide	leflunomide	ADJ
dpc-4021	22	4	can	can	AUX
dpc-4021	22	5	be	be	AUX
dpc-4021	22	6	as	as	ADV
dpc-4021	22	7	effective	effective	ADJ
dpc-4021	22	8	as	as	ADP
dpc-4021	22	9	methotrexate	methotrexate	NOUN
dpc-4021	22	10	in	in	ADP
dpc-4021	22	11	treatment	treatment	NOUN
dpc-4021	22	12	of	of	ADP
dpc-4021	22	13	moderate	moderate	ADJ
dpc-4021	22	14	to	to	ADP
dpc-4021	22	15	severe	severe	ADJ
dpc-4021	22	16	psoriasis	psoriasis	NOUN
dpc-4021	22	17	abstract	abstract	ADJ
dpc-4021	22	18	2	2	NUM
dpc-4021	22	19	original	original	ADJ
dpc-4021	22	20	article	article	NOUN
dpc-4021	22	21	|	|	ADV
dpc-4021	22	22	dermatol	dermatol	ADJ
dpc-4021	22	23	pract	pract	NOUN
dpc-4021	22	24	concept	concept	NOUN
dpc-4021	22	25	.	.	PUNCT
dpc-4021	23	1	2024;14(3):e2024165	2024;14(3):e2024165	NUM
dpc-4021	23	2	introduction	introduction	NOUN
dpc-4021	23	3	psoriasis	psoriasis	NOUN
dpc-4021	23	4	is	be	AUX
dpc-4021	23	5	a	a	DET
dpc-4021	23	6	chronic	chronic	ADJ
dpc-4021	23	7	proliferative	proliferative	NOUN
dpc-4021	23	8	and	and	CCONJ
dpc-4021	23	9	inflammatory	inflammatory	ADJ
dpc-4021	23	10	skin	skin	NOUN
dpc-4021	23	11	disease	disease	NOUN
dpc-4021	23	12	.	.	PUNCT
dpc-4021	24	1	clinically	clinically	ADV
dpc-4021	24	2	,	,	PUNCT
dpc-4021	24	3	the	the	DET
dpc-4021	24	4	disease	disease	NOUN
dpc-4021	24	5	is	be	AUX
dpc-4021	24	6	characterized	characterize	VERB
dpc-4021	24	7	by	by	ADP
dpc-4021	24	8	erythematous	erythematous	ADJ
dpc-4021	24	9	plaques	plaque	NOUN
dpc-4021	24	10	covered	cover	VERB
dpc-4021	24	11	by	by	ADP
dpc-4021	24	12	silvery	silvery	NOUN
dpc-4021	24	13	scales	scale	NOUN
dpc-4021	24	14	mainly	mainly	ADV
dpc-4021	24	15	on	on	ADP
dpc-4021	24	16	the	the	DET
dpc-4021	24	17	extensor	extensor	NOUN
dpc-4021	24	18	surfaces	surface	NOUN
dpc-4021	24	19	,	,	PUNCT
dpc-4021	24	20	scalp	scalp	NOUN
dpc-4021	24	21	,	,	PUNCT
dpc-4021	24	22	and	and	CCONJ
dpc-4021	24	23	lumbosacral	lumbosacral	ADJ
dpc-4021	24	24	region	region	NOUN
dpc-4021	24	25	.	.	PUNCT
dpc-4021	25	1	joints	joint	NOUN
dpc-4021	25	2	and	and	CCONJ
dpc-4021	25	3	eyes	eye	NOUN
dpc-4021	25	4	can	can	AUX
dpc-4021	25	5	be	be	AUX
dpc-4021	25	6	affected	affect	VERB
dpc-4021	25	7	.	.	PUNCT
dpc-4021	26	1	several	several	ADJ
dpc-4021	26	2	types	type	NOUN
dpc-4021	26	3	are	be	AUX
dpc-4021	26	4	described	describe	VERB
dpc-4021	26	5	,	,	PUNCT
dpc-4021	26	6	but	but	CCONJ
dpc-4021	26	7	the	the	DET
dpc-4021	26	8	plaque	plaque	NOUN
dpc-4021	26	9	type	type	NOUN
dpc-4021	26	10	is	be	AUX
dpc-4021	26	11	the	the	DET
dpc-4021	26	12	commonest	commonest	NOUN
dpc-4021	27	1	[	[	X
dpc-4021	27	2	1,2	1,2	NUM
dpc-4021	27	3	]	]	PUNCT
dpc-4021	27	4	.	.	PUNCT
dpc-4021	28	1	disease	disease	NOUN
dpc-4021	28	2	affects	affect	VERB
dpc-4021	28	3	0.2	0.2	NUM
dpc-4021	28	4	%	%	NOUN
dpc-4021	28	5	to	to	PART
dpc-4021	28	6	4.8	4.8	NUM
dpc-4021	28	7	%	%	NOUN
dpc-4021	28	8	of	of	ADP
dpc-4021	28	9	the	the	DET
dpc-4021	28	10	population	population	NOUN
dpc-4021	28	11	.	.	PUNCT
dpc-4021	29	1	it	it	PRON
dpc-4021	29	2	is	be	AUX
dpc-4021	29	3	of	of	ADP
dpc-4021	29	4	unknown	unknown	ADJ
dpc-4021	29	5	etiology	etiology	NOUN
dpc-4021	29	6	.	.	PUNCT
dpc-4021	30	1	however	however	ADV
dpc-4021	30	2	,	,	PUNCT
dpc-4021	30	3	it	it	PRON
dpc-4021	30	4	is	be	AUX
dpc-4021	30	5	considered	consider	VERB
dpc-4021	30	6	an	an	DET
dpc-4021	30	7	autoimmune	autoimmune	ADJ
dpc-4021	30	8	disease	disease	NOUN
dpc-4021	30	9	mediated	mediate	VERB
dpc-4021	30	10	by	by	ADP
dpc-4021	30	11	t	t	PROPN
dpc-4021	30	12	lymphocytes	lymphocyte	NOUN
dpc-4021	30	13	,	,	PUNCT
dpc-4021	30	14	with	with	ADP
dpc-4021	30	15	genetic	genetic	ADJ
dpc-4021	30	16	predisposition	predisposition	NOUN
dpc-4021	30	17	as	as	SCONJ
dpc-4021	30	18	it	it	PRON
dpc-4021	30	19	runs	run	VERB
dpc-4021	30	20	in	in	ADP
dpc-4021	30	21	families	family	NOUN
dpc-4021	30	22	.	.	PUNCT
dpc-4021	31	1	any	any	DET
dpc-4021	31	2	skin	skin	NOUN
dpc-4021	31	3	injury	injury	NOUN
dpc-4021	31	4	(	(	PUNCT
dpc-4021	31	5	eg	eg	PROPN
dpc-4021	31	6	mechanical	mechanical	ADJ
dpc-4021	31	7	,	,	PUNCT
dpc-4021	31	8	chemical	chemical	NOUN
dpc-4021	31	9	,	,	PUNCT
dpc-4021	31	10	radiation	radiation	NOUN
dpc-4021	31	11	)	)	PUNCT
dpc-4021	31	12	seems	seem	VERB
dpc-4021	31	13	to	to	PART
dpc-4021	31	14	induce	induce	VERB
dpc-4021	31	15	the	the	DET
dpc-4021	31	16	psoriatic	psoriatic	ADJ
dpc-4021	31	17	lesions	lesion	NOUN
dpc-4021	31	18	.	.	PUNCT
dpc-4021	32	1	additionally	additionally	ADV
dpc-4021	32	2	,	,	PUNCT
dpc-4021	32	3	the	the	DET
dpc-4021	32	4	disease	disease	NOUN
dpc-4021	32	5	is	be	AUX
dpc-4021	32	6	worsened	worsen	VERB
dpc-4021	32	7	by	by	ADP
dpc-4021	32	8	certain	certain	ADJ
dpc-4021	32	9	drugs	drug	NOUN
dpc-4021	32	10	(	(	PUNCT
dpc-4021	32	11	eg	eg	NOUN
dpc-4021	32	12	chloroquine	chloroquine	NOUN
dpc-4021	32	13	,	,	PUNCT
dpc-4021	32	14	lithium	lithium	NOUN
dpc-4021	32	15	,	,	PUNCT
dpc-4021	32	16	and	and	CCONJ
dpc-4021	32	17	beta	beta	NOUN
dpc-4021	32	18	-	-	PUNCT
dpc-4021	32	19	blockers	blocker	NOUN
dpc-4021	32	20	)	)	PUNCT
dpc-4021	32	21	.	.	PUNCT
dpc-4021	33	1	but	but	CCONJ
dpc-4021	33	2	it	it	PRON
dpc-4021	33	3	improved	improve	VERB
dpc-4021	33	4	in	in	ADP
dpc-4021	33	5	summer	summer	NOUN
dpc-4021	33	6	.	.	PUNCT
dpc-4021	34	1	other	other	ADJ
dpc-4021	34	2	triggering	trigger	VERB
dpc-4021	34	3	factors	factor	NOUN
dpc-4021	34	4	include	include	VERB
dpc-4021	34	5	infections	infection	NOUN
dpc-4021	34	6	,	,	PUNCT
dpc-4021	34	7	stress	stress	NOUN
dpc-4021	34	8	,	,	PUNCT
dpc-4021	34	9	smoking	smoking	NOUN
dpc-4021	34	10	,	,	PUNCT
dpc-4021	34	11	obesity	obesity	NOUN
dpc-4021	34	12	,	,	PUNCT
dpc-4021	34	13	alcoholism	alcoholism	NOUN
dpc-4021	34	14	,	,	PUNCT
dpc-4021	34	15	and	and	CCONJ
dpc-4021	34	16	hypoglycemia	hypoglycemia	NOUN
dpc-4021	35	1	[	[	X
dpc-4021	35	2	3	3	NUM
dpc-4021	35	3	]	]	PUNCT
dpc-4021	35	4	.	.	PUNCT
dpc-4021	36	1	the	the	DET
dpc-4021	36	2	main	main	ADJ
dpc-4021	36	3	pathophysiological	pathophysiological	ADJ
dpc-4021	36	4	changes	change	NOUN
dpc-4021	36	5	include	include	VERB
dpc-4021	36	6	stimulating	stimulate	VERB
dpc-4021	36	7	keratinocyte	keratinocyte	NOUN
dpc-4021	36	8	proliferation	proliferation	NOUN
dpc-4021	36	9	by	by	ADP
dpc-4021	36	10	infiltration	infiltration	NOUN
dpc-4021	36	11	of	of	ADP
dpc-4021	36	12	the	the	DET
dpc-4021	36	13	skin	skin	NOUN
dpc-4021	36	14	by	by	ADP
dpc-4021	36	15	activated	activate	VERB
dpc-4021	36	16	t	t	PROPN
dpc-4021	36	17	-	-	PUNCT
dpc-4021	36	18	cells	cell	NOUN
dpc-4021	36	19	,	,	PUNCT
dpc-4021	36	20	with	with	ADP
dpc-4021	36	21	subsequent	subsequent	ADJ
dpc-4021	36	22	formation	formation	NOUN
dpc-4021	36	23	of	of	ADP
dpc-4021	36	24	thick	thick	ADJ
dpc-4021	36	25	plaques	plaque	NOUN
dpc-4021	36	26	.	.	PUNCT
dpc-4021	37	1	other	other	ADJ
dpc-4021	37	2	features	feature	NOUN
dpc-4021	37	3	include	include	VERB
dpc-4021	37	4	epidermal	epidermal	ADJ
dpc-4021	37	5	hyperplasia	hyperplasia	NOUN
dpc-4021	37	6	and	and	CCONJ
dpc-4021	37	7	parakeratosis	parakeratosis	NOUN
dpc-4021	37	8	.	.	PUNCT
dpc-4021	38	1	the	the	DET
dpc-4021	38	2	epidermal	epidermal	ADJ
dpc-4021	38	3	cells	cell	NOUN
dpc-4021	38	4	also	also	ADV
dpc-4021	38	5	fail	fail	VERB
dpc-4021	38	6	to	to	PART
dpc-4021	38	7	secrete	secrete	VERB
dpc-4021	38	8	lipids	lipids	ADP
dpc-4021	38	9	which	which	PRON
dpc-4021	38	10	results	result	VERB
dpc-4021	38	11	in	in	ADP
dpc-4021	38	12	flaky	flaky	ADJ
dpc-4021	38	13	and	and	CCONJ
dpc-4021	38	14	scaly	scaly	NOUN
dpc-4021	38	15	skin	skin	NOUN
dpc-4021	38	16	,	,	PUNCT
dpc-4021	38	17	which	which	PRON
dpc-4021	38	18	is	be	AUX
dpc-4021	38	19	typical	typical	ADJ
dpc-4021	38	20	of	of	ADP
dpc-4021	38	21	psoriasis	psoriasis	NOUN
dpc-4021	38	22	[	[	X
dpc-4021	38	23	4	4	NUM
dpc-4021	38	24	]	]	PUNCT
dpc-4021	38	25	.	.	PUNCT
dpc-4021	39	1	psoriasis	psoriasis	NOUN
dpc-4021	39	2	can	can	AUX
dpc-4021	39	3	present	present	VERB
dpc-4021	39	4	with	with	ADP
dpc-4021	39	5	different	different	ADJ
dpc-4021	39	6	morphological	morphological	ADJ
dpc-4021	39	7	patterns	pattern	NOUN
dpc-4021	39	8	(	(	PUNCT
dpc-4021	39	9	eg	eg	NOUN
dpc-4021	39	10	plaque	plaque	NOUN
dpc-4021	39	11	,	,	PUNCT
dpc-4021	39	12	guttate	guttate	ADJ
dpc-4021	39	13	,	,	PUNCT
dpc-4021	39	14	rupioid	rupioid	NOUN
dpc-4021	39	15	,	,	PUNCT
dpc-4021	39	16	erythrodermic	erythrodermic	ADJ
dpc-4021	39	17	,	,	PUNCT
dpc-4021	39	18	pustular	pustular	ADJ
dpc-4021	39	19	,	,	PUNCT
dpc-4021	39	20	inverse	inverse	ADJ
dpc-4021	39	21	,	,	PUNCT
dpc-4021	39	22	elephantine	elephantine	ADJ
dpc-4021	39	23	,	,	PUNCT
dpc-4021	39	24	and	and	CCONJ
dpc-4021	39	25	psoriatic	psoriatic	ADJ
dpc-4021	39	26	arthritis	arthritis	NOUN
dpc-4021	39	27	)	)	PUNCT
dpc-4021	40	1	[	[	X
dpc-4021	40	2	5,6	5,6	NUM
dpc-4021	40	3	]	]	X
dpc-4021	40	4	.	.	PUNCT
dpc-4021	41	1	the	the	DET
dpc-4021	41	2	psoriasis	psoriasis	NOUN
dpc-4021	41	3	area	area	NOUN
dpc-4021	41	4	severity	severity	NOUN
dpc-4021	41	5	index	index	NOUN
dpc-4021	41	6	(	(	PUNCT
dpc-4021	41	7	pasi	pasi	NOUN
dpc-4021	41	8	)	)	PUNCT
dpc-4021	41	9	is	be	AUX
dpc-4021	41	10	the	the	DET
dpc-4021	41	11	most	most	ADV
dpc-4021	41	12	widely	widely	ADV
dpc-4021	41	13	used	use	VERB
dpc-4021	41	14	assessment	assessment	NOUN
dpc-4021	41	15	tool	tool	NOUN
dpc-4021	41	16	to	to	PART
dpc-4021	41	17	estimate	estimate	VERB
dpc-4021	41	18	the	the	DET
dpc-4021	41	19	severity	severity	NOUN
dpc-4021	41	20	of	of	ADP
dpc-4021	41	21	the	the	DET
dpc-4021	41	22	condition	condition	NOUN
dpc-4021	41	23	and	and	CCONJ
dpc-4021	41	24	permits	permit	VERB
dpc-4021	41	25	treatment	treatment	NOUN
dpc-4021	41	26	evaluation	evaluation	NOUN
dpc-4021	41	27	.	.	PUNCT
dpc-4021	42	1	topical	topical	ADJ
dpc-4021	42	2	therapy	therapy	NOUN
dpc-4021	42	3	is	be	AUX
dpc-4021	42	4	used	use	VERB
dpc-4021	42	5	for	for	ADP
dpc-4021	42	6	mild	mild	ADJ
dpc-4021	42	7	to	to	ADP
dpc-4021	42	8	moderate	moderate	ADJ
dpc-4021	42	9	psoriasis	psoriasis	NOUN
dpc-4021	42	10	(	(	PUNCT
dpc-4021	42	11	eg	eg	PROPN
dpc-4021	42	12	coal	coal	NOUN
dpc-4021	42	13	tar	tar	NOUN
dpc-4021	42	14	,	,	PUNCT
dpc-4021	42	15	dithranol	dithranol	NOUN
dpc-4021	42	16	,	,	PUNCT
dpc-4021	42	17	corticosteroids	corticosteroid	NOUN
dpc-4021	42	18	,	,	PUNCT
dpc-4021	42	19	vitamin	vitamin	NOUN
dpc-4021	42	20	d	d	NOUN
dpc-4021	42	21	analog	analog	NOUN
dpc-4021	42	22	,	,	PUNCT
dpc-4021	42	23	and	and	CCONJ
dpc-4021	42	24	retinoids	retinoid	NOUN
dpc-4021	42	25	)	)	PUNCT
dpc-4021	43	1	[	[	X
dpc-4021	43	2	7	7	NUM
dpc-4021	43	3	]	]	PUNCT
dpc-4021	43	4	.	.	PUNCT
dpc-4021	44	1	systemic	systemic	ADJ
dpc-4021	44	2	drugs	drug	NOUN
dpc-4021	44	3	are	be	AUX
dpc-4021	44	4	used	use	VERB
dpc-4021	44	5	in	in	ADP
dpc-4021	44	6	severe	severe	ADJ
dpc-4021	44	7	cases	case	NOUN
dpc-4021	44	8	.	.	PUNCT
dpc-4021	45	1	methotrexate	methotrexate	NOUN
dpc-4021	45	2	,	,	PUNCT
dpc-4021	45	3	retinoids	retinoid	NOUN
dpc-4021	45	4	,	,	PUNCT
dpc-4021	45	5	cyclosporine	cyclosporine	NOUN
dpc-4021	45	6	,	,	PUNCT
dpc-4021	45	7	and	and	CCONJ
dpc-4021	45	8	fumarates	fumarate	NOUN
dpc-4021	45	9	are	be	AUX
dpc-4021	45	10	possible	possible	ADJ
dpc-4021	45	11	treatment	treatment	NOUN
dpc-4021	45	12	options	option	NOUN
dpc-4021	45	13	.	.	PUNCT
dpc-4021	46	1	routine	routine	ADJ
dpc-4021	46	2	blood	blood	NOUN
dpc-4021	46	3	,	,	PUNCT
dpc-4021	46	4	liver	liver	NOUN
dpc-4021	46	5	and	and	CCONJ
dpc-4021	46	6	renal	renal	ADJ
dpc-4021	46	7	functions	function	NOUN
dpc-4021	46	8	should	should	AUX
dpc-4021	46	9	be	be	AUX
dpc-4021	46	10	assessed	assess	VERB
dpc-4021	46	11	in	in	ADP
dpc-4021	46	12	patients	patient	NOUN
dpc-4021	46	13	during	during	ADP
dpc-4021	46	14	systemic	systemic	ADJ
dpc-4021	46	15	therapy	therapy	NOUN
dpc-4021	46	16	.	.	PUNCT
dpc-4021	47	1	biological	biological	ADJ
dpc-4021	47	2	agents	agent	NOUN
dpc-4021	47	3	(	(	PUNCT
dpc-4021	47	4	eg	eg	PROPN
dpc-4021	47	5	infliximab	infliximab	PROPN
dpc-4021	47	6	,	,	PUNCT
dpc-4021	47	7	adalimumab	adalimumab	NOUN
dpc-4021	47	8	,	,	PUNCT
dpc-4021	47	9	etanercept	etanercept	NOUN
dpc-4021	47	10	,	,	PUNCT
dpc-4021	47	11	and	and	CCONJ
dpc-4021	47	12	interleukin	interleukin	NOUN
dpc-4021	47	13	antagonists	antagonist	NOUN
dpc-4021	47	14	)	)	PUNCT
dpc-4021	47	15	work	work	NOUN
dpc-4021	47	16	by	by	ADP
dpc-4021	47	17	interrupting	interrupt	VERB
dpc-4021	47	18	the	the	DET
dpc-4021	47	19	immune	immune	ADJ
dpc-4021	47	20	process	process	NOUN
dpc-4021	47	21	.	.	PUNCT
dpc-4021	48	1	however	however	ADV
dpc-4021	48	2	,	,	PUNCT
dpc-4021	48	3	there	there	PRON
dpc-4021	48	4	is	be	VERB
dpc-4021	48	5	a	a	DET
dpc-4021	48	6	serious	serious	ADJ
dpc-4021	48	7	risk	risk	NOUN
dpc-4021	48	8	of	of	ADP
dpc-4021	48	9	infections	infection	NOUN
dpc-4021	48	10	in	in	ADP
dpc-4021	48	11	these	these	DET
dpc-4021	48	12	patients	patient	NOUN
dpc-4021	48	13	(	(	PUNCT
dpc-4021	48	14	on	on	ADP
dpc-4021	48	15	biological	biological	ADJ
dpc-4021	48	16	treatment	treatment	NOUN
dpc-4021	48	17	)	)	PUNCT
dpc-4021	48	18	and	and	CCONJ
dpc-4021	48	19	all	all	DET
dpc-4021	48	20	precautions	precaution	NOUN
dpc-4021	48	21	should	should	AUX
dpc-4021	48	22	be	be	AUX
dpc-4021	48	23	taken	take	VERB
dpc-4021	48	24	to	to	PART
dpc-4021	48	25	prevent	prevent	VERB
dpc-4021	48	26	severe	severe	ADJ
dpc-4021	48	27	immunosuppression	immunosuppression	NOUN
dpc-4021	48	28	in	in	ADP
dpc-4021	48	29	such	such	ADJ
dpc-4021	48	30	patients	patient	NOUN
dpc-4021	48	31	[	[	X
dpc-4021	48	32	8,9	8,9	NUM
dpc-4021	48	33	]	]	PUNCT
dpc-4021	48	34	.	.	PUNCT
dpc-4021	49	1	methotrexate	methotrexate	NOUN
dpc-4021	49	2	(	(	PUNCT
dpc-4021	49	3	mtx	mtx	NOUN
dpc-4021	49	4	)	)	PUNCT
dpc-4021	49	5	is	be	AUX
dpc-4021	49	6	a	a	DET
dpc-4021	49	7	folate	folate	NOUN
dpc-4021	49	8	antagonist	antagonist	NOUN
dpc-4021	49	9	initially	initially	ADV
dpc-4021	49	10	used	use	VERB
dpc-4021	49	11	to	to	PART
dpc-4021	49	12	treat	treat	VERB
dpc-4021	49	13	hematological	hematological	ADJ
dpc-4021	49	14	malignancies	malignancy	NOUN
dpc-4021	49	15	.	.	PUNCT
dpc-4021	50	1	it	it	PRON
dpc-4021	50	2	has	have	AUX
dpc-4021	50	3	been	be	AUX
dpc-4021	50	4	used	use	VERB
dpc-4021	50	5	as	as	ADP
dpc-4021	50	6	an	an	DET
dpc-4021	50	7	anti	anti	ADJ
dpc-4021	50	8	-	-	ADJ
dpc-4021	50	9	inflammatory	inflammatory	ADJ
dpc-4021	50	10	drug	drug	NOUN
dpc-4021	50	11	in	in	ADP
dpc-4021	50	12	psoriasis	psoriasis	NOUN
dpc-4021	50	13	for	for	ADP
dpc-4021	50	14	more	more	ADJ
dpc-4021	50	15	than	than	ADP
dpc-4021	50	16	50	50	NUM
dpc-4021	50	17	years	year	NOUN
dpc-4021	50	18	.	.	PUNCT
dpc-4021	51	1	it	it	PRON
dpc-4021	51	2	is	be	AUX
dpc-4021	51	3	the	the	DET
dpc-4021	51	4	first	first	ADJ
dpc-4021	51	5	-	-	PUNCT
dpc-4021	51	6	line	line	NOUN
dpc-4021	51	7	systemic	systemic	ADJ
dpc-4021	51	8	treatment	treatment	NOUN
dpc-4021	51	9	agent	agent	NOUN
dpc-4021	51	10	in	in	ADP
dpc-4021	51	11	the	the	DET
dpc-4021	51	12	united	united	PROPN
dpc-4021	51	13	states	states	PROPN
dpc-4021	51	14	and	and	CCONJ
dpc-4021	51	15	europe	europe	PROPN
dpc-4021	51	16	.	.	PUNCT
dpc-4021	52	1	it	it	PRON
dpc-4021	52	2	is	be	AUX
dpc-4021	52	3	used	use	VERB
dpc-4021	52	4	for	for	ADP
dpc-4021	52	5	moderate	moderate	ADJ
dpc-4021	52	6	-	-	PUNCT
dpc-4021	52	7	to	to	ADP
dpc-4021	52	8	severe	severe	ADJ
dpc-4021	52	9	psoriasis	psoriasis	NOUN
dpc-4021	52	10	when	when	SCONJ
dpc-4021	52	11	topical	topical	ADJ
dpc-4021	52	12	treatments	treatment	NOUN
dpc-4021	52	13	are	be	AUX
dpc-4021	52	14	ineffective	ineffective	ADJ
dpc-4021	52	15	,	,	PUNCT
dpc-4021	52	16	impractical	impractical	ADJ
dpc-4021	52	17	,	,	PUNCT
dpc-4021	52	18	or	or	CCONJ
dpc-4021	52	19	contraindicated	contraindicate	VERB
dpc-4021	53	1	[	[	X
dpc-4021	53	2	10	10	NUM
dpc-4021	53	3	]	]	PUNCT
dpc-4021	53	4	.	.	PUNCT
dpc-4021	54	1	it	it	PRON
dpc-4021	54	2	was	be	AUX
dpc-4021	54	3	suggested	suggest	VERB
dpc-4021	54	4	to	to	PART
dpc-4021	54	5	exert	exert	VERB
dpc-4021	54	6	its	its	PRON
dpc-4021	54	7	action	action	NOUN
dpc-4021	54	8	by	by	ADP
dpc-4021	54	9	its	its	PRON
dpc-4021	54	10	antiproliferative	antiproliferative	ADJ
dpc-4021	54	11	effects	effect	NOUN
dpc-4021	54	12	,	,	PUNCT
dpc-4021	54	13	increasing	increase	VERB
dpc-4021	54	14	susceptibility	susceptibility	NOUN
dpc-4021	54	15	of	of	ADP
dpc-4021	54	16	t	t	PROPN
dpc-4021	54	17	-	-	PUNCT
dpc-4021	54	18	lymphocytes	lymphocyte	NOUN
dpc-4021	54	19	and	and	CCONJ
dpc-4021	54	20	monocytes	monocyte	VERB
dpc-4021	54	21	to	to	ADP
dpc-4021	54	22	the	the	DET
dpc-4021	54	23	inhibition	inhibition	NOUN
dpc-4021	54	24	of	of	ADP
dpc-4021	54	25	the	the	DET
dpc-4021	54	26	purine	purine	NOUN
dpc-4021	54	27	and	and	CCONJ
dpc-4021	54	28	pyrimidine	pyrimidine	NOUN
dpc-4021	54	29	synthesis	synthesis	NOUN
dpc-4021	54	30	,	,	PUNCT
dpc-4021	54	31	anti	anti	ADJ
dpc-4021	54	32	-	-	ADJ
dpc-4021	54	33	inflammatory	inflammatory	ADJ
dpc-4021	54	34	and	and	CCONJ
dpc-4021	54	35	immunosuppressant	immunosuppressant	ADJ
dpc-4021	54	36	effects	effect	NOUN
dpc-4021	54	37	[	[	X
dpc-4021	54	38	11,12	11,12	NUM
dpc-4021	54	39	]	]	PUNCT
dpc-4021	54	40	.	.	PUNCT
dpc-4021	55	1	leflunomide	leflunomide	PROPN
dpc-4021	55	2	is	be	AUX
dpc-4021	55	3	an	an	DET
dpc-4021	55	4	isoxazole	isoxazole	NOUN
dpc-4021	55	5	derivative	derivative	NOUN
dpc-4021	55	6	.	.	PUNCT
dpc-4021	56	1	it	it	PRON
dpc-4021	56	2	is	be	AUX
dpc-4021	56	3	primarily	primarily	ADV
dpc-4021	56	4	inhibiting	inhibit	VERB
dpc-4021	56	5	the	the	DET
dpc-4021	56	6	dihydro	dihydro	NOUN
dpc-4021	56	7	-	-	PUNCT
dpc-4021	56	8	orotate	orotate	NOUN
dpc-4021	56	9	dehydrogenase	dehydrogenase	NOUN
dpc-4021	56	10	,	,	PUNCT
dpc-4021	56	11	a	a	DET
dpc-4021	56	12	key	key	ADJ
dpc-4021	56	13	enzyme	enzyme	NOUN
dpc-4021	56	14	in	in	ADP
dpc-4021	56	15	the	the	DET
dpc-4021	56	16	de	de	ADJ
dpc-4021	56	17	novo	novo	NOUN
dpc-4021	56	18	synthesis	synthesis	NOUN
dpc-4021	56	19	of	of	ADP
dpc-4021	56	20	pyrimidines	pyrimidine	NOUN
dpc-4021	56	21	,	,	PUNCT
dpc-4021	56	22	and	and	CCONJ
dpc-4021	56	23	subsequently	subsequently	ADV
dpc-4021	56	24	inhibit	inhibit	VERB
dpc-4021	56	25	rna	rna	PROPN
dpc-4021	56	26	and	and	CCONJ
dpc-4021	56	27	dna	dna	PROPN
dpc-4021	56	28	synthesis	synthesis	NOUN
dpc-4021	56	29	.	.	PUNCT
dpc-4021	57	1	activated	activate	VERB
dpc-4021	57	2	t	t	PROPN
dpc-4021	57	3	-	-	PUNCT
dpc-4021	57	4	lymphocytes	lymphocyte	NOUN
dpc-4021	57	5	may	may	AUX
dpc-4021	57	6	be	be	AUX
dpc-4021	57	7	especially	especially	ADV
dpc-4021	57	8	susceptible	susceptible	ADJ
dpc-4021	57	9	to	to	ADP
dpc-4021	57	10	leflunomide	leflunomide	ADJ
dpc-4021	57	11	.	.	PUNCT
dpc-4021	58	1	it	it	PRON
dpc-4021	58	2	also	also	ADV
dpc-4021	58	3	has	have	VERB
dpc-4021	58	4	immunomodulatory	immunomodulatory	ADJ
dpc-4021	58	5	and	and	CCONJ
dpc-4021	58	6	anti	anti	ADJ
dpc-4021	58	7	-	-	ADJ
dpc-4021	58	8	inflammatory	inflammatory	ADJ
dpc-4021	58	9	effects	effect	NOUN
dpc-4021	58	10	[	[	X
dpc-4021	58	11	13	13	NUM
dpc-4021	58	12	]	]	PUNCT
dpc-4021	58	13	.	.	PUNCT
dpc-4021	59	1	leflunomide	leflunomide	PROPN
dpc-4021	59	2	is	be	AUX
dpc-4021	59	3	a	a	DET
dpc-4021	59	4	useful	useful	ADJ
dpc-4021	59	5	and	and	CCONJ
dpc-4021	59	6	well	well	ADV
dpc-4021	59	7	tolerated	tolerate	VERB
dpc-4021	59	8	treatment	treatment	NOUN
dpc-4021	59	9	option	option	NOUN
dpc-4021	59	10	for	for	ADP
dpc-4021	59	11	plaque	plaque	NOUN
dpc-4021	59	12	psoriasis	psoriasis	NOUN
dpc-4021	59	13	.	.	PUNCT
dpc-4021	60	1	it	it	PRON
dpc-4021	60	2	has	have	VERB
dpc-4021	60	3	some	some	DET
dpc-4021	60	4	advantages	advantage	NOUN
dpc-4021	60	5	over	over	ADP
dpc-4021	60	6	mtx	mtx	NOUN
dpc-4021	60	7	in	in	ADP
dpc-4021	60	8	the	the	DET
dpc-4021	60	9	treatment	treatment	NOUN
dpc-4021	60	10	of	of	ADP
dpc-4021	60	11	psoriasis	psoriasis	NOUN
dpc-4021	60	12	(	(	PUNCT
dpc-4021	60	13	eg	eg	NOUN
dpc-4021	60	14	it	it	PRON
dpc-4021	60	15	is	be	AUX
dpc-4021	60	16	well	well	ADV
dpc-4021	60	17	tolerated	tolerate	VERB
dpc-4021	60	18	,	,	PUNCT
dpc-4021	60	19	convenient	convenient	ADJ
dpc-4021	60	20	and	and	CCONJ
dpc-4021	60	21	effective	effective	ADJ
dpc-4021	60	22	)	)	PUNCT
dpc-4021	60	23	.	.	PUNCT
dpc-4021	61	1	in	in	ADP
dpc-4021	61	2	addition	addition	NOUN
dpc-4021	61	3	,	,	PUNCT
dpc-4021	61	4	orally	orally	ADV
dpc-4021	61	5	administered	administer	VERB
dpc-4021	61	6	leflunomide	leflunomide	ADV
dpc-4021	61	7	is	be	AUX
dpc-4021	61	8	cost	cost	NOUN
dpc-4021	61	9	effective	effective	ADJ
dpc-4021	61	10	.	.	PUNCT
dpc-4021	62	1	since	since	SCONJ
dpc-4021	62	2	biologics	biologic	NOUN
dpc-4021	62	3	are	be	AUX
dpc-4021	62	4	costly	costly	ADJ
dpc-4021	62	5	and	and	CCONJ
dpc-4021	62	6	not	not	PART
dpc-4021	62	7	easily	easily	ADV
dpc-4021	62	8	available	available	ADJ
dpc-4021	62	9	,	,	PUNCT
dpc-4021	62	10	leflunomide	leflunomide	ADJ
dpc-4021	62	11	may	may	AUX
dpc-4021	62	12	be	be	AUX
dpc-4021	62	13	one	one	NUM
dpc-4021	62	14	of	of	ADP
dpc-4021	62	15	the	the	DET
dpc-4021	62	16	alternative	alternative	ADJ
dpc-4021	62	17	treatment	treatment	NOUN
dpc-4021	62	18	options	option	NOUN
dpc-4021	62	19	of	of	ADP
dpc-4021	62	20	plaque	plaque	NOUN
dpc-4021	62	21	type	type	NOUN
dpc-4021	62	22	of	of	ADP
dpc-4021	62	23	psoriasis	psoriasis	NOUN
dpc-4021	62	24	[	[	X
dpc-4021	62	25	14,15	14,15	NUM
dpc-4021	62	26	]	]	PUNCT
dpc-4021	62	27	.	.	PUNCT
dpc-4021	63	1	objectives	objective	NOUN
dpc-4021	63	2	as	as	ADP
dpc-4021	63	3	available	available	ADJ
dpc-4021	63	4	data	datum	NOUN
dpc-4021	63	5	directly	directly	ADV
dpc-4021	63	6	comparing	compare	VERB
dpc-4021	63	7	mtx	mtx	NOUN
dpc-4021	63	8	to	to	PART
dpc-4021	63	9	leflunomide	leflunomide	VERB
dpc-4021	63	10	in	in	ADP
dpc-4021	63	11	psoriasis	psoriasis	NOUN
dpc-4021	63	12	are	be	AUX
dpc-4021	63	13	lacking	lack	VERB
dpc-4021	63	14	,	,	PUNCT
dpc-4021	63	15	this	this	DET
dpc-4021	63	16	double	double	ADJ
dpc-4021	63	17	blinded	blind	VERB
dpc-4021	63	18	study	study	NOUN
dpc-4021	63	19	was	be	AUX
dpc-4021	63	20	designed	design	VERB
dpc-4021	63	21	to	to	PART
dpc-4021	63	22	compare	compare	VERB
dpc-4021	63	23	the	the	DET
dpc-4021	63	24	efficacy	efficacy	NOUN
dpc-4021	63	25	of	of	ADP
dpc-4021	63	26	methotrexate	methotrexate	NOUN
dpc-4021	63	27	versus	versus	ADP
dpc-4021	63	28	leflunomide	leflunomide	ADJ
dpc-4021	63	29	in	in	ADP
dpc-4021	63	30	the	the	DET
dpc-4021	63	31	treatment	treatment	NOUN
dpc-4021	63	32	of	of	ADP
dpc-4021	63	33	moderate	moderate	ADJ
dpc-4021	63	34	to	to	ADP
dpc-4021	63	35	severe	severe	ADJ
dpc-4021	63	36	psoriasis	psoriasis	NOUN
dpc-4021	63	37	.	.	PUNCT
dpc-4021	64	1	methods	method	NOUN
dpc-4021	64	2	recruitment	recruitment	NOUN
dpc-4021	64	3	of	of	ADP
dpc-4021	64	4	participants	participant	NOUN
dpc-4021	64	5	this	this	DET
dpc-4021	64	6	comparative	comparative	ADJ
dpc-4021	64	7	clinical	clinical	ADJ
dpc-4021	64	8	study	study	NOUN
dpc-4021	64	9	included	include	VERB
dpc-4021	64	10	40	40	NUM
dpc-4021	64	11	patients	patient	NOUN
dpc-4021	64	12	with	with	ADP
dpc-4021	64	13	chronic	chronic	ADJ
dpc-4021	64	14	plaque	plaque	NOUN
dpc-4021	64	15	psoriasis	psoriasis	NOUN
dpc-4021	64	16	that	that	PRON
dpc-4021	64	17	were	be	AUX
dpc-4021	64	18	diagnosed	diagnose	VERB
dpc-4021	64	19	clinically	clinically	ADV
dpc-4021	64	20	.	.	PUNCT
dpc-4021	65	1	patients	patient	NOUN
dpc-4021	65	2	were	be	AUX
dpc-4021	65	3	recruited	recruit	VERB
dpc-4021	65	4	from	from	ADP
dpc-4021	65	5	the	the	DET
dpc-4021	65	6	dermatology	dermatology	NOUN
dpc-4021	65	7	outpatient	outpatient	NOUN
dpc-4021	65	8	clinic	clinic	NOUN
dpc-4021	65	9	of	of	ADP
dpc-4021	65	10	al	al	PROPN
dpc-4021	65	11	-	-	PUNCT
dpc-4021	65	12	azharuniversity	azharuniversity	PROPN
dpc-4021	65	13	hospital	hospital	NOUN
dpc-4021	65	14	(	(	PUNCT
dpc-4021	65	15	new	new	ADJ
dpc-4021	65	16	damietta	damietta	PROPN
dpc-4021	65	17	)	)	PUNCT
dpc-4021	65	18	between	between	ADP
dpc-4021	65	19	october	october	PROPN
dpc-4021	65	20	2022	2022	NUM
dpc-4021	65	21	and	and	CCONJ
dpc-4021	65	22	september	september	PROPN
dpc-4021	65	23	2023	2023	NUM
dpc-4021	65	24	.	.	PUNCT
dpc-4021	66	1	the	the	DET
dpc-4021	66	2	study	study	NOUN
dpc-4021	66	3	was	be	AUX
dpc-4021	66	4	approved	approve	VERB
dpc-4021	66	5	by	by	ADP
dpc-4021	66	6	the	the	DET
dpc-4021	66	7	research	research	PROPN
dpc-4021	66	8	ethical	ethical	PROPN
dpc-4021	66	9	committee	committee	NOUN
dpc-4021	66	10	,	,	PUNCT
dpc-4021	66	11	damietta	damietta	PROPN
dpc-4021	66	12	faculty	faculty	NOUN
dpc-4021	66	13	of	of	ADP
dpc-4021	66	14	medicine	medicine	NOUN
dpc-4021	66	15	,	,	PUNCT
dpc-4021	66	16	al	al	PROPN
dpc-4021	66	17	-	-	PUNCT
dpc-4021	66	18	azhar	azhar	PROPN
dpc-4021	66	19	university	university	PROPN
dpc-4021	66	20	(	(	PUNCT
dpc-4021	66	21	irb	irb	PROPN
dpc-4021	66	22	0001236722	0001236722	NUM
dpc-4021	66	23	-	-	SYM
dpc-4021	66	24	06	06	NUM
dpc-4021	66	25	-	-	PUNCT
dpc-4021	66	26	002	002	NUM
dpc-4021	66	27	)	)	PUNCT
dpc-4021	66	28	,	,	PUNCT
dpc-4021	66	29	and	and	CCONJ
dpc-4021	66	30	fulfilled	fulfil	VERB
dpc-4021	66	31	all	all	DET
dpc-4021	66	32	the	the	DET
dpc-4021	66	33	ethical	ethical	ADJ
dpc-4021	66	34	aspects	aspect	NOUN
dpc-4021	66	35	required	require	VERB
dpc-4021	66	36	in	in	ADP
dpc-4021	66	37	human	human	ADJ
dpc-4021	66	38	research	research	NOUN
dpc-4021	66	39	.	.	PUNCT
dpc-4021	67	1	all	all	DET
dpc-4021	67	2	patients	patient	NOUN
dpc-4021	67	3	received	receive	VERB
dpc-4021	67	4	full	full	ADJ
dpc-4021	67	5	information	information	NOUN
dpc-4021	67	6	about	about	ADP
dpc-4021	67	7	both	both	DET
dpc-4021	67	8	medications	medication	NOUN
dpc-4021	67	9	used	use	VERB
dpc-4021	67	10	,	,	PUNCT
dpc-4021	67	11	the	the	DET
dpc-4021	67	12	study	study	NOUN
dpc-4021	67	13	design	design	NOUN
dpc-4021	67	14	and	and	CCONJ
dpc-4021	67	15	all	all	DET
dpc-4021	67	16	the	the	DET
dpc-4021	67	17	possible	possible	ADJ
dpc-4021	67	18	side	side	NOUN
dpc-4021	67	19	effects	effect	NOUN
dpc-4021	67	20	.	.	PUNCT
dpc-4021	68	1	all	all	DET
dpc-4021	68	2	recruits	recruit	NOUN
dpc-4021	68	3	provided	provide	VERB
dpc-4021	68	4	an	an	DET
dpc-4021	68	5	informed	informed	ADJ
dpc-4021	68	6	consent	consent	NOUN
dpc-4021	68	7	to	to	PART
dpc-4021	68	8	participate	participate	VERB
dpc-4021	68	9	in	in	ADP
dpc-4021	68	10	the	the	DET
dpc-4021	68	11	study	study	NOUN
dpc-4021	68	12	.	.	PUNCT
dpc-4021	69	1	we	we	PRON
dpc-4021	69	2	excluded	exclude	VERB
dpc-4021	69	3	patients	patient	NOUN
dpc-4021	69	4	younger	young	ADJ
dpc-4021	69	5	than	than	ADP
dpc-4021	69	6	18	18	NUM
dpc-4021	69	7	 	 	SPACE
dpc-4021	69	8	years	year	NOUN
dpc-4021	69	9	or	or	CCONJ
dpc-4021	69	10	older	old	ADJ
dpc-4021	69	11	than	than	ADP
dpc-4021	69	12	60	60	NUM
dpc-4021	69	13	,	,	PUNCT
dpc-4021	69	14	pregnant	pregnant	ADJ
dpc-4021	69	15	and	and	CCONJ
dpc-4021	69	16	lactating	lactate	VERB
dpc-4021	69	17	women	woman	NOUN
dpc-4021	69	18	,	,	PUNCT
dpc-4021	69	19	patients	patient	NOUN
dpc-4021	69	20	with	with	ADP
dpc-4021	69	21	any	any	DET
dpc-4021	69	22	autoimmune	autoimmune	ADJ
dpc-4021	69	23	disease	disease	NOUN
dpc-4021	69	24	(	(	PUNCT
dpc-4021	69	25	eg	eg	NOUN
dpc-4021	69	26	rheumatoid	rheumatoid	NOUN
dpc-4021	69	27	arthritis	arthritis	NOUN
dpc-4021	69	28	,	,	PUNCT
dpc-4021	69	29	systemic	systemic	ADJ
dpc-4021	69	30	lupus	lupus	NOUN
dpc-4021	69	31	)	)	PUNCT
dpc-4021	69	32	patients	patient	NOUN
dpc-4021	69	33	with	with	ADP
dpc-4021	69	34	any	any	DET
dpc-4021	69	35	dermatological	dermatological	ADJ
dpc-4021	69	36	disease	disease	NOUN
dpc-4021	69	37	other	other	ADJ
dpc-4021	69	38	than	than	ADP
dpc-4021	69	39	psoriasis	psoriasis	NOUN
dpc-4021	69	40	,	,	PUNCT
dpc-4021	69	41	patients	patient	NOUN
dpc-4021	69	42	with	with	ADP
dpc-4021	69	43	hematologic	hematologic	NOUN
dpc-4021	69	44	disorders	disorder	NOUN
dpc-4021	69	45	(	(	PUNCT
dpc-4021	69	46	eg	eg	NOUN
dpc-4021	69	47	thrombocytopenia	thrombocytopenia	PROPN
dpc-4021	69	48	,	,	PUNCT
dpc-4021	69	49	anemia	anemia	NOUN
dpc-4021	69	50	)	)	PUNCT
dpc-4021	69	51	,	,	PUNCT
dpc-4021	69	52	patients	patient	NOUN
dpc-4021	69	53	with	with	ADP
dpc-4021	69	54	systemic	systemic	ADJ
dpc-4021	69	55	chronic	chronic	ADJ
dpc-4021	69	56	diseases	disease	NOUN
dpc-4021	69	57	(	(	PUNCT
dpc-4021	69	58	eg	eg	NOUN
dpc-4021	69	59	liver	liver	NOUN
dpc-4021	69	60	,	,	PUNCT
dpc-4021	69	61	kidney	kidney	NOUN
dpc-4021	69	62	or	or	CCONJ
dpc-4021	69	63	heart	heart	NOUN
dpc-4021	69	64	diseases	disease	NOUN
dpc-4021	69	65	)	)	PUNCT
dpc-4021	69	66	,	,	PUNCT
dpc-4021	69	67	patients	patient	NOUN
dpc-4021	69	68	who	who	PRON
dpc-4021	69	69	received	receive	VERB
dpc-4021	69	70	systemic	systemic	ADJ
dpc-4021	69	71	anti	anti	ADJ
dpc-4021	69	72	-	-	ADJ
dpc-4021	69	73	psoriatic	psoriatic	ADJ
dpc-4021	69	74	treatment	treatment	NOUN
dpc-4021	69	75	for	for	ADP
dpc-4021	69	76	the	the	DET
dpc-4021	69	77	last	last	ADJ
dpc-4021	69	78	3	3	NUM
dpc-4021	69	79	  	  	SPACE
dpc-4021	69	80	months	month	NOUN
dpc-4021	69	81	before	before	ADP
dpc-4021	69	82	inclusion	inclusion	NOUN
dpc-4021	69	83	in	in	ADP
dpc-4021	69	84	the	the	DET
dpc-4021	69	85	study	study	NOUN
dpc-4021	69	86	and	and	CCONJ
dpc-4021	69	87	those	those	PRON
dpc-4021	69	88	receiving	receive	VERB
dpc-4021	69	89	any	any	DET
dpc-4021	69	90	topical	topical	ADJ
dpc-4021	69	91	treatment	treatment	NOUN
dpc-4021	69	92	for	for	ADP
dpc-4021	69	93	4	4	NUM
dpc-4021	69	94	weeks	week	NOUN
dpc-4021	69	95	prior	prior	ADV
dpc-4021	69	96	to	to	ADP
dpc-4021	69	97	enrollment	enrollment	NOUN
dpc-4021	69	98	.	.	PUNCT
dpc-4021	70	1	patients	patient	NOUN
dpc-4021	70	2	with	with	ADP
dpc-4021	70	3	history	history	NOUN
dpc-4021	70	4	of	of	ADP
dpc-4021	70	5	allergy	allergy	NOUN
dpc-4021	70	6	to	to	ADP
dpc-4021	70	7	any	any	PRON
dpc-4021	70	8	of	of	ADP
dpc-4021	70	9	the	the	DET
dpc-4021	70	10	medications	medication	NOUN
dpc-4021	70	11	used	use	VERB
dpc-4021	70	12	were	be	AUX
dpc-4021	70	13	also	also	ADV
dpc-4021	70	14	excluded	exclude	VERB
dpc-4021	70	15	.	.	PUNCT
dpc-4021	71	1	randomization	randomization	NOUN
dpc-4021	71	2	and	and	CCONJ
dpc-4021	71	3	assigning	assign	VERB
dpc-4021	71	4	treatment	treatment	NOUN
dpc-4021	71	5	groups	group	NOUN
dpc-4021	71	6	patients	patient	NOUN
dpc-4021	71	7	were	be	AUX
dpc-4021	71	8	randomly	randomly	ADV
dpc-4021	71	9	assigned	assign	VERB
dpc-4021	71	10	to	to	ADP
dpc-4021	71	11	one	one	NUM
dpc-4021	71	12	of	of	ADP
dpc-4021	71	13	the	the	DET
dpc-4021	71	14	two	two	NUM
dpc-4021	71	15	groups	group	NOUN
dpc-4021	71	16	using	use	VERB
dpc-4021	71	17	closed	close	VERB
dpc-4021	71	18	envelop	envelop	NOUN
dpc-4021	71	19	technique	technique	NOUN
dpc-4021	71	20	.	.	PUNCT
dpc-4021	72	1	group	group	PROPN
dpc-4021	72	2	a	a	DET
dpc-4021	72	3	included	include	VERB
dpc-4021	72	4	20	20	NUM
dpc-4021	72	5	patients	patient	NOUN
dpc-4021	72	6	original	original	ADJ
dpc-4021	72	7	article	article	NOUN
dpc-4021	72	8	|	|	ADV
dpc-4021	72	9	dermatol	dermatol	ADJ
dpc-4021	72	10	pract	pract	NOUN
dpc-4021	72	11	concept	concept	NOUN
dpc-4021	72	12	.	.	PUNCT
dpc-4021	73	1	2024;14(3):e2024165	2024;14(3):e2024165	NUM
dpc-4021	73	2	3	3	NUM
dpc-4021	73	3	who	who	PRON
dpc-4021	73	4	received	receive	VERB
dpc-4021	73	5	subcutaneous	subcutaneous	ADJ
dpc-4021	73	6	methotrexate	methotrexate	NOUN
dpc-4021	73	7	injection	injection	NOUN
dpc-4021	73	8	treatment	treatment	NOUN
dpc-4021	73	9	once	once	ADV
dpc-4021	73	10	per	per	ADP
dpc-4021	73	11	week	week	NOUN
dpc-4021	73	12	for	for	ADP
dpc-4021	73	13	3	3	NUM
dpc-4021	73	14	months	month	NOUN
dpc-4021	73	15	.	.	PUNCT
dpc-4021	74	1	group	group	PROPN
dpc-4021	74	2	b	b	PROPN
dpc-4021	74	3	of	of	ADP
dpc-4021	74	4	20	20	NUM
dpc-4021	74	5	patients	patient	NOUN
dpc-4021	74	6	who	who	PRON
dpc-4021	74	7	received	receive	VERB
dpc-4021	74	8	oral	oral	ADJ
dpc-4021	74	9	leflunomide	leflunomide	ADJ
dpc-4021	74	10	regimen	regimen	NOUN
dpc-4021	74	11	loading	loading	NOUN
dpc-4021	74	12	dose	dose	VERB
dpc-4021	74	13	100	100	NUM
dpc-4021	74	14	mg	mg	ADP
dpc-4021	74	15	daily	daily	ADV
dpc-4021	74	16	for	for	ADP
dpc-4021	74	17	the	the	DET
dpc-4021	74	18	first	first	ADJ
dpc-4021	74	19	3	3	NUM
dpc-4021	74	20	days	day	NOUN
dpc-4021	74	21	then	then	ADV
dpc-4021	74	22	20	20	NUM
dpc-4021	74	23	mg	mg	NOUN
dpc-4021	74	24	daily	daily	ADV
dpc-4021	74	25	for	for	ADP
dpc-4021	74	26	3	3	NUM
dpc-4021	74	27	months	month	NOUN
dpc-4021	74	28	.	.	PUNCT
dpc-4021	75	1	randomization	randomization	NOUN
dpc-4021	75	2	was	be	AUX
dpc-4021	75	3	performed	perform	VERB
dpc-4021	75	4	by	by	ADP
dpc-4021	75	5	generation	generation	NOUN
dpc-4021	75	6	of	of	ADP
dpc-4021	75	7	random	random	ADJ
dpc-4021	75	8	numbers	number	NOUN
dpc-4021	75	9	by	by	ADP
dpc-4021	75	10	computer	computer	NOUN
dpc-4021	75	11	and	and	CCONJ
dpc-4021	75	12	each	each	DET
dpc-4021	75	13	number	number	NOUN
dpc-4021	75	14	indicate	indicate	VERB
dpc-4021	75	15	one	one	NUM
dpc-4021	75	16	treatment	treatment	NOUN
dpc-4021	75	17	and	and	CCONJ
dpc-4021	75	18	sealed	seal	VERB
dpc-4021	75	19	in	in	ADP
dpc-4021	75	20	an	an	DET
dpc-4021	75	21	enclosed	enclose	VERB
dpc-4021	75	22	envelope	envelope	NOUN
dpc-4021	75	23	which	which	PRON
dpc-4021	75	24	opened	open	VERB
dpc-4021	75	25	before	before	ADP
dpc-4021	75	26	starting	start	VERB
dpc-4021	75	27	treatment	treatment	NOUN
dpc-4021	75	28	by	by	ADP
dpc-4021	75	29	a	a	DET
dpc-4021	75	30	nurse	nurse	NOUN
dpc-4021	75	31	who	who	PRON
dpc-4021	75	32	was	be	AUX
dpc-4021	75	33	blinded	blind	VERB
dpc-4021	75	34	to	to	ADP
dpc-4021	75	35	the	the	DET
dpc-4021	75	36	other	other	ADJ
dpc-4021	75	37	parts	part	NOUN
dpc-4021	75	38	of	of	ADP
dpc-4021	75	39	the	the	DET
dpc-4021	75	40	study	study	NOUN
dpc-4021	75	41	.	.	PUNCT
dpc-4021	76	1	all	all	DET
dpc-4021	76	2	patients	patient	NOUN
dpc-4021	76	3	were	be	AUX
dpc-4021	76	4	subjected	subject	VERB
dpc-4021	76	5	to	to	ADP
dpc-4021	76	6	full	full	ADJ
dpc-4021	76	7	history	history	NOUN
dpc-4021	76	8	taking	taking	NOUN
dpc-4021	76	9	,	,	PUNCT
dpc-4021	76	10	thorough	thorough	ADJ
dpc-4021	76	11	general	general	ADJ
dpc-4021	76	12	and	and	CCONJ
dpc-4021	76	13	dermatological	dermatological	ADJ
dpc-4021	76	14	examination	examination	NOUN
dpc-4021	76	15	.	.	PUNCT
dpc-4021	77	1	the	the	DET
dpc-4021	77	2	disease	disease	NOUN
dpc-4021	77	3	severity	severity	NOUN
dpc-4021	77	4	as	as	ADV
dpc-4021	77	5	well	well	ADV
dpc-4021	77	6	as	as	ADP
dpc-4021	77	7	treatment	treatment	NOUN
dpc-4021	77	8	response	response	NOUN
dpc-4021	77	9	were	be	AUX
dpc-4021	77	10	determined	determine	VERB
dpc-4021	77	11	by	by	ADP
dpc-4021	77	12	(	(	PUNCT
dpc-4021	77	13	pasi	pasi	NOUN
dpc-4021	77	14	)	)	PUNCT
dpc-4021	77	15	score	score	NOUN
dpc-4021	77	16	at	at	ADP
dpc-4021	77	17	the	the	DET
dpc-4021	77	18	baseline	baseline	NOUN
dpc-4021	77	19	and	and	CCONJ
dpc-4021	77	20	at	at	ADP
dpc-4021	77	21	weeks	week	NOUN
dpc-4021	77	22	4	4	NUM
dpc-4021	77	23	,	,	PUNCT
dpc-4021	77	24	8	8	NUM
dpc-4021	77	25	and	and	CCONJ
dpc-4021	77	26	12	12	NUM
dpc-4021	77	27	.	.	PUNCT
dpc-4021	78	1	the	the	DET
dpc-4021	78	2	documentation	documentation	NOUN
dpc-4021	78	3	of	of	ADP
dpc-4021	78	4	the	the	DET
dpc-4021	78	5	lesion	lesion	NOUN
dpc-4021	78	6	was	be	AUX
dpc-4021	78	7	performed	perform	VERB
dpc-4021	78	8	using	use	VERB
dpc-4021	78	9	digital	digital	ADJ
dpc-4021	78	10	photography	photography	NOUN
dpc-4021	78	11	(	(	PUNCT
dpc-4021	78	12	using	use	VERB
dpc-4021	78	13	iphone	iphone	NOUN
dpc-4021	78	14	12	12	NUM
dpc-4021	78	15	camera	camera	NOUN
dpc-4021	78	16	)	)	PUNCT
dpc-4021	78	17	at	at	ADP
dpc-4021	78	18	the	the	DET
dpc-4021	78	19	baseline	baseline	NOUN
dpc-4021	78	20	and	and	CCONJ
dpc-4021	78	21	week	week	NOUN
dpc-4021	78	22	12	12	NUM
dpc-4021	78	23	.	.	PUNCT
dpc-4021	79	1	the	the	DET
dpc-4021	79	2	laboratory	laboratory	NOUN
dpc-4021	79	3	investigations	investigation	NOUN
dpc-4021	79	4	were	be	AUX
dpc-4021	79	5	performed	perform	VERB
dpc-4021	79	6	at	at	ADP
dpc-4021	79	7	the	the	DET
dpc-4021	79	8	baseline	baseline	NOUN
dpc-4021	79	9	and	and	CCONJ
dpc-4021	79	10	at	at	ADP
dpc-4021	79	11	4	4	NUM
dpc-4021	79	12	,	,	PUNCT
dpc-4021	79	13	8	8	NUM
dpc-4021	79	14	and	and	CCONJ
dpc-4021	79	15	12	12	NUM
dpc-4021	79	16	weeks	week	NOUN
dpc-4021	79	17	after	after	ADP
dpc-4021	79	18	treatment	treatment	NOUN
dpc-4021	79	19	.	.	PUNCT
dpc-4021	80	1	these	these	PRON
dpc-4021	80	2	included	include	VERB
dpc-4021	80	3	complete	complete	ADJ
dpc-4021	80	4	blood	blood	NOUN
dpc-4021	80	5	picture	picture	NOUN
dpc-4021	80	6	(	(	PUNCT
dpc-4021	80	7	cbc	cbc	PROPN
dpc-4021	80	8	)	)	PUNCT
dpc-4021	80	9	,	,	PUNCT
dpc-4021	80	10	liver	liver	NOUN
dpc-4021	80	11	and	and	CCONJ
dpc-4021	80	12	kidney	kidney	NOUN
dpc-4021	80	13	function	function	NOUN
dpc-4021	80	14	tests	test	NOUN
dpc-4021	80	15	.	.	PUNCT
dpc-4021	81	1	in	in	ADP
dpc-4021	81	2	the	the	DET
dpc-4021	81	3	methotrexate	methotrexate	NOUN
dpc-4021	81	4	group	group	NOUN
dpc-4021	81	5	,	,	PUNCT
dpc-4021	81	6	all	all	DET
dpc-4021	81	7	patients	patient	NOUN
dpc-4021	81	8	received	receive	VERB
dpc-4021	81	9	folic	folic	ADJ
dpc-4021	81	10	acid	acid	NOUN
dpc-4021	81	11	5	5	NUM
dpc-4021	81	12	mg	mg	NOUN
dpc-4021	81	13	daily	daily	ADV
dpc-4021	81	14	except	except	SCONJ
dpc-4021	81	15	on	on	ADP
dpc-4021	81	16	the	the	DET
dpc-4021	81	17	day	day	NOUN
dpc-4021	81	18	of	of	ADP
dpc-4021	81	19	injection	injection	NOUN
dpc-4021	81	20	.	.	PUNCT
dpc-4021	82	1	every	every	DET
dpc-4021	82	2	patient	patient	NOUN
dpc-4021	82	3	received	receive	VERB
dpc-4021	82	4	a	a	DET
dpc-4021	82	5	printed	print	VERB
dpc-4021	82	6	checklist	checklist	NOUN
dpc-4021	82	7	of	of	ADP
dpc-4021	82	8	the	the	DET
dpc-4021	82	9	possible	possible	ADJ
dpc-4021	82	10	side	side	NOUN
dpc-4021	82	11	effects	effect	NOUN
dpc-4021	82	12	of	of	ADP
dpc-4021	82	13	the	the	DET
dpc-4021	82	14	treatment	treatment	NOUN
dpc-4021	82	15	and	and	CCONJ
dpc-4021	82	16	was	be	AUX
dpc-4021	82	17	instructed	instruct	VERB
dpc-4021	82	18	to	to	PART
dpc-4021	82	19	report	report	VERB
dpc-4021	82	20	any	any	PRON
dpc-4021	82	21	of	of	ADP
dpc-4021	82	22	the	the	DET
dpc-4021	82	23	mentioned	mention	VERB
dpc-4021	82	24	manifestations	manifestation	NOUN
dpc-4021	82	25	on	on	ADP
dpc-4021	82	26	every	every	DET
dpc-4021	82	27	visit	visit	NOUN
dpc-4021	82	28	.	.	PUNCT
dpc-4021	83	1	the	the	DET
dpc-4021	83	2	manifestations	manifestation	NOUN
dpc-4021	83	3	included	include	VERB
dpc-4021	83	4	in	in	ADP
dpc-4021	83	5	the	the	DET
dpc-4021	83	6	checklist	checklist	NOUN
dpc-4021	83	7	were	be	AUX
dpc-4021	83	8	nausea	nausea	NOUN
dpc-4021	83	9	,	,	PUNCT
dpc-4021	83	10	vomiting	vomiting	NOUN
dpc-4021	83	11	,	,	PUNCT
dpc-4021	83	12	diarrhea	diarrhea	NOUN
dpc-4021	83	13	,	,	PUNCT
dpc-4021	83	14	abdominal	abdominal	ADJ
dpc-4021	83	15	pain	pain	NOUN
dpc-4021	83	16	,	,	PUNCT
dpc-4021	83	17	dyspepsia	dyspepsia	NOUN
dpc-4021	83	18	,	,	PUNCT
dpc-4021	83	19	headache	headache	NOUN
dpc-4021	83	20	,	,	PUNCT
dpc-4021	83	21	dizziness	dizziness	NOUN
dpc-4021	83	22	,	,	PUNCT
dpc-4021	83	23	asthenia	asthenia	PROPN
dpc-4021	83	24	,	,	PUNCT
dpc-4021	83	25	back	back	NOUN
dpc-4021	83	26	pain	pain	NOUN
dpc-4021	83	27	,	,	PUNCT
dpc-4021	83	28	any	any	DET
dpc-4021	83	29	skin	skin	NOUN
dpc-4021	83	30	rash	rash	NOUN
dpc-4021	83	31	,	,	PUNCT
dpc-4021	83	32	pruritus	pruritus	NOUN
dpc-4021	83	33	and	and	CCONJ
dpc-4021	83	34	alopecia	alopecia	NOUN
dpc-4021	83	35	.	.	PUNCT
dpc-4021	84	1	statistical	statistical	ADJ
dpc-4021	84	2	analysis	analysis	NOUN
dpc-4021	84	3	the	the	DET
dpc-4021	84	4	statistical	statistical	ADJ
dpc-4021	84	5	package	package	NOUN
dpc-4021	84	6	for	for	ADP
dpc-4021	84	7	social	social	ADJ
dpc-4021	84	8	science	science	NOUN
dpc-4021	84	9	(	(	PUNCT
dpc-4021	84	10	spss	spss	PROPN
dpc-4021	84	11	)	)	PUNCT
dpc-4021	84	12	,	,	PUNCT
dpc-4021	84	13	version	version	NOUN
dpc-4021	84	14	20	20	NUM
dpc-4021	84	15	(	(	PUNCT
dpc-4021	84	16	ibm	ibm	PROPN
dpc-4021	84	17	®	®	NOUN
dpc-4021	84	18	spss	spss	PROPN
dpc-4021	84	19	®	®	PROPN
dpc-4021	84	20	inc	inc	PROPN
dpc-4021	84	21	.	.	PROPN
dpc-4021	84	22	)	)	PUNCT
dpc-4021	84	23	was	be	AUX
dpc-4021	84	24	used	use	VERB
dpc-4021	84	25	to	to	PART
dpc-4021	84	26	perform	perform	VERB
dpc-4021	84	27	all	all	DET
dpc-4021	84	28	analysis	analysis	NOUN
dpc-4021	84	29	.	.	PUNCT
dpc-4021	85	1	the	the	DET
dpc-4021	85	2	data	datum	NOUN
dpc-4021	85	3	were	be	AUX
dpc-4021	85	4	originally	originally	ADV
dpc-4021	85	5	anonymized	anonymize	VERB
dpc-4021	85	6	by	by	ADP
dpc-4021	85	7	coding	code	VERB
dpc-4021	85	8	and	and	CCONJ
dpc-4021	85	9	fed	feed	VERB
dpc-4021	85	10	to	to	ADP
dpc-4021	85	11	the	the	DET
dpc-4021	85	12	personal	personal	ADJ
dpc-4021	85	13	computer	computer	NOUN
dpc-4021	85	14	.	.	PUNCT
dpc-4021	86	1	categorical	categorical	ADJ
dpc-4021	86	2	variables	variable	NOUN
dpc-4021	86	3	were	be	AUX
dpc-4021	86	4	summarized	summarize	VERB
dpc-4021	86	5	by	by	ADP
dpc-4021	86	6	their	their	PRON
dpc-4021	86	7	relative	relative	ADJ
dpc-4021	86	8	frequency	frequency	NOUN
dpc-4021	86	9	and	and	CCONJ
dpc-4021	86	10	percentages	percentage	NOUN
dpc-4021	86	11	.	.	PUNCT
dpc-4021	87	1	however	however	ADV
dpc-4021	87	2	,	,	PUNCT
dpc-4021	87	3	the	the	DET
dpc-4021	87	4	quantitative	quantitative	ADJ
dpc-4021	87	5	variables	variable	NOUN
dpc-4021	87	6	were	be	AUX
dpc-4021	87	7	represented	represent	VERB
dpc-4021	87	8	by	by	ADP
dpc-4021	87	9	the	the	DET
dpc-4021	87	10	arithmetic	arithmetic	ADJ
dpc-4021	87	11	mean	mean	NOUN
dpc-4021	87	12	and	and	CCONJ
dpc-4021	87	13	standard	standard	ADJ
dpc-4021	87	14	deviation	deviation	NOUN
dpc-4021	87	15	(	(	PUNCT
dpc-4021	87	16	sd	sd	NOUN
dpc-4021	87	17	)	)	PUNCT
dpc-4021	87	18	,	,	PUNCT
dpc-4021	87	19	minimum	minimum	NOUN
dpc-4021	87	20	and	and	CCONJ
dpc-4021	87	21	maximum	maximum	ADJ
dpc-4021	87	22	when	when	SCONJ
dpc-4021	87	23	appropriate	appropriate	ADJ
dpc-4021	87	24	.	.	PUNCT
dpc-4021	88	1	groups	group	NOUN
dpc-4021	88	2	were	be	AUX
dpc-4021	88	3	compared	compare	VERB
dpc-4021	88	4	by	by	ADP
dpc-4021	88	5	student	student	NOUN
dpc-4021	88	6	t	t	PROPN
dpc-4021	88	7	test	test	NOUN
dpc-4021	88	8	when	when	SCONJ
dpc-4021	88	9	quantitative	quantitative	ADJ
dpc-4021	88	10	and	and	CCONJ
dpc-4021	88	11	compared	compare	VERB
dpc-4021	88	12	by	by	ADP
dpc-4021	88	13	pearson	pearson	PROPN
dpc-4021	88	14	chi	chi	PROPN
dpc-4021	88	15	-	-	PUNCT
dpc-4021	88	16	square	square	PROPN
dpc-4021	88	17	or	or	CCONJ
dpc-4021	88	18	fisher	fisher	PROPN
dpc-4021	88	19	exact	exact	ADJ
dpc-4021	88	20	test	test	NOUN
dpc-4021	88	21	(	(	PUNCT
dpc-4021	88	22	when	when	SCONJ
dpc-4021	88	23	appropriate	appropriate	ADJ
dpc-4021	88	24	)	)	PUNCT
dpc-4021	88	25	.	.	PUNCT
dpc-4021	89	1	p	p	NOUN
dpc-4021	89	2	value	value	NOUN
dpc-4021	89	3	≤	≤	NUM
dpc-4021	89	4	0.05	0.05	NUM
dpc-4021	89	5	was	be	AUX
dpc-4021	89	6	considered	consider	VERB
dpc-4021	89	7	statistically	statistically	ADV
dpc-4021	89	8	significant	significant	ADJ
dpc-4021	89	9	,	,	PUNCT
dpc-4021	89	10	at	at	ADP
dpc-4021	89	11	confidence	confidence	NOUN
dpc-4021	89	12	intervals	interval	NOUN
dpc-4021	89	13	(	(	PUNCT
dpc-4021	89	14	ci	ci	NOUN
dpc-4021	89	15	)	)	PUNCT
dpc-4021	89	16	of	of	ADP
dpc-4021	89	17	95.0	95.0	NUM
dpc-4021	89	18	%	%	NOUN
dpc-4021	89	19	.	.	PUNCT
dpc-4021	90	1	results	result	VERB
dpc-4021	90	2	forty	forty	NUM
dpc-4021	90	3	patients	patient	NOUN
dpc-4021	90	4	completed	complete	VERB
dpc-4021	90	5	the	the	DET
dpc-4021	90	6	study	study	NOUN
dpc-4021	90	7	and	and	CCONJ
dpc-4021	90	8	were	be	AUX
dpc-4021	90	9	included	include	VERB
dpc-4021	90	10	in	in	ADP
dpc-4021	90	11	the	the	DET
dpc-4021	90	12	analysis	analysis	NOUN
dpc-4021	90	13	.	.	PUNCT
dpc-4021	91	1	demographic	demographic	ADJ
dpc-4021	91	2	and	and	CCONJ
dpc-4021	91	3	clinical	clinical	ADJ
dpc-4021	91	4	characteristics	characteristic	NOUN
dpc-4021	91	5	of	of	ADP
dpc-4021	91	6	the	the	DET
dpc-4021	91	7	studied	study	VERB
dpc-4021	91	8	patients	patient	NOUN
dpc-4021	91	9	are	be	AUX
dpc-4021	91	10	listed	list	VERB
dpc-4021	91	11	in	in	ADP
dpc-4021	91	12	table	table	NOUN
dpc-4021	91	13	1	1	NUM
dpc-4021	91	14	.	.	PUNCT
dpc-4021	92	1	both	both	DET
dpc-4021	92	2	groups	group	NOUN
dpc-4021	92	3	showed	show	VERB
dpc-4021	92	4	matching	matching	NOUN
dpc-4021	92	5	characteristics	characteristic	NOUN
dpc-4021	92	6	in	in	ADP
dpc-4021	92	7	aspects	aspect	NOUN
dpc-4021	92	8	of	of	ADP
dpc-4021	92	9	gender	gender	NOUN
dpc-4021	92	10	,	,	PUNCT
dpc-4021	92	11	age	age	NOUN
dpc-4021	92	12	,	,	PUNCT
dpc-4021	92	13	disease	disease	NOUN
dpc-4021	92	14	duration	duration	NOUN
dpc-4021	92	15	and	and	CCONJ
dpc-4021	92	16	presence	presence	NOUN
dpc-4021	92	17	of	of	ADP
dpc-4021	92	18	positive	positive	ADJ
dpc-4021	92	19	family	family	NOUN
dpc-4021	92	20	history	history	NOUN
dpc-4021	92	21	.	.	PUNCT
dpc-4021	93	1	among	among	ADP
dpc-4021	93	2	the	the	DET
dpc-4021	93	3	methotrexate	methotrexate	NOUN
dpc-4021	93	4	group	group	NOUN
dpc-4021	93	5	(	(	PUNCT
dpc-4021	93	6	figures	figure	NOUN
dpc-4021	93	7	1	1	NUM
dpc-4021	93	8	-	-	SYM
dpc-4021	93	9	3	3	NUM
dpc-4021	93	10	)	)	PUNCT
dpc-4021	93	11	;	;	PUNCT
dpc-4021	93	12	the	the	DET
dpc-4021	93	13	mean	mean	ADJ
dpc-4021	93	14	pasi	pasi	NOUN
dpc-4021	93	15	score	score	NOUN
dpc-4021	93	16	at	at	ADP
dpc-4021	93	17	the	the	DET
dpc-4021	93	18	baseline	baseline	NOUN
dpc-4021	93	19	was	be	AUX
dpc-4021	93	20	33	33	NUM
dpc-4021	93	21	±	±	NUM
dpc-4021	93	22	11.68	11.68	NUM
dpc-4021	93	23	,	,	PUNCT
dpc-4021	93	24	by	by	ADP
dpc-4021	93	25	the	the	DET
dpc-4021	93	26	end	end	NOUN
dpc-4021	93	27	of	of	ADP
dpc-4021	93	28	the	the	DET
dpc-4021	93	29	fourth	fourth	ADJ
dpc-4021	93	30	week	week	NOUN
dpc-4021	93	31	it	it	PRON
dpc-4021	93	32	improved	improve	VERB
dpc-4021	93	33	to	to	ADP
dpc-4021	93	34	14.66	14.66	NUM
dpc-4021	93	35	±	±	NUM
dpc-4021	93	36	7.35	7.35	NUM
dpc-4021	93	37	and	and	CCONJ
dpc-4021	93	38	at	at	ADP
dpc-4021	93	39	the	the	DET
dpc-4021	93	40	end	end	NOUN
dpc-4021	93	41	of	of	ADP
dpc-4021	93	42	the	the	DET
dpc-4021	93	43	study	study	NOUN
dpc-4021	93	44	at	at	ADP
dpc-4021	93	45	week	week	NOUN
dpc-4021	93	46	12	12	NUM
dpc-4021	93	47	it	it	PRON
dpc-4021	93	48	improved	improve	VERB
dpc-4021	93	49	to	to	ADP
dpc-4021	93	50	1.95	1.95	NUM
dpc-4021	93	51	±	±	NUM
dpc-4021	93	52	1.33	1.33	NUM
dpc-4021	93	53	.	.	PUNCT
dpc-4021	94	1	while	while	SCONJ
dpc-4021	94	2	among	among	ADP
dpc-4021	94	3	the	the	DET
dpc-4021	94	4	leflunamide	leflunamide	NOUN
dpc-4021	94	5	group	group	NOUN
dpc-4021	94	6	(	(	PUNCT
dpc-4021	94	7	figures	figure	NOUN
dpc-4021	94	8	4	4	NUM
dpc-4021	94	9	-	-	SYM
dpc-4021	94	10	8)	8)	NUM
dpc-4021	94	11	;	;	PUNCT
dpc-4021	94	12	the	the	DET
dpc-4021	94	13	mean	mean	ADJ
dpc-4021	94	14	pasi	pasi	NOUN
dpc-4021	94	15	score	score	NOUN
dpc-4021	94	16	at	at	ADP
dpc-4021	94	17	the	the	DET
dpc-4021	94	18	baseline	baseline	NOUN
dpc-4021	94	19	was	be	AUX
dpc-4021	94	20	31.75	31.75	NUM
dpc-4021	94	21	±	±	NUM
dpc-4021	94	22	7.71	7.71	NUM
dpc-4021	94	23	and	and	CCONJ
dpc-4021	94	24	improved	improve	VERB
dpc-4021	94	25	at	at	ADP
dpc-4021	94	26	the	the	DET
dpc-4021	94	27	end	end	NOUN
dpc-4021	94	28	of	of	ADP
dpc-4021	94	29	the	the	DET
dpc-4021	94	30	4th	4th	ADJ
dpc-4021	94	31	week	week	NOUN
dpc-4021	94	32	to	to	ADP
dpc-4021	94	33	17.46	17.46	NUM
dpc-4021	94	34	and	and	CCONJ
dpc-4021	94	35	by	by	ADP
dpc-4021	94	36	the	the	DET
dpc-4021	94	37	end	end	NOUN
dpc-4021	94	38	of	of	ADP
dpc-4021	94	39	the	the	DET
dpc-4021	94	40	study	study	NOUN
dpc-4021	94	41	at	at	ADP
dpc-4021	94	42	week	week	NOUN
dpc-4021	94	43	12	12	NUM
dpc-4021	94	44	to	to	PART
dpc-4021	94	45	1.94	1.94	NUM
dpc-4021	94	46	±	±	NUM
dpc-4021	94	47	1.28	1.28	NUM
dpc-4021	94	48	.	.	PUNCT
dpc-4021	95	1	both	both	DET
dpc-4021	95	2	groups	group	NOUN
dpc-4021	95	3	showed	show	VERB
dpc-4021	95	4	comparable	comparable	ADJ
dpc-4021	95	5	improvement	improvement	NOUN
dpc-4021	95	6	at	at	ADP
dpc-4021	95	7	all	all	DET
dpc-4021	95	8	the	the	DET
dpc-4021	95	9	3	3	NUM
dpc-4021	95	10	visits	visit	NOUN
dpc-4021	95	11	(	(	PUNCT
dpc-4021	95	12	p	p	X
dpc-4021	95	13	=	=	NOUN
dpc-4021	95	14	0.693	0.693	NUM
dpc-4021	95	15	,	,	PUNCT
dpc-4021	95	16	0.141	0.141	NUM
dpc-4021	95	17	,	,	PUNCT
dpc-4021	95	18	0.99	0.99	NUM
dpc-4021	95	19	,	,	PUNCT
dpc-4021	95	20	respectively	respectively	ADV
dpc-4021	95	21	)	)	PUNCT
dpc-4021	95	22	.	.	PUNCT
dpc-4021	96	1	the	the	DET
dpc-4021	96	2	laboratory	laboratory	NOUN
dpc-4021	96	3	investigations	investigation	NOUN
dpc-4021	96	4	after	after	ADP
dpc-4021	96	5	12	12	NUM
dpc-4021	96	6	weeks	week	NOUN
dpc-4021	96	7	of	of	ADP
dpc-4021	96	8	treatment	treatment	NOUN
dpc-4021	96	9	were	be	AUX
dpc-4021	96	10	comparable	comparable	ADJ
dpc-4021	96	11	between	between	ADP
dpc-4021	96	12	both	both	PRON
dpc-4021	96	13	methotrexate	methotrexate	ADJ
dpc-4021	96	14	and	and	CCONJ
dpc-4021	96	15	leflunomide	leflunomide	ADJ
dpc-4021	96	16	groups	group	NOUN
dpc-4021	96	17	,	,	PUNCT
dpc-4021	96	18	except	except	SCONJ
dpc-4021	96	19	for	for	ADP
dpc-4021	96	20	significant	significant	ADJ
dpc-4021	96	21	increase	increase	NOUN
dpc-4021	96	22	in	in	ADP
dpc-4021	96	23	red	red	ADJ
dpc-4021	96	24	blood	blood	NOUN
dpc-4021	96	25	cell	cell	NOUN
dpc-4021	96	26	count	count	NOUN
dpc-4021	96	27	,	,	PUNCT
dpc-4021	96	28	hemoglobin	hemoglobin	NOUN
dpc-4021	96	29	concentrations	concentration	NOUN
dpc-4021	96	30	,	,	PUNCT
dpc-4021	96	31	and	and	CCONJ
dpc-4021	96	32	total	total	ADJ
dpc-4021	96	33	protein	protein	NOUN
dpc-4021	96	34	in	in	ADP
dpc-4021	96	35	the	the	DET
dpc-4021	96	36	methotrexate	methotrexate	NOUN
dpc-4021	96	37	group	group	NOUN
dpc-4021	96	38	,	,	PUNCT
dpc-4021	96	39	while	while	SCONJ
dpc-4021	96	40	albumin	albumin	NOUN
dpc-4021	96	41	was	be	AUX
dpc-4021	96	42	significantly	significantly	ADV
dpc-4021	96	43	lower	low	ADJ
dpc-4021	96	44	in	in	ADP
dpc-4021	96	45	methotrexate	methotrexate	NOUN
dpc-4021	96	46	than	than	ADP
dpc-4021	96	47	the	the	DET
dpc-4021	96	48	leflunomide	leflunomide	ADJ
dpc-4021	96	49	group	group	NOUN
dpc-4021	96	50	side	side	NOUN
dpc-4021	96	51	effects	effect	NOUN
dpc-4021	96	52	:	:	PUNCT
dpc-4021	96	53	no	no	DET
dpc-4021	96	54	table	table	NOUN
dpc-4021	96	55	1	1	NUM
dpc-4021	96	56	.	.	PUNCT
dpc-4021	96	57	demographic	demographic	ADJ
dpc-4021	96	58	and	and	CCONJ
dpc-4021	96	59	clinical	clinical	ADJ
dpc-4021	96	60	characteristics	characteristic	NOUN
dpc-4021	96	61	among	among	ADP
dpc-4021	96	62	study	study	NOUN
dpc-4021	96	63	groups	group	NOUN
dpc-4021	96	64	variables	variable	NOUN
dpc-4021	96	65	methotrexate	methotrexate	VERB
dpc-4021	96	66	group	group	PROPN
dpc-4021	96	67	(	(	PUNCT
dpc-4021	96	68	n=20	n=20	PROPN
dpc-4021	96	69	)	)	PUNCT
dpc-4021	96	70	leflunomide	leflunomide	ADJ
dpc-4021	96	71	group	group	NOUN
dpc-4021	96	72	(	(	PUNCT
dpc-4021	96	73	n=20	n=20	PROPN
dpc-4021	96	74	)	)	PUNCT
dpc-4021	96	75	p	p	NOUN
dpc-4021	96	76	value	value	NOUN
dpc-4021	96	77	sex	sex	NOUN
dpc-4021	96	78	(	(	PUNCT
dpc-4021	96	79	n	n	CCONJ
dpc-4021	96	80	,	,	PUNCT
dpc-4021	96	81	%	%	INTJ
dpc-4021	96	82	)	)	PUNCT
dpc-4021	96	83	male	male	ADJ
dpc-4021	96	84	female	female	ADJ
dpc-4021	96	85	11	11	NUM
dpc-4021	96	86	(	(	PUNCT
dpc-4021	96	87	55.0	55.0	NUM
dpc-4021	96	88	%	%	NOUN
dpc-4021	96	89	)	)	PUNCT
dpc-4021	96	90	9	9	NUM
dpc-4021	96	91	(	(	PUNCT
dpc-4021	96	92	45.0	45.0	NUM
dpc-4021	96	93	%	%	NOUN
dpc-4021	96	94	)	)	PUNCT
dpc-4021	96	95	14	14	NUM
dpc-4021	96	96	(	(	PUNCT
dpc-4021	96	97	70.0	70.0	NUM
dpc-4021	96	98	%	%	NOUN
dpc-4021	96	99	)	)	PUNCT
dpc-4021	96	100	6	6	NUM
dpc-4021	96	101	(	(	PUNCT
dpc-4021	96	102	30.0	30.0	NUM
dpc-4021	96	103	%	%	NOUN
dpc-4021	96	104	)	)	PUNCT
dpc-4021	96	105	0.327	0.327	NUM
dpc-4021	96	106	age	age	NOUN
dpc-4021	96	107	(	(	PUNCT
dpc-4021	96	108	years	year	NOUN
dpc-4021	96	109	)	)	PUNCT
dpc-4021	96	110	mean±sd	mean±sd	ADP
dpc-4021	96	111	38.9	38.9	NUM
dpc-4021	96	112	±	±	NUM
dpc-4021	96	113	12.88	12.88	NUM
dpc-4021	96	114	37.6	37.6	NUM
dpc-4021	96	115	±	±	NUM
dpc-4021	96	116	13.6	13.6	NUM
dpc-4021	96	117	0.758	0.758	NUM
dpc-4021	96	118	range	range	NOUN
dpc-4021	96	119	(	(	PUNCT
dpc-4021	96	120	min	min	NOUN
dpc-4021	96	121	.	.	PROPN
dpc-4021	96	122	–	–	PUNCT
dpc-4021	96	123	max	max	PROPN
dpc-4021	96	124	.	.	PUNCT
dpc-4021	96	125	)	)	PUNCT
dpc-4021	96	126	42	42	NUM
dpc-4021	96	127	(	(	PUNCT
dpc-4021	96	128	18	18	NUM
dpc-4021	96	129	60	60	NUM
dpc-4021	96	130	)	)	PUNCT
dpc-4021	96	131	33	33	NUM
dpc-4021	96	132	(	(	PUNCT
dpc-4021	96	133	26	26	NUM
dpc-4021	96	134	59	59	NUM
dpc-4021	96	135	)	)	PUNCT
dpc-4021	96	136	occupation	occupation	NOUN
dpc-4021	96	137	(	(	PUNCT
dpc-4021	96	138	n	n	CCONJ
dpc-4021	96	139	,	,	PUNCT
dpc-4021	96	140	%	%	INTJ
dpc-4021	96	141	)	)	PUNCT
dpc-4021	96	142	housewife	housewife	NOUN
dpc-4021	96	143	4	4	NUM
dpc-4021	96	144	(	(	PUNCT
dpc-4021	96	145	20	20	NUM
dpc-4021	96	146	%	%	NOUN
dpc-4021	96	147	)	)	PUNCT
dpc-4021	96	148	6	6	NUM
dpc-4021	96	149	(	(	PUNCT
dpc-4021	96	150	30	30	NUM
dpc-4021	96	151	%	%	NOUN
dpc-4021	96	152	)	)	PUNCT
dpc-4021	96	153	0.902	0.902	NUM
dpc-4021	96	154	employee	employee	NOUN
dpc-4021	96	155	8	8	NUM
dpc-4021	96	156	(	(	PUNCT
dpc-4021	96	157	40	40	NUM
dpc-4021	96	158	%	%	NOUN
dpc-4021	96	159	)	)	PUNCT
dpc-4021	96	160	7	7	NUM
dpc-4021	96	161	(	(	PUNCT
dpc-4021	96	162	35	35	NUM
dpc-4021	96	163	%	%	NOUN
dpc-4021	96	164	)	)	PUNCT
dpc-4021	96	165	student	student	NOUN
dpc-4021	96	166	3	3	NUM
dpc-4021	96	167	(	(	PUNCT
dpc-4021	96	168	15	15	NUM
dpc-4021	96	169	%	%	NOUN
dpc-4021	96	170	)	)	PUNCT
dpc-4021	96	171	3	3	NUM
dpc-4021	96	172	(	(	PUNCT
dpc-4021	96	173	15	15	NUM
dpc-4021	96	174	%	%	NOUN
dpc-4021	96	175	)	)	PUNCT
dpc-4021	96	176	other	other	ADJ
dpc-4021	96	177	5	5	NUM
dpc-4021	96	178	(	(	PUNCT
dpc-4021	96	179	25	25	NUM
dpc-4021	96	180	%	%	NOUN
dpc-4021	96	181	)	)	PUNCT
dpc-4021	96	182	4	4	NUM
dpc-4021	96	183	(	(	PUNCT
dpc-4021	96	184	20	20	NUM
dpc-4021	96	185	%	%	NOUN
dpc-4021	96	186	)	)	PUNCT
dpc-4021	96	187	economic	economic	ADJ
dpc-4021	96	188	status	status	NOUN
dpc-4021	96	189	(	(	PUNCT
dpc-4021	96	190	n	n	CCONJ
dpc-4021	96	191	,	,	PUNCT
dpc-4021	96	192	%	%	INTJ
dpc-4021	96	193	)	)	PUNCT
dpc-4021	96	194	high	high	ADJ
dpc-4021	96	195	2	2	NUM
dpc-4021	96	196	(	(	PUNCT
dpc-4021	96	197	10	10	NUM
dpc-4021	96	198	%	%	NOUN
dpc-4021	96	199	)	)	PUNCT
dpc-4021	96	200	2	2	NUM
dpc-4021	96	201	(	(	PUNCT
dpc-4021	96	202	10	10	NUM
dpc-4021	96	203	%	%	NOUN
dpc-4021	96	204	)	)	PUNCT
dpc-4021	96	205	0.891	0.891	NUM
dpc-4021	96	206	intermediate	intermediate	ADJ
dpc-4021	96	207	16	16	NUM
dpc-4021	96	208	(	(	PUNCT
dpc-4021	96	209	80	80	NUM
dpc-4021	96	210	%	%	NOUN
dpc-4021	96	211	)	)	PUNCT
dpc-4021	96	212	15	15	NUM
dpc-4021	96	213	(	(	PUNCT
dpc-4021	96	214	75	75	NUM
dpc-4021	96	215	%	%	NOUN
dpc-4021	96	216	)	)	PUNCT
dpc-4021	96	217	low	low	ADJ
dpc-4021	96	218	2	2	NUM
dpc-4021	96	219	(	(	PUNCT
dpc-4021	96	220	10	10	NUM
dpc-4021	96	221	%	%	NOUN
dpc-4021	96	222	)	)	PUNCT
dpc-4021	96	223	3	3	NUM
dpc-4021	96	224	(	(	PUNCT
dpc-4021	96	225	15	15	NUM
dpc-4021	96	226	%	%	NOUN
dpc-4021	96	227	)	)	PUNCT
dpc-4021	96	228	fh	fh	INTJ
dpc-4021	96	229	of	of	ADP
dpc-4021	96	230	psoriasis	psoriasis	NOUN
dpc-4021	96	231	2	2	NUM
dpc-4021	96	232	(	(	PUNCT
dpc-4021	96	233	10	10	NUM
dpc-4021	96	234	%	%	NOUN
dpc-4021	96	235	)	)	PUNCT
dpc-4021	96	236	3	3	NUM
dpc-4021	96	237	(	(	PUNCT
dpc-4021	96	238	15	15	NUM
dpc-4021	96	239	%	%	NOUN
dpc-4021	96	240	)	)	PUNCT
dpc-4021	96	241	0.663	0.663	NUM
dpc-4021	96	242	duration	duration	NOUN
dpc-4021	96	243	of	of	ADP
dpc-4021	96	244	the	the	DET
dpc-4021	96	245	disease	disease	NOUN
dpc-4021	96	246	mean±sd	mean±sd	ADP
dpc-4021	96	247	11.2	11.2	NUM
dpc-4021	96	248	±	±	NUM
dpc-4021	96	249	8.69	8.69	NUM
dpc-4021	96	250	10.75	10.75	NUM
dpc-4021	96	251	±	±	NUM
dpc-4021	96	252	8.06	8.06	NUM
dpc-4021	96	253	0.866	0.866	NUM
dpc-4021	96	254	range	range	NOUN
dpc-4021	96	255	(	(	PUNCT
dpc-4021	96	256	min	min	NOUN
dpc-4021	96	257	.	.	PROPN
dpc-4021	96	258	–	–	PUNCT
dpc-4021	96	259	max	max	PROPN
dpc-4021	96	260	.	.	PUNCT
dpc-4021	96	261	)	)	PUNCT
dpc-4021	97	1	28	28	NUM
dpc-4021	97	2	(	(	PUNCT
dpc-4021	97	3	2	2	NUM
dpc-4021	97	4	30	30	NUM
dpc-4021	97	5	)	)	PUNCT
dpc-4021	97	6	27	27	NUM
dpc-4021	97	7	(	(	PUNCT
dpc-4021	97	8	3	3	NUM
dpc-4021	97	9	30	30	NUM
dpc-4021	97	10	)	)	PUNCT
dpc-4021	97	11	fh	fh	NOUN
dpc-4021	97	12	=	=	PUNCT
dpc-4021	97	13	positive	positive	ADJ
dpc-4021	97	14	family	family	NOUN
dpc-4021	97	15	history	history	NOUN
dpc-4021	97	16	…	…	PUNCT
dpc-4021	97	17	;	;	PUNCT
dpc-4021	97	18	sd	sd	NOUN
dpc-4021	97	19	=	=	SYM
dpc-4021	97	20	standard	standard	ADJ
dpc-4021	97	21	deviation	deviation	NOUN
dpc-4021	97	22	.	.	PUNCT
dpc-4021	98	1	4	4	NUM
dpc-4021	98	2	original	original	ADJ
dpc-4021	98	3	article	article	NOUN
dpc-4021	98	4	|	|	ADV
dpc-4021	98	5	dermatol	dermatol	ADJ
dpc-4021	98	6	pract	pract	NOUN
dpc-4021	98	7	concept	concept	NOUN
dpc-4021	98	8	.	.	PUNCT
dpc-4021	99	1	2024;14(3):e2024165	2024;14(3):e2024165	NUM
dpc-4021	99	2	figure	figure	NOUN
dpc-4021	99	3	1	1	NUM
dpc-4021	99	4	.	.	PUNCT
dpc-4021	99	5	male	male	ADJ
dpc-4021	99	6	patient	patient	NOUN
dpc-4021	99	7	,	,	PUNCT
dpc-4021	99	8	60	60	NUM
dpc-4021	99	9	years	year	NOUN
dpc-4021	99	10	old	old	ADJ
dpc-4021	99	11	,	,	PUNCT
dpc-4021	99	12	with	with	ADP
dpc-4021	99	13	psoriasis	psoriasis	NOUN
dpc-4021	99	14	vulgaris	vulgaris	NOUN
dpc-4021	99	15	his	his	PRON
dpc-4021	99	16	psoriasis	psoriasis	NOUN
dpc-4021	99	17	area	area	NOUN
dpc-4021	99	18	severity	severity	NOUN
dpc-4021	99	19	index	index	NOUN
dpc-4021	99	20	(	(	PUNCT
dpc-4021	99	21	a	a	NOUN
dpc-4021	99	22	)	)	PUNCT
dpc-4021	99	23	before	before	ADP
dpc-4021	99	24	metotrexate	metotrexate	NOUN
dpc-4021	99	25	was	be	AUX
dpc-4021	99	26	34.1	34.1	NUM
dpc-4021	99	27	that	that	PRON
dpc-4021	99	28	decreased	decrease	VERB
dpc-4021	99	29	to	to	ADP
dpc-4021	99	30	0	0	NUM
dpc-4021	99	31	(	(	PUNCT
dpc-4021	99	32	b	b	NOUN
dpc-4021	99	33	)	)	PUNCT
dpc-4021	99	34	after	after	ADP
dpc-4021	99	35	12	12	NUM
dpc-4021	99	36	weeks	week	NOUN
dpc-4021	99	37	of	of	ADP
dpc-4021	99	38	treatment	treatment	NOUN
dpc-4021	99	39	.	.	PUNCT
dpc-4021	100	1	figure	figure	NOUN
dpc-4021	100	2	2	2	NUM
dpc-4021	100	3	.	.	PUNCT
dpc-4021	100	4	male	male	ADJ
dpc-4021	100	5	patient	patient	NOUN
dpc-4021	100	6	,	,	PUNCT
dpc-4021	100	7	55	55	NUM
dpc-4021	100	8	years	year	NOUN
dpc-4021	100	9	old	old	ADJ
dpc-4021	100	10	,	,	PUNCT
dpc-4021	100	11	with	with	ADP
dpc-4021	100	12	psoriasis	psoriasis	NOUN
dpc-4021	100	13	vulgaris	vulgaris	NOUN
dpc-4021	100	14	his	his	PRON
dpc-4021	100	15	psoriasis	psoriasis	NOUN
dpc-4021	100	16	area	area	NOUN
dpc-4021	100	17	severity	severity	NOUN
dpc-4021	100	18	index	index	NOUN
dpc-4021	100	19	(	(	PUNCT
dpc-4021	100	20	a	a	NOUN
dpc-4021	100	21	)	)	PUNCT
dpc-4021	100	22	before	before	ADP
dpc-4021	100	23	metotrexate	metotrexate	NOUN
dpc-4021	100	24	was	be	AUX
dpc-4021	100	25	43.1	43.1	NUM
dpc-4021	100	26	that	that	PRON
dpc-4021	100	27	decreased	decrease	VERB
dpc-4021	100	28	to	to	ADP
dpc-4021	100	29	0	0	NUM
dpc-4021	101	1	(	(	PUNCT
dpc-4021	101	2	b	b	NOUN
dpc-4021	101	3	)	)	PUNCT
dpc-4021	101	4	after	after	ADP
dpc-4021	101	5	12	12	NUM
dpc-4021	101	6	weeks	week	NOUN
dpc-4021	101	7	of	of	ADP
dpc-4021	101	8	treatment	treatment	NOUN
dpc-4021	101	9	.	.	PUNCT
dpc-4021	102	1	figure	figure	NOUN
dpc-4021	102	2	3	3	NUM
dpc-4021	102	3	.	.	PUNCT
dpc-4021	102	4	male	male	ADJ
dpc-4021	102	5	patient	patient	NOUN
dpc-4021	102	6	,	,	PUNCT
dpc-4021	102	7	40	40	NUM
dpc-4021	102	8	years	year	NOUN
dpc-4021	102	9	old	old	ADJ
dpc-4021	102	10	,	,	PUNCT
dpc-4021	102	11	with	with	ADP
dpc-4021	102	12	psoriasis	psoriasis	NOUN
dpc-4021	102	13	vulgaris	vulgaris	NOUN
dpc-4021	102	14	his	his	PRON
dpc-4021	102	15	psoriasis	psoriasis	NOUN
dpc-4021	102	16	area	area	NOUN
dpc-4021	102	17	severity	severity	NOUN
dpc-4021	102	18	index	index	NOUN
dpc-4021	102	19	(	(	PUNCT
dpc-4021	102	20	a	a	NOUN
dpc-4021	102	21	)	)	PUNCT
dpc-4021	102	22	before	before	ADP
dpc-4021	102	23	metotrexate	metotrexate	NOUN
dpc-4021	102	24	was	be	AUX
dpc-4021	102	25	34.2	34.2	NUM
dpc-4021	102	26	that	that	PRON
dpc-4021	102	27	decreased	decrease	VERB
dpc-4021	102	28	to	to	ADP
dpc-4021	102	29	2.3	2.3	NUM
dpc-4021	102	30	(	(	PUNCT
dpc-4021	102	31	b	b	NOUN
dpc-4021	102	32	)	)	PUNCT
dpc-4021	102	33	after	after	ADP
dpc-4021	102	34	12	12	NUM
dpc-4021	102	35	weeks	week	NOUN
dpc-4021	102	36	of	of	ADP
dpc-4021	102	37	treatment	treatment	NOUN
dpc-4021	102	38	.	.	PUNCT
dpc-4021	103	1	original	original	ADJ
dpc-4021	103	2	article	article	NOUN
dpc-4021	103	3	|	|	ADV
dpc-4021	103	4	dermatol	dermatol	ADJ
dpc-4021	103	5	pract	pract	NOUN
dpc-4021	103	6	concept	concept	NOUN
dpc-4021	103	7	.	.	PUNCT
dpc-4021	104	1	2024;14(3):e2024165	2024;14(3):e2024165	NUM
dpc-4021	104	2	5	5	NUM
dpc-4021	104	3	figure	figure	NOUN
dpc-4021	104	4	4	4	NUM
dpc-4021	104	5	.	.	PUNCT
dpc-4021	104	6	female	female	ADJ
dpc-4021	104	7	patient	patient	NOUN
dpc-4021	104	8	60	60	NUM
dpc-4021	104	9	years	year	NOUN
dpc-4021	104	10	old	old	ADJ
dpc-4021	104	11	with	with	ADP
dpc-4021	104	12	psoriasis	psoriasis	NOUN
dpc-4021	104	13	vulgaris	vulgaris	NOUN
dpc-4021	104	14	her	her	PRON
dpc-4021	104	15	psoriasis	psoriasis	NOUN
dpc-4021	104	16	area	area	NOUN
dpc-4021	104	17	severity	severity	NOUN
dpc-4021	104	18	index	index	NOUN
dpc-4021	104	19	(	(	PUNCT
dpc-4021	104	20	a	a	NOUN
dpc-4021	104	21	)	)	PUNCT
dpc-4021	104	22	before	before	ADP
dpc-4021	104	23	oral	oral	ADJ
dpc-4021	104	24	leflunomide	leflunomide	NOUN
dpc-4021	104	25	was	be	AUX
dpc-4021	104	26	36.3	36.3	NUM
dpc-4021	104	27	that	that	PRON
dpc-4021	104	28	decreased	decrease	VERB
dpc-4021	104	29	to	to	ADP
dpc-4021	104	30	2.5	2.5	NUM
dpc-4021	104	31	(	(	PUNCT
dpc-4021	104	32	b	b	NOUN
dpc-4021	104	33	)	)	PUNCT
dpc-4021	104	34	after	after	ADP
dpc-4021	104	35	12	12	NUM
dpc-4021	104	36	weeks	week	NOUN
dpc-4021	104	37	of	of	ADP
dpc-4021	104	38	treatment	treatment	NOUN
dpc-4021	104	39	.	.	PUNCT
dpc-4021	105	1	figure	figure	NOUN
dpc-4021	105	2	5	5	NUM
dpc-4021	105	3	.	.	PUNCT
dpc-4021	105	4	male	male	ADJ
dpc-4021	105	5	patient	patient	NOUN
dpc-4021	105	6	27	27	NUM
dpc-4021	105	7	years	year	NOUN
dpc-4021	105	8	old	old	ADJ
dpc-4021	105	9	with	with	ADP
dpc-4021	105	10	psoriasis	psoriasis	NOUN
dpc-4021	105	11	vulgaris	vulgaris	NOUN
dpc-4021	105	12	his	his	PRON
dpc-4021	105	13	psoriasis	psoriasis	NOUN
dpc-4021	105	14	area	area	NOUN
dpc-4021	105	15	severity	severity	NOUN
dpc-4021	105	16	index	index	NOUN
dpc-4021	105	17	(	(	PUNCT
dpc-4021	105	18	a	a	NOUN
dpc-4021	105	19	)	)	PUNCT
dpc-4021	105	20	before	before	ADP
dpc-4021	105	21	oral	oral	ADJ
dpc-4021	105	22	leflunomide	leflunomide	NOUN
dpc-4021	105	23	was	be	AUX
dpc-4021	105	24	21.6	21.6	NUM
dpc-4021	105	25	that	that	PRON
dpc-4021	105	26	decreased	decrease	VERB
dpc-4021	105	27	to	to	ADP
dpc-4021	105	28	2.4	2.4	NUM
dpc-4021	105	29	(	(	PUNCT
dpc-4021	105	30	b	b	NOUN
dpc-4021	105	31	)	)	PUNCT
dpc-4021	105	32	after	after	ADP
dpc-4021	105	33	12	12	NUM
dpc-4021	105	34	weeks	week	NOUN
dpc-4021	105	35	of	of	ADP
dpc-4021	105	36	treatment	treatment	NOUN
dpc-4021	105	37	.	.	PUNCT
dpc-4021	106	1	significant	significant	ADJ
dpc-4021	106	2	difference	difference	NOUN
dpc-4021	106	3	was	be	AUX
dpc-4021	106	4	found	find	VERB
dpc-4021	106	5	between	between	ADP
dpc-4021	106	6	both	both	DET
dpc-4021	106	7	groups	group	NOUN
dpc-4021	106	8	in	in	ADP
dpc-4021	106	9	any	any	PRON
dpc-4021	106	10	of	of	ADP
dpc-4021	106	11	the	the	DET
dpc-4021	106	12	reported	report	VERB
dpc-4021	106	13	side	side	NOUN
dpc-4021	106	14	effects	effect	NOUN
dpc-4021	106	15	.	.	PUNCT
dpc-4021	107	1	none	none	NOUN
dpc-4021	107	2	of	of	ADP
dpc-4021	107	3	the	the	DET
dpc-4021	107	4	patients	patient	NOUN
dpc-4021	107	5	among	among	ADP
dpc-4021	107	6	both	both	DET
dpc-4021	107	7	groups	group	NOUN
dpc-4021	107	8	discontinued	discontinue	VERB
dpc-4021	107	9	the	the	DET
dpc-4021	107	10	treatment	treatment	NOUN
dpc-4021	107	11	because	because	SCONJ
dpc-4021	107	12	of	of	ADP
dpc-4021	107	13	the	the	DET
dpc-4021	107	14	side	side	NOUN
dpc-4021	107	15	effects	effect	NOUN
dpc-4021	107	16	,	,	PUNCT
dpc-4021	107	17	nausea	nausea	NOUN
dpc-4021	107	18	and	and	CCONJ
dpc-4021	107	19	vomiting	vomiting	NOUN
dpc-4021	107	20	were	be	AUX
dpc-4021	107	21	the	the	DET
dpc-4021	107	22	most	most	ADV
dpc-4021	107	23	frequent	frequent	ADJ
dpc-4021	107	24	side	side	NOUN
dpc-4021	107	25	effect	effect	NOUN
dpc-4021	107	26	among	among	ADP
dpc-4021	107	27	patients	patient	NOUN
dpc-4021	107	28	within	within	ADP
dpc-4021	107	29	the	the	DET
dpc-4021	107	30	leflunamide	leflunamide	NOUN
dpc-4021	107	31	group	group	NOUN
dpc-4021	107	32	,	,	PUNCT
dpc-4021	107	33	this	this	PRON
dpc-4021	107	34	was	be	AUX
dpc-4021	107	35	similar	similar	ADJ
dpc-4021	107	36	to	to	ADP
dpc-4021	107	37	the	the	DET
dpc-4021	107	38	methotrexate	methotrexate	NOUN
dpc-4021	107	39	group	group	NOUN
dpc-4021	107	40	(	(	PUNCT
dpc-4021	107	41	p	p	NOUN
dpc-4021	107	42	=	=	SYM
dpc-4021	107	43	677	677	NUM
dpc-4021	107	44	and	and	CCONJ
dpc-4021	107	45	465	465	NUM
dpc-4021	107	46	respectively	respectively	ADV
dpc-4021	107	47	)	)	PUNCT
dpc-4021	107	48	.	.	PUNCT
dpc-4021	108	1	gastrointestinal	gastrointestinal	ADJ
dpc-4021	108	2	manifestation	manifestation	PROPN
dpc-4021	108	3	,	,	PUNCT
dpc-4021	108	4	general	general	ADJ
dpc-4021	108	5	and	and	CCONJ
dpc-4021	108	6	dermatological	dermatological	ADJ
dpc-4021	108	7	side	side	NOUN
dpc-4021	108	8	effects	effect	NOUN
dpc-4021	108	9	were	be	AUX
dpc-4021	108	10	comparable	comparable	ADJ
dpc-4021	108	11	between	between	ADP
dpc-4021	108	12	both	both	DET
dpc-4021	108	13	groups	group	NOUN
dpc-4021	108	14	(	(	PUNCT
dpc-4021	108	15	table	table	NOUN
dpc-4021	108	16	2	2	NUM
dpc-4021	108	17	)	)	PUNCT
dpc-4021	108	18	.	.	PUNCT
dpc-4021	109	1	conclusions	conclusion	NOUN
dpc-4021	109	2	methotrexate	methotrexate	NOUN
dpc-4021	109	3	has	have	AUX
dpc-4021	109	4	been	be	AUX
dpc-4021	109	5	the	the	DET
dpc-4021	109	6	treatment	treatment	NOUN
dpc-4021	109	7	of	of	ADP
dpc-4021	109	8	choice	choice	NOUN
dpc-4021	109	9	for	for	ADP
dpc-4021	109	10	severe	severe	ADJ
dpc-4021	109	11	psoriasis	psoriasis	NOUN
dpc-4021	109	12	for	for	ADP
dpc-4021	109	13	decades	decade	NOUN
dpc-4021	109	14	the	the	DET
dpc-4021	109	15	main	main	ADJ
dpc-4021	109	16	objective	objective	NOUN
dpc-4021	109	17	of	of	ADP
dpc-4021	109	18	the	the	DET
dpc-4021	109	19	current	current	ADJ
dpc-4021	109	20	study	study	NOUN
dpc-4021	109	21	was	be	AUX
dpc-4021	109	22	to	to	PART
dpc-4021	109	23	compare	compare	VERB
dpc-4021	109	24	the	the	DET
dpc-4021	109	25	efficacy	efficacy	NOUN
dpc-4021	109	26	and	and	CCONJ
dpc-4021	109	27	safety	safety	NOUN
dpc-4021	109	28	of	of	ADP
dpc-4021	109	29	the	the	DET
dpc-4021	109	30	anti	anti	ADJ
dpc-4021	109	31	-	-	ADJ
dpc-4021	109	32	arthritic	arthritic	ADJ
dpc-4021	109	33	medication	medication	NOUN
dpc-4021	109	34	leflunamide	leflunamide	NOUN
dpc-4021	109	35	versus	versus	X
dpc-4021	109	36	methotrexate	methotrexate	NOUN
dpc-4021	109	37	in	in	ADP
dpc-4021	109	38	treating	treat	VERB
dpc-4021	109	39	moderate	moderate	ADJ
dpc-4021	109	40	to	to	ADP
dpc-4021	109	41	severe	severe	ADJ
dpc-4021	109	42	cases	case	NOUN
dpc-4021	109	43	with	with	ADP
dpc-4021	109	44	psoriasis	psoriasis	NOUN
dpc-4021	109	45	[	[	X
dpc-4021	109	46	16	16	NUM
dpc-4021	109	47	]	]	PUNCT
dpc-4021	109	48	.	.	PUNCT
dpc-4021	110	1	leflunomide	leflunomide	ADJ
dpc-4021	110	2	,	,	PUNCT
dpc-4021	110	3	a	a	DET
dpc-4021	110	4	disease	disease	NOUN
dpc-4021	110	5	-	-	PUNCT
dpc-4021	110	6	modifying	modify	VERB
dpc-4021	110	7	antirheumatic	antirheumatic	ADJ
dpc-4021	110	8	drug	drug	NOUN
dpc-4021	110	9	,	,	PUNCT
dpc-4021	110	10	was	be	AUX
dpc-4021	110	11	initially	initially	ADV
dpc-4021	110	12	licensed	license	VERB
dpc-4021	110	13	for	for	ADP
dpc-4021	110	14	the	the	DET
dpc-4021	110	15	treatment	treatment	NOUN
dpc-4021	110	16	of	of	ADP
dpc-4021	110	17	psoriatic	psoriatic	ADJ
dpc-4021	110	18	arthritis	arthritis	NOUN
dpc-4021	110	19	.	.	PUNCT
dpc-4021	111	1	patients	patient	NOUN
dpc-4021	111	2	treated	treat	VERB
dpc-4021	111	3	with	with	ADP
dpc-4021	111	4	leflunamide	leflunamide	NOUN
dpc-4021	111	5	for	for	ADP
dpc-4021	111	6	psoriatic	psoriatic	ADJ
dpc-4021	111	7	arthritis	arthritis	NOUN
dpc-4021	111	8	showed	show	VERB
dpc-4021	111	9	promising	promise	VERB
dpc-4021	111	10	short	short	ADJ
dpc-4021	111	11	and	and	CCONJ
dpc-4021	111	12	long	long	ADJ
dpc-4021	111	13	-	-	PUNCT
dpc-4021	111	14	term	term	NOUN
dpc-4021	111	15	improvement	improvement	NOUN
dpc-4021	111	16	of	of	ADP
dpc-4021	111	17	cutaneous	cutaneous	ADJ
dpc-4021	111	18	psoriasis	psoriasis	NOUN
dpc-4021	111	19	lesions	lesion	NOUN
dpc-4021	111	20	suggesting	suggest	VERB
dpc-4021	111	21	that	that	SCONJ
dpc-4021	111	22	it	it	PRON
dpc-4021	111	23	can	can	AUX
dpc-4021	111	24	be	be	AUX
dpc-4021	111	25	a	a	DET
dpc-4021	111	26	good	good	ADJ
dpc-4021	111	27	potential	potential	NOUN
dpc-4021	111	28	for	for	ADP
dpc-4021	111	29	treating	treat	VERB
dpc-4021	111	30	psoriasis	psoriasis	NOUN
dpc-4021	111	31	[	[	X
dpc-4021	111	32	17	17	NUM
dpc-4021	111	33	]	]	PUNCT
dpc-4021	111	34	.	.	PUNCT
dpc-4021	112	1	our	our	PRON
dpc-4021	112	2	results	result	NOUN
dpc-4021	112	3	were	be	AUX
dpc-4021	112	4	in	in	ADP
dpc-4021	112	5	accordance	accordance	NOUN
dpc-4021	112	6	with	with	ADP
dpc-4021	112	7	previous	previous	ADJ
dpc-4021	112	8	double	double	ADJ
dpc-4021	112	9	blinded	blind	VERB
dpc-4021	112	10	trials	trial	NOUN
dpc-4021	112	11	studied	study	VERB
dpc-4021	112	12	leflunomide	leflunomide	ADV
dpc-4021	112	13	as	as	ADP
dpc-4021	112	14	a	a	DET
dpc-4021	112	15	monotherapy	monotherapy	NOUN
dpc-4021	112	16	for	for	ADP
dpc-4021	112	17	psoriasis	psoriasis	NOUN
dpc-4021	112	18	compared	compare	VERB
dpc-4021	112	19	to	to	ADP
dpc-4021	112	20	placebo	placebo	NOUN
dpc-4021	112	21	[	[	PUNCT
dpc-4021	112	22	18	18	NUM
dpc-4021	112	23	-	-	SYM
dpc-4021	112	24	20	20	NUM
dpc-4021	112	25	]	]	PUNCT
dpc-4021	112	26	.	.	PUNCT
dpc-4021	113	1	compared	compare	VERB
dpc-4021	113	2	to	to	ADP
dpc-4021	113	3	placebo	placebo	NOUN
dpc-4021	113	4	;	;	PUNCT
dpc-4021	113	5	these	these	DET
dpc-4021	113	6	studies	study	NOUN
dpc-4021	113	7	showed	show	VERB
dpc-4021	113	8	significant	significant	ADJ
dpc-4021	113	9	reduction	reduction	NOUN
dpc-4021	113	10	of	of	ADP
dpc-4021	113	11	pasi	pasi	NOUN
dpc-4021	113	12	among	among	ADP
dpc-4021	113	13	treated	treat	VERB
dpc-4021	113	14	patients	patient	NOUN
dpc-4021	113	15	.	.	PUNCT
dpc-4021	114	1	we	we	PRON
dpc-4021	114	2	suggest	suggest	VERB
dpc-4021	114	3	that	that	SCONJ
dpc-4021	114	4	the	the	DET
dpc-4021	114	5	effect	effect	NOUN
dpc-4021	114	6	of	of	ADP
dpc-4021	114	7	leflunomide	leflunomide	NOUN
dpc-4021	114	8	on	on	ADP
dpc-4021	114	9	psoriasis	psoriasis	NOUN
dpc-4021	114	10	could	could	AUX
dpc-4021	114	11	be	be	AUX
dpc-4021	114	12	attributed	attribute	VERB
dpc-4021	114	13	to	to	ADP
dpc-4021	114	14	prevention	prevention	NOUN
dpc-4021	114	15	of	of	ADP
dpc-4021	114	16	pyrimidine	pyrimidine	NOUN
dpc-4021	114	17	synthesis	synthesis	NOUN
dpc-4021	114	18	pathway	pathway	NOUN
dpc-4021	114	19	by	by	ADP
dpc-4021	114	20	inhibiting	inhibit	VERB
dpc-4021	114	21	the	the	DET
dpc-4021	114	22	enzyme	enzyme	NOUN
dpc-4021	114	23	dihydroorotate	dihydroorotate	NOUN
dpc-4021	114	24	dehydrogenase	dehydrogenase	NOUN
dpc-4021	114	25	on	on	ADP
dpc-4021	114	26	the	the	DET
dpc-4021	114	27	other	other	ADJ
dpc-4021	114	28	side	side	NOUN
dpc-4021	114	29	,	,	PUNCT
dpc-4021	114	30	thami	thami	NOUN
dpc-4021	114	31	and	and	CCONJ
dpc-4021	114	32	garg	garg	NOUN
dpc-4021	114	33	included	include	VERB
dpc-4021	114	34	10	10	NUM
dpc-4021	114	35	patients	patient	NOUN
dpc-4021	114	36	with	with	ADP
dpc-4021	114	37	different	different	ADJ
dpc-4021	114	38	severity	severity	NOUN
dpc-4021	114	39	and	and	CCONJ
dpc-4021	114	40	types	type	NOUN
dpc-4021	114	41	of	of	ADP
dpc-4021	114	42	psoriasis	psoriasis	NOUN
dpc-4021	114	43	and	and	CCONJ
dpc-4021	114	44	showed	show	VERB
dpc-4021	114	45	no	no	DET
dpc-4021	114	46	clinically	clinically	ADV
dpc-4021	114	47	significant	significant	ADJ
dpc-4021	114	48	improvement	improvement	NOUN
dpc-4021	114	49	after	after	ADP
dpc-4021	114	50	6	6	NUM
dpc-4021	114	51	to	to	PART
dpc-4021	114	52	8	8	NUM
dpc-4021	114	53	months	month	NOUN
dpc-4021	114	54	of	of	ADP
dpc-4021	114	55	treatment	treatment	NOUN
dpc-4021	114	56	with	with	ADP
dpc-4021	114	57	leflunomide	leflunomide	ADJ
dpc-4021	114	58	,	,	PUNCT
dpc-4021	114	59	20	20	NUM
dpc-4021	114	60	mg	mg	NUM
dpc-4021	114	61	/	/	SYM
dpc-4021	114	62	d	d	PROPN
dpc-4021	115	1	[	[	X
dpc-4021	115	2	21	21	NUM
dpc-4021	115	3	]	]	PUNCT
dpc-4021	115	4	.	.	PUNCT
dpc-4021	116	1	in	in	ADP
dpc-4021	116	2	another	another	DET
dpc-4021	116	3	study	study	NOUN
dpc-4021	116	4	,	,	PUNCT
dpc-4021	116	5	8	8	NUM
dpc-4021	116	6	of	of	ADP
dpc-4021	116	7	12	12	NUM
dpc-4021	116	8	patients	patient	NOUN
dpc-4021	116	9	with	with	ADP
dpc-4021	116	10	psoriatic	psoriatic	ADJ
dpc-4021	116	11	arthritis	arthritis	NOUN
dpc-4021	116	12	had	have	AUX
dpc-4021	116	13	moderate	moderate	ADJ
dpc-4021	116	14	to	to	PART
dpc-4021	116	15	marked	mark	VERB
dpc-4021	116	16	clinical	clinical	ADJ
dpc-4021	116	17	improvement	improvement	NOUN
dpc-4021	116	18	in	in	ADP
dpc-4021	116	19	their	their	PRON
dpc-4021	116	20	psoriasis	psoriasis	NOUN
dpc-4021	116	21	after	after	ADP
dpc-4021	116	22	2	2	NUM
dpc-4021	116	23	to	to	PART
dpc-4021	116	24	3	3	NUM
dpc-4021	116	25	months	month	NOUN
dpc-4021	116	26	of	of	ADP
dpc-4021	116	27	treatment	treatment	NOUN
dpc-4021	116	28	with	with	ADP
dpc-4021	116	29	leflunomide	leflunomide	ADJ
dpc-4021	116	30	alone	alone	ADV
dpc-4021	116	31	or	or	CCONJ
dpc-4021	116	32	in	in	ADP
dpc-4021	116	33	combination	combination	NOUN
dpc-4021	116	34	with	with	ADP
dpc-4021	116	35	another	another	DET
dpc-4021	116	36	disease	disease	NOUN
dpc-4021	116	37	-	-	PUNCT
dpc-4021	116	38	modifying	modify	VERB
dpc-4021	116	39	antirheumatic	antirheumatic	ADJ
dpc-4021	116	40	drug	drug	NOUN
dpc-4021	116	41	[	[	X
dpc-4021	116	42	20	20	NUM
dpc-4021	116	43	]	]	PUNCT
dpc-4021	116	44	.	.	PUNCT
dpc-4021	117	1	other	other	ADJ
dpc-4021	117	2	case	case	NOUN
dpc-4021	117	3	-	-	PUNCT
dpc-4021	117	4	series	series	NOUN
dpc-4021	117	5	of	of	ADP
dpc-4021	117	6	8	8	NUM
dpc-4021	117	7	patients	patient	NOUN
dpc-4021	117	8	receiving	receive	VERB
dpc-4021	117	9	leflunomide	leflunomide	NOUN
dpc-4021	117	10	,	,	PUNCT
dpc-4021	117	11	20mg	20mg	NOUN
dpc-4021	117	12	/	/	SYM
dpc-4021	117	13	d	d	NOUN
dpc-4021	117	14	,	,	PUNCT
dpc-4021	117	15	over	over	ADP
dpc-4021	117	16	12	12	NUM
dpc-4021	117	17	weeks	week	NOUN
dpc-4021	117	18	showed	show	VERB
dpc-4021	117	19	a	a	DET
dpc-4021	117	20	reduction	reduction	NOUN
dpc-4021	117	21	in	in	ADP
dpc-4021	117	22	pasi	pasi	NOUN
dpc-4021	117	23	score	score	NOUN
dpc-4021	117	24	and	and	CCONJ
dpc-4021	117	25	improvement	improvement	NOUN
dpc-4021	117	26	in	in	ADP
dpc-4021	117	27	quality	quality	NOUN
dpc-4021	117	28	of	of	ADP
dpc-4021	117	29	life	life	NOUN
dpc-4021	117	30	in	in	ADP
dpc-4021	117	31	6	6	NUM
dpc-4021	117	32	patients	patient	NOUN
dpc-4021	117	33	[	[	X
dpc-4021	117	34	19	19	NUM
dpc-4021	117	35	]	]	PUNCT
dpc-4021	117	36	.	.	PUNCT
dpc-4021	118	1	6	6	NUM
dpc-4021	118	2	original	original	ADJ
dpc-4021	118	3	article	article	NOUN
dpc-4021	118	4	|	|	ADV
dpc-4021	118	5	dermatol	dermatol	ADJ
dpc-4021	118	6	pract	pract	NOUN
dpc-4021	118	7	concept	concept	NOUN
dpc-4021	118	8	.	.	PUNCT
dpc-4021	119	1	2024;14(3):e2024165	2024;14(3):e2024165	NUM
dpc-4021	119	2	figure	figure	NOUN
dpc-4021	119	3	7	7	NUM
dpc-4021	119	4	.	.	PUNCT
dpc-4021	119	5	female	female	ADJ
dpc-4021	119	6	patient	patient	NOUN
dpc-4021	119	7	,	,	PUNCT
dpc-4021	119	8	58	58	NUM
dpc-4021	119	9	years	year	NOUN
dpc-4021	119	10	old	old	ADJ
dpc-4021	119	11	,	,	PUNCT
dpc-4021	119	12	with	with	ADP
dpc-4021	119	13	psoriasis	psoriasis	NOUN
dpc-4021	119	14	vulgaris	vulgaris	NOUN
dpc-4021	119	15	her	her	PRON
dpc-4021	119	16	psoriasis	psoriasis	NOUN
dpc-4021	119	17	area	area	NOUN
dpc-4021	119	18	severity	severity	NOUN
dpc-4021	119	19	index	index	NOUN
dpc-4021	119	20	(	(	PUNCT
dpc-4021	119	21	a	a	NOUN
dpc-4021	119	22	)	)	PUNCT
dpc-4021	119	23	before	before	ADP
dpc-4021	119	24	oral	oral	ADJ
dpc-4021	119	25	leflunomide	leflunomide	NOUN
dpc-4021	119	26	was	be	AUX
dpc-4021	119	27	25.2	25.2	NUM
dpc-4021	119	28	that	that	PRON
dpc-4021	119	29	decreased	decrease	VERB
dpc-4021	119	30	to	to	ADP
dpc-4021	119	31	2.4	2.4	NUM
dpc-4021	119	32	(	(	PUNCT
dpc-4021	119	33	b	b	NOUN
dpc-4021	119	34	)	)	PUNCT
dpc-4021	119	35	after	after	ADP
dpc-4021	119	36	12	12	NUM
dpc-4021	119	37	weeks	week	NOUN
dpc-4021	119	38	of	of	ADP
dpc-4021	119	39	treatment	treatment	NOUN
dpc-4021	119	40	.	.	PUNCT
dpc-4021	120	1	figure	figure	NOUN
dpc-4021	120	2	8	8	NUM
dpc-4021	120	3	.	.	PUNCT
dpc-4021	120	4	female	female	ADJ
dpc-4021	120	5	patient	patient	NOUN
dpc-4021	120	6	,	,	PUNCT
dpc-4021	120	7	56	56	NUM
dpc-4021	120	8	years	year	NOUN
dpc-4021	120	9	old	old	ADJ
dpc-4021	120	10	,	,	PUNCT
dpc-4021	120	11	with	with	ADP
dpc-4021	120	12	psoriasis	psoriasis	NOUN
dpc-4021	120	13	vulgaris	vulgaris	NOUN
dpc-4021	120	14	her	her	PRON
dpc-4021	120	15	psoriasis	psoriasis	NOUN
dpc-4021	120	16	area	area	NOUN
dpc-4021	120	17	severity	severity	NOUN
dpc-4021	120	18	index	index	NOUN
dpc-4021	120	19	(	(	PUNCT
dpc-4021	120	20	a	a	NOUN
dpc-4021	120	21	)	)	PUNCT
dpc-4021	120	22	before	before	ADP
dpc-4021	120	23	oral	oral	ADJ
dpc-4021	120	24	leflunomide	leflunomide	NOUN
dpc-4021	120	25	was	be	AUX
dpc-4021	120	26	25	25	NUM
dpc-4021	120	27	that	that	PRON
dpc-4021	120	28	decreased	decrease	VERB
dpc-4021	120	29	to	to	ADP
dpc-4021	120	30	0	0	NUM
dpc-4021	120	31	(	(	PUNCT
dpc-4021	120	32	b	b	NOUN
dpc-4021	120	33	)	)	PUNCT
dpc-4021	120	34	after	after	ADP
dpc-4021	120	35	12	12	NUM
dpc-4021	120	36	weeks	week	NOUN
dpc-4021	120	37	of	of	ADP
dpc-4021	120	38	treatment	treatment	NOUN
dpc-4021	120	39	.	.	PUNCT
dpc-4021	121	1	figure	figure	NOUN
dpc-4021	121	2	6	6	NUM
dpc-4021	121	3	.	.	PUNCT
dpc-4021	122	1	male	male	ADJ
dpc-4021	122	2	patient	patient	NOUN
dpc-4021	122	3	,	,	PUNCT
dpc-4021	122	4	27	27	NUM
dpc-4021	122	5	years	year	NOUN
dpc-4021	122	6	old	old	ADJ
dpc-4021	122	7	,	,	PUNCT
dpc-4021	122	8	with	with	ADP
dpc-4021	122	9	psoriasis	psoriasis	NOUN
dpc-4021	122	10	vulgaris	vulgaris	NOUN
dpc-4021	122	11	his	his	PRON
dpc-4021	122	12	psoriasis	psoriasis	NOUN
dpc-4021	122	13	area	area	NOUN
dpc-4021	122	14	severity	severity	NOUN
dpc-4021	122	15	index	index	NOUN
dpc-4021	122	16	(	(	PUNCT
dpc-4021	122	17	a	a	NOUN
dpc-4021	122	18	)	)	PUNCT
dpc-4021	122	19	before	before	ADP
dpc-4021	122	20	oral	oral	ADJ
dpc-4021	122	21	leflunomide	leflunomide	NOUN
dpc-4021	122	22	was	be	AUX
dpc-4021	122	23	59.92	59.92	NUM
dpc-4021	122	24	that	that	PRON
dpc-4021	122	25	decreased	decrease	VERB
dpc-4021	122	26	to	to	ADP
dpc-4021	122	27	2.2	2.2	NUM
dpc-4021	122	28	(	(	PUNCT
dpc-4021	122	29	b	b	NOUN
dpc-4021	122	30	)	)	PUNCT
dpc-4021	122	31	after	after	ADP
dpc-4021	122	32	12	12	NUM
dpc-4021	122	33	weeks	week	NOUN
dpc-4021	122	34	of	of	ADP
dpc-4021	122	35	treatment	treatment	NOUN
dpc-4021	122	36	.	.	PUNCT
dpc-4021	123	1	original	original	ADJ
dpc-4021	123	2	article	article	NOUN
dpc-4021	123	3	|	|	ADV
dpc-4021	123	4	dermatol	dermatol	ADJ
dpc-4021	123	5	pract	pract	NOUN
dpc-4021	123	6	concept	concept	NOUN
dpc-4021	123	7	.	.	PUNCT
dpc-4021	124	1	2024;14(3):e2024165	2024;14(3):e2024165	NUM
dpc-4021	124	2	7	7	NUM
dpc-4021	124	3	to	to	ADP
dpc-4021	124	4	moderate	moderate	ADJ
dpc-4021	124	5	anemias	anemia	NOUN
dpc-4021	124	6	,	,	PUNCT
dpc-4021	124	7	mild	mild	ADJ
dpc-4021	124	8	to	to	ADP
dpc-4021	124	9	moderate	moderate	ADJ
dpc-4021	124	10	liver	liver	NOUN
dpc-4021	124	11	adverse	adverse	ADJ
dpc-4021	124	12	events	event	NOUN
dpc-4021	124	13	.	.	PUNCT
dpc-4021	125	1	however	however	ADV
dpc-4021	125	2	,	,	PUNCT
dpc-4021	125	3	chronic	chronic	ADJ
dpc-4021	125	4	kidney	kidney	NOUN
dpc-4021	125	5	injury	injury	NOUN
dpc-4021	125	6	did	do	AUX
dpc-4021	125	7	not	not	PART
dpc-4021	125	8	differ	differ	VERB
dpc-4021	125	9	between	between	ADP
dpc-4021	125	10	drugs	drug	NOUN
dpc-4021	125	11	.	.	PUNCT
dpc-4021	126	1	in	in	ADP
dpc-4021	126	2	addition	addition	NOUN
dpc-4021	126	3	,	,	PUNCT
dpc-4021	126	4	acute	acute	ADJ
dpc-4021	126	5	kidney	kidney	NOUN
dpc-4021	126	6	injury	injury	NOUN
dpc-4021	126	7	,	,	PUNCT
dpc-4021	126	8	serious	serious	ADJ
dpc-4021	126	9	infections	infection	NOUN
dpc-4021	126	10	and	and	CCONJ
dpc-4021	126	11	major	major	ADJ
dpc-4021	126	12	gastrointestinal	gastrointestinal	ADJ
dpc-4021	126	13	adverse	adverse	ADJ
dpc-4021	126	14	effects	effect	NOUN
dpc-4021	126	15	had	have	VERB
dpc-4021	126	16	no	no	DET
dpc-4021	126	17	clinically	clinically	ADV
dpc-4021	126	18	significant	significant	ADJ
dpc-4021	126	19	difference	difference	NOUN
dpc-4021	126	20	between	between	ADP
dpc-4021	126	21	therapies	therapy	NOUN
dpc-4021	126	22	.	.	PUNCT
dpc-4021	127	1	these	these	DET
dpc-4021	127	2	results	result	NOUN
dpc-4021	127	3	confirm	confirm	VERB
dpc-4021	127	4	the	the	DET
dpc-4021	127	5	value	value	NOUN
dpc-4021	127	6	of	of	ADP
dpc-4021	127	7	the	the	DET
dpc-4021	127	8	current	current	ADJ
dpc-4021	127	9	study	study	NOUN
dpc-4021	127	10	,	,	PUNCT
dpc-4021	127	11	where	where	SCONJ
dpc-4021	127	12	leflunomide	leflunomide	ADJ
dpc-4021	127	13	was	be	AUX
dpc-4021	127	14	associated	associate	VERB
dpc-4021	127	15	with	with	ADP
dpc-4021	127	16	better	well	ADJ
dpc-4021	127	17	profile	profile	NOUN
dpc-4021	127	18	of	of	ADP
dpc-4021	127	19	side	side	NOUN
dpc-4021	127	20	effects	effect	NOUN
dpc-4021	127	21	regardless	regardless	ADV
dpc-4021	127	22	of	of	ADP
dpc-4021	127	23	the	the	DET
dpc-4021	127	24	insignificant	insignificant	ADJ
dpc-4021	127	25	difference	difference	NOUN
dpc-4021	127	26	between	between	ADP
dpc-4021	127	27	groups	group	NOUN
dpc-4021	127	28	.	.	PUNCT
dpc-4021	128	1	this	this	PRON
dpc-4021	128	2	could	could	AUX
dpc-4021	128	3	be	be	AUX
dpc-4021	128	4	explained	explain	VERB
dpc-4021	128	5	by	by	ADP
dpc-4021	128	6	the	the	DET
dpc-4021	128	7	small	small	ADJ
dpc-4021	128	8	number	number	NOUN
dpc-4021	128	9	of	of	ADP
dpc-4021	128	10	included	include	VERB
dpc-4021	128	11	subjects	subject	NOUN
dpc-4021	128	12	in	in	ADP
dpc-4021	128	13	each	each	DET
dpc-4021	128	14	group	group	NOUN
dpc-4021	128	15	.	.	PUNCT
dpc-4021	129	1	l	l	PUNCT
dpc-4021	130	1	although	although	SCONJ
dpc-4021	130	2	our	our	PRON
dpc-4021	130	3	study	study	NOUN
dpc-4021	130	4	had	have	VERB
dpc-4021	130	5	several	several	ADJ
dpc-4021	130	6	methodological	methodological	ADJ
dpc-4021	130	7	and	and	CCONJ
dpc-4021	130	8	scientific	scientific	ADJ
dpc-4021	130	9	strengths	strength	NOUN
dpc-4021	130	10	as	as	ADP
dpc-4021	130	11	the	the	DET
dpc-4021	130	12	double	double	ADJ
dpc-4021	130	13	blinded	blind	VERB
dpc-4021	130	14	design	design	NOUN
dpc-4021	130	15	,	,	PUNCT
dpc-4021	130	16	the	the	DET
dpc-4021	130	17	computer	computer	NOUN
dpc-4021	130	18	assisted	assist	VERB
dpc-4021	130	19	randomization	randomization	NOUN
dpc-4021	130	20	as	as	ADV
dpc-4021	130	21	well	well	ADV
dpc-4021	130	22	as	as	ADP
dpc-4021	130	23	the	the	DET
dpc-4021	130	24	new	new	ADJ
dpc-4021	130	25	research	research	NOUN
dpc-4021	130	26	question	question	NOUN
dpc-4021	130	27	comparing	compare	VERB
dpc-4021	130	28	two	two	NUM
dpc-4021	130	29	medications	medication	NOUN
dpc-4021	130	30	that	that	PRON
dpc-4021	130	31	were	be	AUX
dpc-4021	130	32	not	not	PART
dpc-4021	130	33	compared	compare	VERB
dpc-4021	130	34	in	in	ADP
dpc-4021	130	35	psoriasis	psoriasis	NOUN
dpc-4021	130	36	before	before	ADV
dpc-4021	130	37	,	,	PUNCT
dpc-4021	130	38	it	it	PRON
dpc-4021	130	39	is	be	AUX
dpc-4021	130	40	still	still	ADV
dpc-4021	130	41	important	important	ADJ
dpc-4021	130	42	to	to	PART
dpc-4021	130	43	consider	consider	VERB
dpc-4021	130	44	certain	certain	ADJ
dpc-4021	130	45	limitations	limitation	NOUN
dpc-4021	130	46	when	when	SCONJ
dpc-4021	130	47	reading	read	VERB
dpc-4021	130	48	our	our	PRON
dpc-4021	130	49	results	result	NOUN
dpc-4021	130	50	,	,	PUNCT
dpc-4021	130	51	we	we	PRON
dpc-4021	130	52	did	do	AUX
dpc-4021	130	53	not	not	PART
dpc-4021	130	54	perform	perform	VERB
dpc-4021	130	55	a	a	DET
dpc-4021	130	56	sample	sample	NOUN
dpc-4021	130	57	size	size	NOUN
dpc-4021	130	58	calculation	calculation	NOUN
dpc-4021	130	59	,	,	PUNCT
dpc-4021	130	60	we	we	PRON
dpc-4021	130	61	only	only	ADV
dpc-4021	130	62	could	could	AUX
dpc-4021	130	63	study	study	VERB
dpc-4021	130	64	a	a	DET
dpc-4021	130	65	limited	limited	ADJ
dpc-4021	130	66	number	number	NOUN
dpc-4021	130	67	of	of	ADP
dpc-4021	130	68	participants	participant	NOUN
dpc-4021	130	69	and	and	CCONJ
dpc-4021	130	70	we	we	PRON
dpc-4021	130	71	did	do	AUX
dpc-4021	130	72	not	not	PART
dpc-4021	130	73	follow	follow	VERB
dpc-4021	130	74	up	up	ADP
dpc-4021	130	75	for	for	ADP
dpc-4021	130	76	long	long	ADJ
dpc-4021	130	77	term	term	NOUN
dpc-4021	130	78	effects	effect	NOUN
dpc-4021	130	79	and	and	CCONJ
dpc-4021	130	80	recurrences	recurrence	NOUN
dpc-4021	130	81	.	.	PUNCT
dpc-4021	131	1	in	in	ADP
dpc-4021	131	2	conclusion	conclusion	NOUN
dpc-4021	131	3	,	,	PUNCT
dpc-4021	131	4	leflunamide	leflunamide	NOUN
dpc-4021	131	5	is	be	AUX
dpc-4021	131	6	an	an	DET
dpc-4021	131	7	anti	anti	ADJ
dpc-4021	131	8	-	-	ADJ
dpc-4021	131	9	arthritic	arthritic	ADJ
dpc-4021	131	10	and	and	CCONJ
dpc-4021	131	11	lowcost	lowcost	PROPN
dpc-4021	131	12	drug	drug	NOUN
dpc-4021	131	13	that	that	PRON
dpc-4021	131	14	can	can	AUX
dpc-4021	131	15	effectively	effectively	ADV
dpc-4021	131	16	treat	treat	VERB
dpc-4021	131	17	moderate	moderate	ADJ
dpc-4021	131	18	to	to	ADP
dpc-4021	131	19	severe	severe	ADJ
dpc-4021	131	20	psoriasis	psoriasis	NOUN
dpc-4021	131	21	as	as	ADV
dpc-4021	131	22	effective	effective	ADJ
dpc-4021	131	23	as	as	ADP
dpc-4021	131	24	mtx	mtx	NOUN
dpc-4021	131	25	.	.	PROPN
dpc-4021	131	26	references	reference	NOUN
dpc-4021	131	27	1	1	NUM
dpc-4021	131	28	.	.	PUNCT
dpc-4021	131	29	schwartzman	schwartzman	PROPN
dpc-4021	131	30	m	m	PROPN
dpc-4021	131	31	,	,	PUNCT
dpc-4021	131	32	abutalib	abutalib	PROPN
dpc-4021	132	1	z	z	X
dpc-4021	132	2	,	,	PUNCT
dpc-4021	132	3	mandl	mandl	PROPN
dpc-4021	132	4	la	la	PROPN
dpc-4021	132	5	.	.	PUNCT
dpc-4021	133	1	current	current	ADJ
dpc-4021	133	2	medication	medication	NOUN
dpc-4021	133	3	practices	practice	NOUN
dpc-4021	133	4	and	and	CCONJ
dpc-4021	133	5	preferences	preference	NOUN
dpc-4021	133	6	among	among	ADP
dpc-4021	133	7	patients	patient	NOUN
dpc-4021	133	8	with	with	ADP
dpc-4021	133	9	psoriatic	psoriatic	ADJ
dpc-4021	133	10	arthritis	arthritis	NOUN
dpc-4021	133	11	.	.	PUNCT
dpc-4021	134	1	j	j	PROPN
dpc-4021	134	2	clin	clin	PROPN
dpc-4021	134	3	rheumatol	rheumatol	NOUN
dpc-4021	134	4	.	.	PUNCT
dpc-4021	135	1	2022;28(2):55	2022;28(2):55	NUM
dpc-4021	135	2	-	-	SYM
dpc-4021	135	3	61	61	NUM
dpc-4021	135	4	.	.	PUNCT
dpc-4021	136	1	doi	doi	NOUN
dpc-4021	136	2	:	:	PUNCT
dpc-4021	136	3	10.1097	10.1097	NUM
dpc-4021	136	4	/rhu.0000000000001799	/rhu.0000000000001799	NOUN
dpc-4021	136	5	.	.	PUNCT
dpc-4021	137	1	pmid	pmid	NOUN
dpc-4021	137	2	:	:	PUNCT
dpc-4021	137	3	35192589	35192589	NUM
dpc-4021	137	4	.	.	PUNCT
dpc-4021	138	1	pmcid	pmcid	NOUN
dpc-4021	138	2	:	:	PUNCT
dpc-4021	138	3	pmc	pmc	PROPN
dpc-4021	138	4	8887780	8887780	NUM
dpc-4021	138	5	.	.	PUNCT
dpc-4021	139	1	2	2	X
dpc-4021	139	2	.	.	X
dpc-4021	139	3	walter	walter	PROPN
dpc-4021	139	4	k.	k.	PROPN
dpc-4021	139	5	psoriasis	psoriasis	NOUN
dpc-4021	139	6	.	.	PUNCT
dpc-4021	140	1	jama	jama	NOUN
dpc-4021	140	2	.	.	PUNCT
dpc-4021	141	1	2022	2022	NUM
dpc-4021	141	2	may	may	AUX
dpc-4021	141	3	17;327(19):1936	17;327(19):1936	NUM
dpc-4021	141	4	.	.	PUNCT
dpc-4021	142	1	doi	doi	NOUN
dpc-4021	142	2	:	:	PUNCT
dpc-4021	142	3	10.1001	10.1001	NUM
dpc-4021	142	4	/	/	SYM
dpc-4021	142	5	jama.2022.5270	jama.2022.5270	NUM
dpc-4021	142	6	.	.	PUNCT
dpc-4021	143	1	pmid	pmid	NOUN
dpc-4021	143	2	:	:	PUNCT
dpc-4021	143	3	35579640	35579640	NUM
dpc-4021	143	4	..	..	PUNCT
dpc-4021	143	5	3	3	X
dpc-4021	143	6	.	.	X
dpc-4021	143	7	bu	bu	PROPN
dpc-4021	143	8	j	j	PROPN
dpc-4021	143	9	,	,	PUNCT
dpc-4021	143	10	ding	de	VERB
dpc-4021	143	11	r	r	NOUN
dpc-4021	143	12	,	,	PUNCT
dpc-4021	143	13	zhou	zhou	PROPN
dpc-4021	143	14	l	l	PROPN
dpc-4021	143	15	,	,	PUNCT
dpc-4021	143	16	chen	chen	PROPN
dpc-4021	143	17	x	x	PROPN
dpc-4021	143	18	,	,	PUNCT
dpc-4021	143	19	shen	shen	PROPN
dpc-4021	143	20	e.	e.	PROPN
dpc-4021	143	21	epidemiology	epidemiology	PROPN
dpc-4021	143	22	of	of	ADP
dpc-4021	143	23	psoriasis	psoriasis	NOUN
dpc-4021	143	24	and	and	CCONJ
dpc-4021	143	25	comorbid	comorbid	NOUN
dpc-4021	143	26	diseases	disease	NOUN
dpc-4021	143	27	:	:	PUNCT
dpc-4021	143	28	a	a	DET
dpc-4021	143	29	narrative	narrative	NOUN
dpc-4021	143	30	review	review	NOUN
dpc-4021	143	31	.	.	PUNCT
dpc-4021	144	1	front	front	ADJ
dpc-4021	144	2	immunol	immunol	NOUN
dpc-4021	144	3	.	.	PUNCT
dpc-4021	145	1	2022	2022	NUM
dpc-4021	145	2	jun	jun	PROPN
dpc-4021	145	3	10;13:880201	10;13:880201	NUM
dpc-4021	145	4	.	.	PUNCT
dpc-4021	146	1	doi	doi	NOUN
dpc-4021	146	2	:	:	PUNCT
dpc-4021	146	3	10.3389	10.3389	NUM
dpc-4021	146	4	/	/	SYM
dpc-4021	146	5	fimmu.2022.880201	fimmu.2022.880201	NOUN
dpc-4021	146	6	.	.	PUNCT
dpc-4021	147	1	pmid	pmid	NOUN
dpc-4021	147	2	:	:	PUNCT
dpc-4021	147	3	35757712	35757712	NUM
dpc-4021	147	4	;	;	PUNCT
dpc-4021	147	5	pmcid	pmcid	NOUN
dpc-4021	147	6	:	:	PUNCT
dpc-4021	147	7	pmc9226890	pmc9226890	NOUN
dpc-4021	147	8	.	.	PUNCT
dpc-4021	148	1	in	in	ADP
dpc-4021	148	2	a	a	DET
dpc-4021	148	3	prospective	prospective	ADJ
dpc-4021	148	4	observational	observational	ADJ
dpc-4021	148	5	study	study	NOUN
dpc-4021	148	6	,	,	PUNCT
dpc-4021	148	7	behrens	behrens	PROPN
dpc-4021	148	8	et	et	PROPN
dpc-4021	148	9	al	al	PROPN
dpc-4021	148	10	investigated	investigate	VERB
dpc-4021	148	11	the	the	DET
dpc-4021	148	12	effectiveness	effectiveness	NOUN
dpc-4021	148	13	and	and	CCONJ
dpc-4021	148	14	tolerability	tolerability	NOUN
dpc-4021	148	15	of	of	ADP
dpc-4021	148	16	leflunomide	leflunomide	NOUN
dpc-4021	148	17	in	in	ADP
dpc-4021	148	18	treatment	treatment	NOUN
dpc-4021	148	19	of	of	ADP
dpc-4021	148	20	psoriatic	psoriatic	ADJ
dpc-4021	148	21	arthritis	arthritis	NOUN
dpc-4021	148	22	[	[	X
dpc-4021	148	23	23	23	NUM
dpc-4021	148	24	]	]	PUNCT
dpc-4021	148	25	.	.	PUNCT
dpc-4021	149	1	they	they	PRON
dpc-4021	149	2	reached	reach	VERB
dpc-4021	149	3	the	the	DET
dpc-4021	149	4	conclusion	conclusion	NOUN
dpc-4021	149	5	that	that	SCONJ
dpc-4021	149	6	leflunomide	leflunomide	ADJ
dpc-4021	149	7	is	be	AUX
dpc-4021	149	8	an	an	DET
dpc-4021	149	9	effective	effective	ADJ
dpc-4021	149	10	,	,	PUNCT
dpc-4021	149	11	safe	safe	ADJ
dpc-4021	149	12	(	(	PUNCT
dpc-4021	149	13	well	well	ADV
dpc-4021	149	14	-	-	PUNCT
dpc-4021	149	15	tolerated	tolerate	VERB
dpc-4021	149	16	)	)	PUNCT
dpc-4021	149	17	treatment	treatment	NOUN
dpc-4021	149	18	option	option	NOUN
dpc-4021	149	19	for	for	ADP
dpc-4021	149	20	psoriatic	psoriatic	ADJ
dpc-4021	149	21	arthritis	arthritis	NOUN
dpc-4021	149	22	on	on	ADP
dpc-4021	149	23	a	a	DET
dpc-4021	149	24	clinical	clinical	ADJ
dpc-4021	149	25	basis	basis	NOUN
dpc-4021	149	26	.	.	PUNCT
dpc-4021	150	1	it	it	PRON
dpc-4021	150	2	affects	affect	VERB
dpc-4021	150	3	peripheral	peripheral	ADJ
dpc-4021	150	4	arthritis	arthritis	NOUN
dpc-4021	150	5	,	,	PUNCT
dpc-4021	150	6	and	and	CCONJ
dpc-4021	150	7	other	other	ADJ
dpc-4021	150	8	constitutional	constitutional	ADJ
dpc-4021	150	9	manifestations	manifestation	NOUN
dpc-4021	150	10	of	of	ADP
dpc-4021	150	11	arthritis	arthritis	NOUN
dpc-4021	150	12	(	(	PUNCT
dpc-4021	150	13	eg	eg	NOUN
dpc-4021	150	14	pain	pain	NOUN
dpc-4021	150	15	,	,	PUNCT
dpc-4021	150	16	fatigue	fatigue	NOUN
dpc-4021	150	17	)	)	PUNCT
dpc-4021	150	18	and	and	CCONJ
dpc-4021	150	19	it	it	PRON
dpc-4021	150	20	was	be	AUX
dpc-4021	150	21	associated	associate	VERB
dpc-4021	150	22	with	with	ADP
dpc-4021	150	23	significant	significant	ADJ
dpc-4021	150	24	reduction	reduction	NOUN
dpc-4021	150	25	of	of	ADP
dpc-4021	150	26	skin	skin	NOUN
dpc-4021	150	27	manifestations	manifestation	NOUN
dpc-4021	150	28	.	.	PUNCT
dpc-4021	151	1	all	all	DET
dpc-4021	151	2	the	the	DET
dpc-4021	151	3	previous	previous	ADJ
dpc-4021	151	4	studies	study	NOUN
dpc-4021	151	5	indicate	indicate	VERB
dpc-4021	151	6	the	the	DET
dpc-4021	151	7	efficacy	efficacy	NOUN
dpc-4021	151	8	and	and	CCONJ
dpc-4021	151	9	safety	safety	NOUN
dpc-4021	151	10	of	of	ADP
dpc-4021	151	11	leflounomide	leflounomide	NOUN
dpc-4021	151	12	in	in	ADP
dpc-4021	151	13	treatment	treatment	NOUN
dpc-4021	151	14	of	of	ADP
dpc-4021	151	15	psoriasis	psoriasis	NOUN
dpc-4021	151	16	or	or	CCONJ
dpc-4021	151	17	psoriatic	psoriatic	ADJ
dpc-4021	151	18	arthritis	arthritis	NOUN
dpc-4021	151	19	when	when	SCONJ
dpc-4021	151	20	compared	compare	VERB
dpc-4021	151	21	to	to	ADP
dpc-4021	151	22	placebo	placebo	NOUN
dpc-4021	151	23	or	or	CCONJ
dpc-4021	151	24	without	without	ADP
dpc-4021	151	25	comparison	comparison	NOUN
dpc-4021	151	26	to	to	ADP
dpc-4021	151	27	placebo	placebo	NOUN
dpc-4021	151	28	.	.	PUNCT
dpc-4021	152	1	however	however	ADV
dpc-4021	152	2	,	,	PUNCT
dpc-4021	152	3	the	the	DET
dpc-4021	152	4	efficacy	efficacy	NOUN
dpc-4021	152	5	and	and	CCONJ
dpc-4021	152	6	safety	safety	NOUN
dpc-4021	152	7	of	of	ADP
dpc-4021	152	8	leflunomide	leflunomide	ADJ
dpc-4021	152	9	are	be	AUX
dpc-4021	152	10	in	in	ADP
dpc-4021	152	11	need	need	NOUN
dpc-4021	152	12	to	to	PART
dpc-4021	152	13	be	be	AUX
dpc-4021	152	14	confirmed	confirm	VERB
dpc-4021	152	15	in	in	ADP
dpc-4021	152	16	comparison	comparison	NOUN
dpc-4021	152	17	to	to	ADP
dpc-4021	152	18	a	a	DET
dpc-4021	152	19	standard	standard	ADJ
dpc-4021	152	20	treatment	treatment	NOUN
dpc-4021	152	21	option	option	NOUN
dpc-4021	152	22	.	.	PUNCT
dpc-4021	153	1	hence	hence	ADV
dpc-4021	153	2	,	,	PUNCT
dpc-4021	153	3	the	the	DET
dpc-4021	153	4	current	current	ADJ
dpc-4021	153	5	work	work	NOUN
dpc-4021	153	6	was	be	AUX
dpc-4021	153	7	designed	design	VERB
dpc-4021	153	8	,	,	PUNCT
dpc-4021	153	9	carried	carry	VERB
dpc-4021	153	10	out	out	ADP
dpc-4021	153	11	and	and	CCONJ
dpc-4021	153	12	yielded	yield	VERB
dpc-4021	153	13	the	the	DET
dpc-4021	153	14	reported	report	VERB
dpc-4021	153	15	results	result	NOUN
dpc-4021	153	16	.	.	PUNCT
dpc-4021	154	1	mulder	mulder	PROPN
dpc-4021	154	2	et	et	PROPN
dpc-4021	154	3	al	al	PROPN
dpc-4021	154	4	compared	compare	VERB
dpc-4021	154	5	methotrexate	methotrexate	PROPN
dpc-4021	154	6	monotherapy	monotherapy	NOUN
dpc-4021	154	7	(	(	PUNCT
dpc-4021	154	8	25	25	NUM
dpc-4021	154	9	mg	mg	NOUN
dpc-4021	154	10	once	once	ADV
dpc-4021	154	11	weekly	weekly	ADV
dpc-4021	154	12	)	)	PUNCT
dpc-4021	154	13	to	to	PART
dpc-4021	154	14	methotrexate	methotrexate	VERB
dpc-4021	154	15	(	(	PUNCT
dpc-4021	154	16	as	as	ADP
dpc-4021	154	17	the	the	DET
dpc-4021	154	18	previous	previous	ADJ
dpc-4021	154	19	dose	dose	NOUN
dpc-4021	154	20	)	)	PUNCT
dpc-4021	154	21	plus	plus	CCONJ
dpc-4021	154	22	leflunomide	leflunomide	ADJ
dpc-4021	154	23	(	(	PUNCT
dpc-4021	154	24	20	20	NUM
dpc-4021	154	25	mg	mg	NOUN
dpc-4021	154	26	once	once	ADV
dpc-4021	154	27	daily	daily	ADV
dpc-4021	154	28	)	)	PUNCT
dpc-4021	154	29	in	in	ADP
dpc-4021	154	30	patients	patient	NOUN
dpc-4021	154	31	with	with	ADP
dpc-4021	154	32	psoriatic	psoriatic	ADJ
dpc-4021	154	33	arthritis	arthritis	NOUN
dpc-4021	154	34	[	[	X
dpc-4021	154	35	15	15	NUM
dpc-4021	154	36	]	]	PUNCT
dpc-4021	154	37	.	.	PUNCT
dpc-4021	155	1	they	they	PRON
dpc-4021	155	2	concluded	conclude	VERB
dpc-4021	155	3	that	that	SCONJ
dpc-4021	155	4	combination	combination	NOUN
dpc-4021	155	5	therapy	therapy	NOUN
dpc-4021	155	6	is	be	AUX
dpc-4021	155	7	more	more	ADV
dpc-4021	155	8	effective	effective	ADJ
dpc-4021	155	9	but	but	CCONJ
dpc-4021	155	10	less	less	ADV
dpc-4021	155	11	tolerated	tolerate	VERB
dpc-4021	155	12	than	than	ADP
dpc-4021	155	13	monotherapy	monotherapy	NOUN
dpc-4021	155	14	.	.	PUNCT
dpc-4021	156	1	this	this	PRON
dpc-4021	156	2	confirms	confirm	VERB
dpc-4021	156	3	the	the	DET
dpc-4021	156	4	need	need	NOUN
dpc-4021	156	5	for	for	ADP
dpc-4021	156	6	the	the	DET
dpc-4021	156	7	current	current	ADJ
dpc-4021	156	8	work	work	NOUN
dpc-4021	156	9	.	.	PUNCT
dpc-4021	157	1	in	in	ADP
dpc-4021	157	2	a	a	DET
dpc-4021	157	3	more	more	ADV
dpc-4021	157	4	recent	recent	ADJ
dpc-4021	157	5	systematic	systematic	ADJ
dpc-4021	157	6	review	review	NOUN
dpc-4021	157	7	,	,	PUNCT
dpc-4021	157	8	hsieh	hsieh	PROPN
dpc-4021	157	9	and	and	CCONJ
dpc-4021	157	10	tsai	tsai	PROPN
dpc-4021	157	11	investigated	investigate	VERB
dpc-4021	157	12	the	the	DET
dpc-4021	157	13	combination	combination	NOUN
dpc-4021	157	14	therapy	therapy	NOUN
dpc-4021	157	15	of	of	ADP
dpc-4021	157	16	methotrexate	methotrexate	NOUN
dpc-4021	157	17	with	with	ADP
dpc-4021	157	18	other	other	ADJ
dpc-4021	157	19	disease	disease	NOUN
dpc-4021	157	20	modifying	modify	VERB
dpc-4021	157	21	drugs	drug	NOUN
dpc-4021	157	22	for	for	ADP
dpc-4021	157	23	treatment	treatment	NOUN
dpc-4021	157	24	of	of	ADP
dpc-4021	157	25	psoriasis	psoriasis	NOUN
dpc-4021	157	26	[	[	X
dpc-4021	157	27	24	24	NUM
dpc-4021	157	28	]	]	PUNCT
dpc-4021	157	29	.	.	PUNCT
dpc-4021	158	1	they	they	PRON
dpc-4021	158	2	reported	report	VERB
dpc-4021	158	3	a	a	DET
dpc-4021	158	4	better	well	ADJ
dpc-4021	158	5	effect	effect	NOUN
dpc-4021	158	6	with	with	ADP
dpc-4021	158	7	combination	combination	NOUN
dpc-4021	158	8	therapy	therapy	NOUN
dpc-4021	158	9	.	.	PUNCT
dpc-4021	159	1	however	however	ADV
dpc-4021	159	2	,	,	PUNCT
dpc-4021	159	3	they	they	PRON
dpc-4021	159	4	need	need	VERB
dpc-4021	159	5	stronger	strong	ADJ
dpc-4021	159	6	evidence	evidence	NOUN
dpc-4021	159	7	to	to	PART
dpc-4021	159	8	recommend	recommend	VERB
dpc-4021	159	9	such	such	ADJ
dpc-4021	159	10	combinations	combination	NOUN
dpc-4021	159	11	,	,	PUNCT
dpc-4021	159	12	as	as	SCONJ
dpc-4021	159	13	their	their	PRON
dpc-4021	159	14	studies	study	NOUN
dpc-4021	159	15	were	be	AUX
dpc-4021	159	16	small	small	ADV
dpc-4021	159	17	-	-	PUNCT
dpc-4021	159	18	scaled	scale	VERB
dpc-4021	159	19	and	and	CCONJ
dpc-4021	159	20	retrospective	retrospective	ADJ
dpc-4021	159	21	in	in	ADP
dpc-4021	159	22	nature	nature	NOUN
dpc-4021	159	23	.	.	PUNCT
dpc-4021	160	1	this	this	DET
dpc-4021	160	2	finding	finding	NOUN
dpc-4021	160	3	regains	regain	VERB
dpc-4021	160	4	the	the	DET
dpc-4021	160	5	treatment	treatment	NOUN
dpc-4021	160	6	options	option	NOUN
dpc-4021	160	7	again	again	ADV
dpc-4021	160	8	to	to	ADP
dpc-4021	160	9	monotherapy	monotherapy	NOUN
dpc-4021	160	10	.	.	PUNCT
dpc-4021	161	1	thus	thus	ADV
dpc-4021	161	2	,	,	PUNCT
dpc-4021	161	3	research	research	NOUN
dpc-4021	161	4	much	much	ADV
dpc-4021	161	5	be	be	AUX
dpc-4021	161	6	continued	continue	VERB
dpc-4021	161	7	for	for	ADP
dpc-4021	161	8	the	the	DET
dpc-4021	161	9	most	most	ADV
dpc-4021	161	10	effective	effective	ADJ
dpc-4021	161	11	and	and	CCONJ
dpc-4021	161	12	well	well	ADV
dpc-4021	161	13	-	-	PUNCT
dpc-4021	161	14	tolerated	tolerate	VERB
dpc-4021	161	15	treatment	treatment	NOUN
dpc-4021	161	16	option	option	NOUN
dpc-4021	161	17	.	.	PUNCT
dpc-4021	162	1	mazhar	mazhar	PROPN
dpc-4021	162	2	et	et	PROPN
dpc-4021	162	3	al	al	PROPN
dpc-4021	162	4	)	)	PUNCT
dpc-4021	162	5	conducted	conduct	VERB
dpc-4021	162	6	an	an	DET
dpc-4021	162	7	observational	observational	ADJ
dpc-4021	162	8	study	study	NOUN
dpc-4021	162	9	on	on	ADP
dpc-4021	162	10	6294	6294	NUM
dpc-4021	162	11	adult	adult	NOUN
dpc-4021	162	12	patients	patient	NOUN
dpc-4021	162	13	with	with	ADP
dpc-4021	162	14	psoriasis	psoriasis	NOUN
dpc-4021	162	15	with	with	ADP
dpc-4021	162	16	or	or	CCONJ
dpc-4021	162	17	without	without	ADP
dpc-4021	162	18	psoriatic	psoriatic	ADJ
dpc-4021	162	19	arthritis	arthritis	NOUN
dpc-4021	162	20	,	,	PUNCT
dpc-4021	162	21	who	who	PRON
dpc-4021	162	22	started	start	VERB
dpc-4021	162	23	the	the	DET
dpc-4021	162	24	treatment	treatment	NOUN
dpc-4021	162	25	by	by	ADP
dpc-4021	162	26	methotrexate	methotrexate	NOUN
dpc-4021	162	27	or	or	CCONJ
dpc-4021	162	28	other	other	ADJ
dpc-4021	162	29	biologics	biologic	NOUN
dpc-4021	162	30	between	between	ADP
dpc-4021	162	31	2006	2006	NUM
dpc-4021	162	32	and	and	CCONJ
dpc-4021	162	33	2021	2021	NUM
dpc-4021	162	34	[	[	X
dpc-4021	162	35	25	25	NUM
dpc-4021	162	36	]	]	PUNCT
dpc-4021	162	37	.	.	PUNCT
dpc-4021	163	1	they	they	PRON
dpc-4021	163	2	aimed	aim	VERB
dpc-4021	163	3	to	to	PART
dpc-4021	163	4	address	address	VERB
dpc-4021	163	5	side	side	NOUN
dpc-4021	163	6	effects	effect	NOUN
dpc-4021	163	7	between	between	ADP
dpc-4021	163	8	different	different	ADJ
dpc-4021	163	9	therapeutic	therapeutic	ADJ
dpc-4021	163	10	drugs	drug	NOUN
dpc-4021	163	11	.	.	PUNCT
dpc-4021	164	1	they	they	PRON
dpc-4021	164	2	reported	report	VERB
dpc-4021	164	3	that	that	SCONJ
dpc-4021	164	4	patients	patient	NOUN
dpc-4021	164	5	on	on	ADP
dpc-4021	164	6	methotrexate	methotrexate	NOUN
dpc-4021	164	7	had	have	VERB
dpc-4021	164	8	higher	high	ADJ
dpc-4021	164	9	risk	risk	NOUN
dpc-4021	164	10	of	of	ADP
dpc-4021	164	11	mild	mild	ADJ
dpc-4021	164	12	table	table	NOUN
dpc-4021	164	13	2	2	NUM
dpc-4021	164	14	.	.	PUNCT
dpc-4021	164	15	gastrointestinal	gastrointestinal	ADJ
dpc-4021	164	16	,	,	PUNCT
dpc-4021	164	17	general	general	ADJ
dpc-4021	164	18	and	and	CCONJ
dpc-4021	164	19	dermatological	dermatological	ADJ
dpc-4021	164	20	manifestations	manifestation	NOUN
dpc-4021	164	21	among	among	ADP
dpc-4021	164	22	the	the	DET
dpc-4021	164	23	study	study	NOUN
dpc-4021	164	24	groups	group	NOUN
dpc-4021	164	25	methotrexate	methotrexate	VERB
dpc-4021	164	26	group	group	NOUN
dpc-4021	164	27	(	(	PUNCT
dpc-4021	164	28	n	n	NOUN
dpc-4021	164	29	=	=	SYM
dpc-4021	164	30	20	20	NUM
dpc-4021	164	31	)	)	PUNCT
dpc-4021	164	32	leflunomide	leflunomide	ADJ
dpc-4021	164	33	group	group	NOUN
dpc-4021	164	34	(	(	PUNCT
dpc-4021	164	35	n	n	NOUN
dpc-4021	164	36	=	=	SYM
dpc-4021	164	37	20	20	NUM
dpc-4021	164	38	)	)	PUNCT
dpc-4021	164	39	test	test	NOUN
dpc-4021	164	40	p	p	NOUN
dpc-4021	164	41	value	value	NOUN
dpc-4021	164	42	nausea	nausea	NOUN
dpc-4021	164	43	4	4	NUM
dpc-4021	164	44	(	(	PUNCT
dpc-4021	164	45	20	20	NUM
dpc-4021	164	46	%	%	NOUN
dpc-4021	164	47	)	)	PUNCT
dpc-4021	164	48	3	3	NUM
dpc-4021	164	49	(	(	PUNCT
dpc-4021	164	50	15	15	NUM
dpc-4021	164	51	%	%	NOUN
dpc-4021	164	52	)	)	PUNCT
dpc-4021	164	53	0.173	0.173	NUM
dpc-4021	164	54	0.677	0.677	NUM
dpc-4021	164	55	vomiting	vomiting	NOUN
dpc-4021	164	56	0	0	NUM
dpc-4021	165	1	(	(	PUNCT
dpc-4021	165	2	0	0	NUM
dpc-4021	165	3	%	%	NOUN
dpc-4021	165	4	)	)	PUNCT
dpc-4021	165	5	1	1	NUM
dpc-4021	165	6	(	(	PUNCT
dpc-4021	165	7	5	5	NUM
dpc-4021	165	8	%	%	NOUN
dpc-4021	165	9	)	)	PUNCT
dpc-4021	165	10	1.026	1.026	NUM
dpc-4021	165	11	0.311	0.311	NUM
dpc-4021	165	12	diarrhea	diarrhea	NOUN
dpc-4021	165	13	4	4	NUM
dpc-4021	165	14	(	(	PUNCT
dpc-4021	165	15	20	20	NUM
dpc-4021	165	16	%	%	NOUN
dpc-4021	165	17	)	)	PUNCT
dpc-4021	165	18	6	6	NUM
dpc-4021	165	19	(	(	PUNCT
dpc-4021	165	20	30	30	NUM
dpc-4021	165	21	%	%	NOUN
dpc-4021	165	22	)	)	PUNCT
dpc-4021	165	23	0.533	0.533	NUM
dpc-4021	165	24	0.465	0.465	NUM
dpc-4021	165	25	abdominal	abdominal	ADJ
dpc-4021	165	26	pain	pain	NOUN
dpc-4021	165	27	0	0	PUNCT
dpc-4021	166	1	(	(	PUNCT
dpc-4021	166	2	0	0	NUM
dpc-4021	166	3	%	%	NOUN
dpc-4021	166	4	)	)	PUNCT
dpc-4021	166	5	2	2	NUM
dpc-4021	166	6	(	(	PUNCT
dpc-4021	166	7	10	10	NUM
dpc-4021	166	8	%	%	NOUN
dpc-4021	166	9	)	)	PUNCT
dpc-4021	166	10	2.105	2.105	NUM
dpc-4021	166	11	0.147	0.147	NUM
dpc-4021	166	12	dyspepsia	dyspepsia	NOUN
dpc-4021	166	13	3	3	NUM
dpc-4021	166	14	(	(	PUNCT
dpc-4021	166	15	15	15	NUM
dpc-4021	166	16	%	%	NOUN
dpc-4021	166	17	)	)	PUNCT
dpc-4021	166	18	3	3	NUM
dpc-4021	166	19	(	(	PUNCT
dpc-4021	166	20	15	15	NUM
dpc-4021	166	21	%	%	NOUN
dpc-4021	166	22	)	)	PUNCT
dpc-4021	166	23	0.001	0.001	NUM
dpc-4021	166	24	1.0	1.0	NUM
dpc-4021	166	25	headache	headache	NOUN
dpc-4021	166	26	5	5	NUM
dpc-4021	166	27	(	(	PUNCT
dpc-4021	166	28	25	25	NUM
dpc-4021	166	29	%	%	NOUN
dpc-4021	166	30	)	)	PUNCT
dpc-4021	166	31	3	3	NUM
dpc-4021	166	32	(	(	PUNCT
dpc-4021	166	33	15	15	NUM
dpc-4021	166	34	%	%	NOUN
dpc-4021	166	35	)	)	PUNCT
dpc-4021	166	36	0.625	0.625	NUM
dpc-4021	166	37	0.429	0.429	NUM
dpc-4021	166	38	dizziness	dizziness	NOUN
dpc-4021	166	39	2	2	NUM
dpc-4021	166	40	(	(	PUNCT
dpc-4021	166	41	10	10	NUM
dpc-4021	166	42	%	%	NOUN
dpc-4021	166	43	)	)	PUNCT
dpc-4021	166	44	0	0	NUM
dpc-4021	167	1	(	(	PUNCT
dpc-4021	167	2	0	0	NUM
dpc-4021	167	3	%	%	NOUN
dpc-4021	167	4	)	)	PUNCT
dpc-4021	167	5	2.105	2.105	NUM
dpc-4021	167	6	0.147	0.147	NUM
dpc-4021	167	7	asthenia	asthenia	NOUN
dpc-4021	167	8	3	3	NUM
dpc-4021	167	9	(	(	PUNCT
dpc-4021	167	10	15	15	NUM
dpc-4021	167	11	%	%	NOUN
dpc-4021	167	12	)	)	PUNCT
dpc-4021	167	13	2	2	NUM
dpc-4021	167	14	(	(	PUNCT
dpc-4021	167	15	10	10	NUM
dpc-4021	167	16	%	%	NOUN
dpc-4021	167	17	)	)	PUNCT
dpc-4021	167	18	0.229	0.229	NUM
dpc-4021	167	19	0.633	0.633	NUM
dpc-4021	167	20	back	back	NOUN
dpc-4021	167	21	pain	pain	NOUN
dpc-4021	167	22	2	2	NUM
dpc-4021	167	23	(	(	PUNCT
dpc-4021	167	24	10	10	NUM
dpc-4021	167	25	%	%	NOUN
dpc-4021	167	26	)	)	PUNCT
dpc-4021	167	27	1	1	NUM
dpc-4021	167	28	(	(	PUNCT
dpc-4021	167	29	5	5	NUM
dpc-4021	167	30	%	%	NOUN
dpc-4021	167	31	)	)	PUNCT
dpc-4021	167	32	0.36	0.36	NUM
dpc-4021	167	33	0.548	0.548	NUM
dpc-4021	167	34	rash	rash	ADJ
dpc-4021	167	35	2	2	NUM
dpc-4021	167	36	(	(	PUNCT
dpc-4021	167	37	10	10	NUM
dpc-4021	167	38	%	%	NOUN
dpc-4021	167	39	)	)	PUNCT
dpc-4021	167	40	3	3	NUM
dpc-4021	167	41	(	(	PUNCT
dpc-4021	167	42	15	15	NUM
dpc-4021	167	43	%	%	NOUN
dpc-4021	167	44	)	)	PUNCT
dpc-4021	167	45	0.229	0.229	NUM
dpc-4021	167	46	0.633	0.633	NUM
dpc-4021	167	47	pruritus	pruritus	NOUN
dpc-4021	167	48	1	1	NUM
dpc-4021	167	49	(	(	PUNCT
dpc-4021	167	50	5	5	NUM
dpc-4021	167	51	%	%	NOUN
dpc-4021	167	52	)	)	PUNCT
dpc-4021	167	53	0	0	NUM
dpc-4021	167	54	(	(	PUNCT
dpc-4021	167	55	0	0	NUM
dpc-4021	167	56	%	%	NOUN
dpc-4021	167	57	)	)	PUNCT
dpc-4021	167	58	1.026	1.026	NUM
dpc-4021	167	59	0.311	0.311	NUM
dpc-4021	167	60	alopecia	alopecia	NOUN
dpc-4021	167	61	3	3	NUM
dpc-4021	167	62	(	(	PUNCT
dpc-4021	167	63	15	15	NUM
dpc-4021	167	64	%	%	NOUN
dpc-4021	167	65	)	)	PUNCT
dpc-4021	167	66	2	2	NUM
dpc-4021	167	67	(	(	PUNCT
dpc-4021	167	68	10	10	NUM
dpc-4021	167	69	%	%	NOUN
dpc-4021	167	70	)	)	PUNCT
dpc-4021	167	71	0.229	0.229	NUM
dpc-4021	167	72	0.633	0.633	NUM
dpc-4021	167	73	8	8	NUM
dpc-4021	167	74	original	original	ADJ
dpc-4021	167	75	article	article	NOUN
dpc-4021	167	76	|	|	ADV
dpc-4021	167	77	dermatol	dermatol	ADJ
dpc-4021	167	78	pract	pract	NOUN
dpc-4021	167	79	concept	concept	NOUN
dpc-4021	167	80	.	.	PUNCT
dpc-4021	168	1	2024;14(3):e2024165	2024;14(3):e2024165	NUM
dpc-4021	168	2	a	a	DET
dpc-4021	168	3	randomized	randomized	ADJ
dpc-4021	168	4	,	,	PUNCT
dpc-4021	168	5	placebo	placebo	NOUN
dpc-4021	168	6	-	-	PUNCT
dpc-4021	168	7	controlled	control	VERB
dpc-4021	168	8	,	,	PUNCT
dpc-4021	168	9	double	double	ADJ
dpc-4021	168	10	-	-	PUNCT
dpc-4021	168	11	blind	blind	ADJ
dpc-4021	168	12	clinical	clinical	ADJ
dpc-4021	168	13	trial	trial	NOUN
dpc-4021	168	14	(	(	PUNCT
dpc-4021	168	15	complete	complete	ADJ
dpc-4021	168	16	-	-	PUNCT
dpc-4021	168	17	psa	psa	NOUN
dpc-4021	168	18	)	)	PUNCT
dpc-4021	168	19	.	.	PUNCT
dpc-4021	169	1	trials	trial	NOUN
dpc-4021	169	2	.	.	PUNCT
dpc-4021	170	1	2020	2020	NUM
dpc-4021	170	2	feb	feb	PROPN
dpc-4021	170	3	10;21(1):155	10;21(1):155	NUM
dpc-4021	170	4	.	.	PUNCT
dpc-4021	170	5	doi	doi	NOUN
dpc-4021	170	6	:	:	PUNCT
dpc-4021	170	7	10.1186	10.1186	NUM
dpc-4021	170	8	/s13063	/s13063	NUM
dpc-4021	170	9	-	-	PUNCT
dpc-4021	170	10	020	020	NUM
dpc-4021	170	11	-	-	PUNCT
dpc-4021	170	12	4097	4097	NUM
dpc-4021	170	13	-	-	SYM
dpc-4021	170	14	6	6	NUM
dpc-4021	170	15	.	.	PUNCT
dpc-4021	171	1	pmid	pmid	NOUN
dpc-4021	171	2	:	:	PUNCT
dpc-4021	171	3	32041657	32041657	NUM
dpc-4021	171	4	;	;	PUNCT
dpc-4021	171	5	pmcid	pmcid	NOUN
dpc-4021	171	6	:	:	PUNCT
dpc-4021	171	7	pmc7011519	pmc7011519	ADJ
dpc-4021	171	8	.	.	PUNCT
dpc-4021	172	1	15	15	X
dpc-4021	172	2	.	.	PUNCT
dpc-4021	173	1	alabas	alabas	PROPN
dpc-4021	173	2	oa	oa	PROPN
dpc-4021	173	3	,	,	PUNCT
dpc-4021	173	4	mason	mason	PROPN
dpc-4021	173	5	kj	kj	PROPN
dpc-4021	173	6	,	,	PUNCT
dpc-4021	173	7	yiu	yiu	PROPN
dpc-4021	173	8	zzn	zzn	NOUN
dpc-4021	173	9	,	,	PUNCT
dpc-4021	173	10	et	et	PROPN
dpc-4021	173	11	al	al	PROPN
dpc-4021	173	12	;	;	PUNCT
dpc-4021	173	13	badbir	badbir	PROPN
dpc-4021	173	14	study	study	NOUN
dpc-4021	173	15	group	group	NOUN
dpc-4021	173	16	.	.	PUNCT
dpc-4021	174	1	effectiveness	effectiveness	NOUN
dpc-4021	174	2	and	and	CCONJ
dpc-4021	174	3	persistence	persistence	NOUN
dpc-4021	174	4	of	of	ADP
dpc-4021	174	5	acitretin	acitretin	NOUN
dpc-4021	174	6	,	,	PUNCT
dpc-4021	174	7	ciclosporin	ciclosporin	NOUN
dpc-4021	174	8	,	,	PUNCT
dpc-4021	174	9	fumaric	fumaric	ADJ
dpc-4021	174	10	acid	acid	NOUN
dpc-4021	174	11	esters	ester	NOUN
dpc-4021	174	12	and	and	CCONJ
dpc-4021	174	13	methotrexate	methotrexate	VERB
dpc-4021	174	14	for	for	ADP
dpc-4021	174	15	patients	patient	NOUN
dpc-4021	174	16	with	with	ADP
dpc-4021	174	17	moderate	moderate	ADJ
dpc-4021	174	18	-	-	PUNCT
dpc-4021	174	19	to	to	ADP
dpc-4021	174	20	severe	severe	ADJ
dpc-4021	174	21	psoriasis	psoriasis	NOUN
dpc-4021	174	22	:	:	PUNCT
dpc-4021	174	23	a	a	DET
dpc-4021	174	24	cohort	cohort	NOUN
dpc-4021	174	25	study	study	NOUN
dpc-4021	174	26	from	from	ADP
dpc-4021	174	27	badbir	badbir	PROPN
dpc-4021	174	28	.	.	PUNCT
dpc-4021	175	1	br	br	PROPN
dpc-4021	175	2	j	j	PROPN
dpc-4021	175	3	dermatol	dermatol	NOUN
dpc-4021	175	4	.	.	PUNCT
dpc-4021	176	1	2023	2023	NUM
dpc-4021	176	2	apr	apr	NOUN
dpc-4021	176	3	20;188(5):618	20;188(5):618	NUM
dpc-4021	176	4	-	-	SYM
dpc-4021	176	5	627	627	NUM
dpc-4021	176	6	.	.	PUNCT
dpc-4021	176	7	doi	doi	NOUN
dpc-4021	176	8	:	:	PUNCT
dpc-4021	176	9	10.1093	10.1093	NUM
dpc-4021	176	10	/	/	SYM
dpc-4021	176	11	bjd	bjd	PROPN
dpc-4021	176	12	/	/	SYM
dpc-4021	176	13	ljad004	ljad004	PROPN
dpc-4021	176	14	.	.	PUNCT
dpc-4021	177	1	pmid	pmid	NOUN
dpc-4021	177	2	:	:	PUNCT
dpc-4021	177	3	36763783	36763783	NUM
dpc-4021	177	4	.	.	PUNCT
dpc-4021	178	1	16	16	NUM
dpc-4021	178	2	.	.	PUNCT
dpc-4021	178	3	affleck	affleck	PROPN
dpc-4021	178	4	ag	ag	PROPN
dpc-4021	178	5	,	,	PUNCT
dpc-4021	178	6	williams	williams	PROPN
dpc-4021	178	7	h.	h.	PROPN
dpc-4021	178	8	is	be	AUX
dpc-4021	178	9	leflunomide	leflunomide	ADJ
dpc-4021	178	10	effective	effective	ADJ
dpc-4021	178	11	in	in	ADP
dpc-4021	178	12	the	the	DET
dpc-4021	178	13	treatment	treatment	NOUN
dpc-4021	178	14	of	of	ADP
dpc-4021	178	15	psoriasis	psoriasis	NOUN
dpc-4021	178	16	in	in	ADP
dpc-4021	178	17	a	a	DET
dpc-4021	178	18	patient	patient	NOUN
dpc-4021	178	19	who	who	PRON
dpc-4021	178	20	is	be	AUX
dpc-4021	178	21	unable	unable	ADJ
dpc-4021	178	22	to	to	PART
dpc-4021	178	23	benefit	benefit	VERB
dpc-4021	178	24	from	from	ADP
dpc-4021	178	25	standard	standard	ADJ
dpc-4021	178	26	firstand	firstand	ADJ
dpc-4021	178	27	second	second	ADJ
dpc-4021	178	28	-	-	PUNCT
dpc-4021	178	29	line	line	NOUN
dpc-4021	178	30	therapies	therapy	NOUN
dpc-4021	178	31	and	and	CCONJ
dpc-4021	178	32	needs	need	VERB
dpc-4021	178	33	an	an	DET
dpc-4021	178	34	affordable	affordable	ADJ
dpc-4021	178	35	treatment	treatment	NOUN
dpc-4021	178	36	option	option	NOUN
dpc-4021	178	37	?	?	PUNCT
dpc-4021	179	1	arch	arch	ADJ
dpc-4021	179	2	dermatol	dermatol	NOUN
dpc-4021	179	3	.	.	PUNCT
dpc-4021	180	1	2008	2008	NUM
dpc-4021	180	2	dec;144(12):1642	dec;144(12):1642	PROPN
dpc-4021	180	3	-	-	PUNCT
dpc-4021	181	1	3	3	NUM
dpc-4021	181	2	.	.	PUNCT
dpc-4021	181	3	doi	doi	NOUN
dpc-4021	181	4	:	:	PUNCT
dpc-4021	181	5	10.1001	10.1001	NUM
dpc-4021	181	6	/	/	SYM
dpc-4021	181	7	archdermatol.2008.502	archdermatol.2008.502	PROPN
dpc-4021	181	8	.	.	PUNCT
dpc-4021	182	1	pmid	pmid	NOUN
dpc-4021	182	2	:	:	PUNCT
dpc-4021	182	3	19075151	19075151	NUM
dpc-4021	182	4	.	.	PUNCT
dpc-4021	183	1	17	17	NUM
dpc-4021	183	2	.	.	PUNCT
dpc-4021	184	1	kaltwasser	kaltwasser	PROPN
dpc-4021	184	2	jp	jp	PROPN
dpc-4021	184	3	,	,	PUNCT
dpc-4021	184	4	nash	nash	PROPN
dpc-4021	184	5	p	p	NOUN
dpc-4021	184	6	,	,	PUNCT
dpc-4021	184	7	gladman	gladman	NOUN
dpc-4021	184	8	d	d	PROPN
dpc-4021	184	9	,	,	PUNCT
dpc-4021	184	10	et	et	PROPN
dpc-4021	184	11	al	al	PROPN
dpc-4021	184	12	.	.	PROPN
dpc-4021	185	1	treatment	treatment	NOUN
dpc-4021	185	2	of	of	ADP
dpc-4021	185	3	psoriatic	psoriatic	ADJ
dpc-4021	185	4	arthritis	arthritis	NOUN
dpc-4021	185	5	study	study	NOUN
dpc-4021	185	6	group	group	NOUN
dpc-4021	185	7	.	.	PUNCT
dpc-4021	186	1	efficacy	efficacy	NOUN
dpc-4021	186	2	and	and	CCONJ
dpc-4021	186	3	safety	safety	NOUN
dpc-4021	186	4	of	of	ADP
dpc-4021	186	5	leflunomide	leflunomide	NOUN
dpc-4021	186	6	in	in	ADP
dpc-4021	186	7	the	the	DET
dpc-4021	186	8	treatment	treatment	NOUN
dpc-4021	186	9	of	of	ADP
dpc-4021	186	10	psoriatic	psoriatic	ADJ
dpc-4021	186	11	arthritis	arthritis	NOUN
dpc-4021	186	12	and	and	CCONJ
dpc-4021	186	13	psoriasis	psoriasis	NOUN
dpc-4021	186	14	:	:	PUNCT
dpc-4021	186	15	a	a	DET
dpc-4021	186	16	multinational	multinational	ADJ
dpc-4021	186	17	,	,	PUNCT
dpc-4021	186	18	double	double	ADJ
dpc-4021	186	19	-	-	PUNCT
dpc-4021	186	20	blind	blind	ADJ
dpc-4021	186	21	,	,	PUNCT
dpc-4021	186	22	randomized	randomize	VERB
dpc-4021	186	23	,	,	PUNCT
dpc-4021	186	24	placebo	placebo	NOUN
dpc-4021	186	25	-	-	PUNCT
dpc-4021	186	26	controlled	control	VERB
dpc-4021	186	27	clinical	clinical	ADJ
dpc-4021	186	28	trial	trial	NOUN
dpc-4021	186	29	.	.	PUNCT
dpc-4021	187	1	arthritis	arthritis	NOUN
dpc-4021	187	2	rheum	rheum	NOUN
dpc-4021	187	3	.	.	PUNCT
dpc-4021	188	1	2004	2004	NUM
dpc-4021	189	1	jun;50(6):1939	jun;50(6):1939	PROPN
dpc-4021	189	2	-	-	PUNCT
dpc-4021	189	3	50	50	PROPN
dpc-4021	189	4	.	.	PUNCT
dpc-4021	190	1	doi	doi	NOUN
dpc-4021	190	2	:	:	PUNCT
dpc-4021	190	3	10.1002	10.1002	NUM
dpc-4021	190	4	/	/	SYM
dpc-4021	190	5	art	art	NOUN
dpc-4021	190	6	.20253	.20253	NOUN
dpc-4021	190	7	.	.	PUNCT
dpc-4021	191	1	pmid	pmid	NOUN
dpc-4021	191	2	:	:	PUNCT
dpc-4021	191	3	15188371	15188371	NUM
dpc-4021	191	4	.	.	PUNCT
dpc-4021	192	1	18	18	NUM
dpc-4021	192	2	.	.	X
dpc-4021	192	3	tlacuilo	tlacuilo	PROPN
dpc-4021	192	4	-	-	PUNCT
dpc-4021	192	5	parra	parra	PROPN
dpc-4021	192	6	ja	ja	PROPN
dpc-4021	192	7	,	,	PUNCT
dpc-4021	192	8	guevara	guevara	PROPN
dpc-4021	192	9	-	-	PUNCT
dpc-4021	192	10	gutiérrez	gutiérrez	NOUN
dpc-4021	192	11	e	e	PROPN
dpc-4021	192	12	,	,	PUNCT
dpc-4021	192	13	rodríguez	rodríguez	NOUN
dpc-4021	192	14	-	-	PUNCT
dpc-4021	192	15	castellanos	castellanos	PROPN
dpc-4021	192	16	ma	ma	PROPN
dpc-4021	192	17	,	,	PUNCT
dpc-4021	192	18	ornelas	ornelas	PROPN
dpc-4021	192	19	-	-	PUNCT
dpc-4021	192	20	aguirre	aguirre	PROPN
dpc-4021	192	21	jm	jm	PROPN
dpc-4021	192	22	,	,	PUNCT
dpc-4021	192	23	barba	barba	NOUN
dpc-4021	192	24	-	-	PUNCT
dpc-4021	192	25	gómez	gómez	PROPN
dpc-4021	192	26	jf	jf	PROPN
dpc-4021	192	27	,	,	PUNCT
dpc-4021	192	28	salazar	salazar	NOUN
dpc-4021	192	29	-	-	PUNCT
dpc-4021	192	30	páramo	páramo	NOUN
dpc-4021	192	31	m.	m.	NOUN
dpc-4021	192	32	leflunomide	leflunomide	NOUN
dpc-4021	192	33	in	in	ADP
dpc-4021	192	34	the	the	DET
dpc-4021	192	35	treatment	treatment	NOUN
dpc-4021	192	36	of	of	ADP
dpc-4021	192	37	psoriasis	psoriasis	NOUN
dpc-4021	192	38	:	:	PUNCT
dpc-4021	192	39	results	result	NOUN
dpc-4021	192	40	of	of	ADP
dpc-4021	192	41	a	a	DET
dpc-4021	192	42	phase	phase	NOUN
dpc-4021	192	43	ii	ii	NOUN
dpc-4021	192	44	open	open	ADJ
dpc-4021	192	45	trial	trial	NOUN
dpc-4021	192	46	.	.	PUNCT
dpc-4021	193	1	br	br	PROPN
dpc-4021	193	2	j	j	PROPN
dpc-4021	193	3	dermatol	dermatol	NOUN
dpc-4021	193	4	.	.	PUNCT
dpc-4021	194	1	2004	2004	NUM
dpc-4021	194	2	may;150(5):970	may;150(5):970	PROPN
dpc-4021	194	3	-	-	PUNCT
dpc-4021	194	4	6	6	NUM
dpc-4021	194	5	.	.	PUNCT
dpc-4021	194	6	doi	doi	NOUN
dpc-4021	194	7	:	:	PUNCT
dpc-4021	194	8	10.1111	10.1111	NUM
dpc-4021	194	9	/	/	SYM
dpc-4021	194	10	j.1365	j.1365	NOUN
dpc-4021	194	11	-	-	PUNCT
dpc-4021	194	12	2133	2133	NUM
dpc-4021	194	13	.2004.05836.x	.2004.05836.x	NOUN
dpc-4021	194	14	.	.	PUNCT
dpc-4021	195	1	pmid	pmid	NOUN
dpc-4021	195	2	:	:	PUNCT
dpc-4021	195	3	15149511	15149511	NUM
dpc-4021	195	4	19	19	NUM
dpc-4021	195	5	.	.	PUNCT
dpc-4021	196	1	nash	nash	PROPN
dpc-4021	196	2	p	p	PROPN
dpc-4021	196	3	,	,	PUNCT
dpc-4021	196	4	thaçi	thaçi	NOUN
dpc-4021	196	5	d	d	PROPN
dpc-4021	196	6	,	,	PUNCT
dpc-4021	196	7	behrens	behrens	PROPN
dpc-4021	196	8	f	f	PROPN
dpc-4021	196	9	,	,	PUNCT
dpc-4021	196	10	falk	falk	NOUN
dpc-4021	196	11	f	f	PROPN
dpc-4021	196	12	,	,	PUNCT
dpc-4021	196	13	kaltwasser	kaltwasser	PROPN
dpc-4021	196	14	jp	jp	PROPN
dpc-4021	196	15	.	.	PUNCT
dpc-4021	197	1	leflunomide	leflunomide	PROPN
dpc-4021	197	2	improves	improve	VERB
dpc-4021	197	3	psoriasis	psoriasis	NOUN
dpc-4021	197	4	in	in	ADP
dpc-4021	197	5	patients	patient	NOUN
dpc-4021	197	6	with	with	ADP
dpc-4021	197	7	psoriatic	psoriatic	ADJ
dpc-4021	197	8	arthritis	arthritis	NOUN
dpc-4021	197	9	:	:	PUNCT
dpc-4021	197	10	an	an	DET
dpc-4021	197	11	in	in	ADP
dpc-4021	197	12	-	-	PUNCT
dpc-4021	197	13	depth	depth	NOUN
dpc-4021	197	14	analysis	analysis	NOUN
dpc-4021	197	15	of	of	ADP
dpc-4021	197	16	data	datum	NOUN
dpc-4021	197	17	from	from	ADP
dpc-4021	197	18	the	the	DET
dpc-4021	197	19	topas	topas	NOUN
dpc-4021	197	20	study	study	NOUN
dpc-4021	197	21	.	.	PUNCT
dpc-4021	198	1	dermatology	dermatology	NOUN
dpc-4021	198	2	.	.	PUNCT
dpc-4021	199	1	2006;212(3):238	2006;212(3):238	NUM
dpc-4021	199	2	-	-	SYM
dpc-4021	199	3	49	49	NUM
dpc-4021	199	4	.	.	PUNCT
dpc-4021	200	1	doi	doi	NOUN
dpc-4021	200	2	:	:	PUNCT
dpc-4021	200	3	10.1159/000091251	10.1159/000091251	NUM
dpc-4021	200	4	.	.	PUNCT
dpc-4021	201	1	pmid	pmid	NOUN
dpc-4021	201	2	:	:	PUNCT
dpc-4021	201	3	16549920	16549920	NUM
dpc-4021	201	4	.	.	PUNCT
dpc-4021	202	1	20	20	NUM
dpc-4021	202	2	.	.	X
dpc-4021	202	3	thami	thami	PROPN
dpc-4021	202	4	gp	gp	PROPN
dpc-4021	202	5	,	,	PUNCT
dpc-4021	202	6	garg	garg	PROPN
dpc-4021	202	7	g.	g.	PROPN
dpc-4021	202	8	leflunomide	leflunomide	PROPN
dpc-4021	202	9	in	in	ADP
dpc-4021	202	10	psoriasis	psoriasis	NOUN
dpc-4021	202	11	and	and	CCONJ
dpc-4021	202	12	psoriatic	psoriatic	ADJ
dpc-4021	202	13	arthritis	arthritis	NOUN
dpc-4021	202	14	:	:	PUNCT
dpc-4021	202	15	a	a	DET
dpc-4021	202	16	preliminary	preliminary	ADJ
dpc-4021	202	17	study	study	NOUN
dpc-4021	202	18	.	.	PUNCT
dpc-4021	203	1	arch	arch	ADJ
dpc-4021	203	2	dermatol	dermatol	NOUN
dpc-4021	203	3	.	.	PUNCT
dpc-4021	204	1	2004	2004	NUM
dpc-4021	204	2	oct;140(10	oct;140(10	NUM
dpc-4021	204	3	):	):	PUNCT
dpc-4021	204	4	1288	1288	NUM
dpc-4021	204	5	-	-	SYM
dpc-4021	204	6	9	9	NUM
dpc-4021	205	1	.	.	PUNCT
dpc-4021	205	2	doi	doi	NOUN
dpc-4021	205	3	:	:	PUNCT
dpc-4021	205	4	10.1001	10.1001	NUM
dpc-4021	205	5	/	/	SYM
dpc-4021	205	6	archderm.140.10.1288	archderm.140.10.1288	NOUN
dpc-4021	205	7	.	.	PUNCT
dpc-4021	206	1	pmid	pmid	NOUN
dpc-4021	206	2	:	:	PUNCT
dpc-4021	206	3	15492204	15492204	NUM
dpc-4021	206	4	.	.	PUNCT
dpc-4021	207	1	21	21	NUM
dpc-4021	207	2	.	.	PUNCT
dpc-4021	207	3	liang	liang	PROPN
dpc-4021	207	4	gc	gc	PROPN
dpc-4021	207	5	,	,	PUNCT
dpc-4021	207	6	barr	barr	PROPN
dpc-4021	207	7	wg	wg	PROPN
dpc-4021	207	8	.	.	PUNCT
dpc-4021	208	1	open	open	ADJ
dpc-4021	208	2	trial	trial	NOUN
dpc-4021	208	3	of	of	ADP
dpc-4021	208	4	leflunomide	leflunomide	NOUN
dpc-4021	208	5	for	for	ADP
dpc-4021	208	6	refractory	refractory	NOUN
dpc-4021	208	7	psoriasis	psoriasis	NOUN
dpc-4021	208	8	and	and	CCONJ
dpc-4021	208	9	psoriatic	psoriatic	ADJ
dpc-4021	208	10	arthritis	arthritis	NOUN
dpc-4021	208	11	.	.	PUNCT
dpc-4021	209	1	j	j	PROPN
dpc-4021	209	2	clin	clin	PROPN
dpc-4021	209	3	rheumatol	rheumatol	NOUN
dpc-4021	209	4	.	.	PUNCT
dpc-4021	210	1	2001	2001	NUM
dpc-4021	210	2	dec;7(6):366	dec;7(6):366	PROPN
dpc-4021	210	3	-	-	PUNCT
dpc-4021	210	4	70	70	NUM
dpc-4021	210	5	.	.	PUNCT
dpc-4021	211	1	doi	doi	NOUN
dpc-4021	211	2	:	:	PUNCT
dpc-4021	211	3	10.1097/00124743	10.1097/00124743	NUM
dpc-4021	211	4	-	-	SYM
dpc-4021	211	5	200112000	200112000	NUM
dpc-4021	211	6	-	-	PUNCT
dpc-4021	211	7	00003	00003	NUM
dpc-4021	211	8	.	.	PUNCT
dpc-4021	212	1	pmid	pmid	NOUN
dpc-4021	212	2	:	:	PUNCT
dpc-4021	212	3	17039176	17039176	NUM
dpc-4021	212	4	.	.	PUNCT
dpc-4021	213	1	22	22	NUM
dpc-4021	213	2	.	.	PUNCT
dpc-4021	214	1	behrens	behrens	PROPN
dpc-4021	214	2	f	f	PROPN
dpc-4021	214	3	,	,	PUNCT
dpc-4021	214	4	finkenwirth	finkenwirth	ADV
dpc-4021	214	5	c	c	NOUN
dpc-4021	214	6	,	,	PUNCT
dpc-4021	214	7	pavelka	pavelka	PROPN
dpc-4021	214	8	k	k	X
dpc-4021	214	9	,	,	PUNCT
dpc-4021	214	10	et	et	PROPN
dpc-4021	214	11	al	al	PROPN
dpc-4021	214	12	.	.	PROPN
dpc-4021	214	13	leflunomide	leflunomide	PROPN
dpc-4021	214	14	in	in	ADP
dpc-4021	214	15	psoriatic	psoriatic	ADJ
dpc-4021	214	16	arthritis	arthritis	NOUN
dpc-4021	214	17	:	:	PUNCT
dpc-4021	214	18	results	result	VERB
dpc-4021	214	19	from	from	ADP
dpc-4021	214	20	a	a	DET
dpc-4021	214	21	large	large	ADJ
dpc-4021	214	22	european	european	ADJ
dpc-4021	214	23	prospective	prospective	ADJ
dpc-4021	214	24	observational	observational	ADJ
dpc-4021	214	25	study	study	NOUN
dpc-4021	214	26	.	.	PUNCT
dpc-4021	215	1	arthritis	arthritis	NOUN
dpc-4021	215	2	care	care	NOUN
dpc-4021	215	3	res	re	NOUN
dpc-4021	215	4	(	(	PUNCT
dpc-4021	215	5	hoboken	hoboken	PROPN
dpc-4021	215	6	)	)	PUNCT
dpc-4021	215	7	.	.	PUNCT
dpc-4021	216	1	2013	2013	NUM
dpc-4021	216	2	mar;65(3):464	mar;65(3):464	SYM
dpc-4021	216	3	-	-	PUNCT
dpc-4021	216	4	70	70	NUM
dpc-4021	216	5	.	.	PUNCT
dpc-4021	217	1	doi	doi	NOUN
dpc-4021	217	2	:	:	PUNCT
dpc-4021	217	3	10.1002	10.1002	NUM
dpc-4021	217	4	/	/	SYM
dpc-4021	217	5	acr.21848	acr.21848	PROPN
dpc-4021	217	6	.	.	PUNCT
dpc-4021	218	1	pmid	pmid	NOUN
dpc-4021	218	2	:	:	PUNCT
dpc-4021	218	3	23042698	23042698	NUM
dpc-4021	218	4	.	.	PUNCT
dpc-4021	219	1	23	23	NUM
dpc-4021	219	2	.	.	PUNCT
dpc-4021	220	1	hsieh	hsieh	PROPN
dpc-4021	220	2	ts	ts	PROPN
dpc-4021	220	3	,	,	PUNCT
dpc-4021	220	4	tsai	tsai	PROPN
dpc-4021	220	5	tf	tf	PROPN
dpc-4021	220	6	.	.	PUNCT
dpc-4021	220	7	combination	combination	NOUN
dpc-4021	220	8	therapy	therapy	NOUN
dpc-4021	220	9	for	for	ADP
dpc-4021	220	10	psoriasis	psoriasis	NOUN
dpc-4021	220	11	with	with	ADP
dpc-4021	220	12	methotrexate	methotrexate	NOUN
dpc-4021	220	13	and	and	CCONJ
dpc-4021	220	14	other	other	ADJ
dpc-4021	220	15	oral	oral	ADJ
dpc-4021	220	16	disease	disease	NOUN
dpc-4021	220	17	-	-	PUNCT
dpc-4021	220	18	modifying	modify	VERB
dpc-4021	220	19	antirheumatic	antirheumatic	ADJ
dpc-4021	220	20	drugs	drug	NOUN
dpc-4021	220	21	:	:	PUNCT
dpc-4021	220	22	a	a	DET
dpc-4021	220	23	systematic	systematic	ADJ
dpc-4021	220	24	review	review	NOUN
dpc-4021	220	25	.	.	PUNCT
dpc-4021	221	1	dermatol	dermatol	NOUN
dpc-4021	221	2	ther	ther	ADV
dpc-4021	221	3	(	(	PUNCT
dpc-4021	221	4	heidelb	heidelb	NOUN
dpc-4021	221	5	)	)	PUNCT
dpc-4021	221	6	.	.	PUNCT
dpc-4021	222	1	2023	2023	NUM
dpc-4021	222	2	apr;13(4):891	apr;13(4):891	NOUN
dpc-4021	222	3	-	-	SYM
dpc-4021	222	4	909	909	NUM
dpc-4021	222	5	.	.	PUNCT
dpc-4021	223	1	doi	doi	NOUN
dpc-4021	223	2	:	:	PUNCT
dpc-4021	223	3	10.1007	10.1007	NUM
dpc-4021	223	4	/	/	SYM
dpc-4021	223	5	s13555	s13555	PROPN
dpc-4021	223	6	-	-	PUNCT
dpc-4021	223	7	023	023	NUM
dpc-4021	223	8	-	-	PUNCT
dpc-4021	223	9	00903	00903	NUM
dpc-4021	223	10	-	-	PUNCT
dpc-4021	223	11	5	5	NUM
dpc-4021	223	12	.	.	PUNCT
dpc-4021	224	1	epub	epub	NOUN
dpc-4021	224	2	2023	2023	NUM
dpc-4021	224	3	mar	mar	PROPN
dpc-4021	224	4	21	21	NUM
dpc-4021	224	5	.	.	PUNCT
dpc-4021	225	1	pmid	pmid	NOUN
dpc-4021	225	2	:	:	PUNCT
dpc-4021	225	3	36943580	36943580	NUM
dpc-4021	225	4	;	;	PUNCT
dpc-4021	225	5	pmcid	pmcid	NOUN
dpc-4021	225	6	:	:	PUNCT
dpc-4021	225	7	pmc10060456	pmc10060456	NOUN
dpc-4021	225	8	.	.	PUNCT
dpc-4021	226	1	24	24	NUM
dpc-4021	226	2	.	.	PUNCT
dpc-4021	227	1	mazhar	mazhar	PROPN
dpc-4021	227	2	f	f	PROPN
dpc-4021	227	3	,	,	PUNCT
dpc-4021	227	4	krantz	krantz	PROPN
dpc-4021	227	5	å	å	PROPN
dpc-4021	227	6	,	,	PUNCT
dpc-4021	227	7	schalin	schalin	PROPN
dpc-4021	227	8	l	l	PROPN
dpc-4021	227	9	,	,	PUNCT
dpc-4021	227	10	lysell	lysell	PROPN
dpc-4021	227	11	j	j	PROPN
dpc-4021	227	12	,	,	PUNCT
dpc-4021	227	13	carrero	carrero	PROPN
dpc-4021	227	14	jj	jj	PROPN
dpc-4021	227	15	.	.	PROPN
dpc-4021	227	16	occurrence	occurrence	NOUN
dpc-4021	227	17	of	of	ADP
dpc-4021	227	18	adverse	adverse	ADJ
dpc-4021	227	19	events	event	NOUN
dpc-4021	227	20	associated	associate	VERB
dpc-4021	227	21	with	with	ADP
dpc-4021	227	22	the	the	DET
dpc-4021	227	23	initiation	initiation	NOUN
dpc-4021	227	24	of	of	ADP
dpc-4021	227	25	methotrexate	methotrexate	NOUN
dpc-4021	227	26	and	and	CCONJ
dpc-4021	227	27	biologics	biologic	NOUN
dpc-4021	227	28	for	for	ADP
dpc-4021	227	29	the	the	DET
dpc-4021	227	30	treatment	treatment	NOUN
dpc-4021	227	31	of	of	ADP
dpc-4021	227	32	psoriasis	psoriasis	NOUN
dpc-4021	227	33	in	in	ADP
dpc-4021	227	34	routine	routine	ADJ
dpc-4021	227	35	clinical	clinical	ADJ
dpc-4021	227	36	practice	practice	NOUN
dpc-4021	227	37	.	.	PUNCT
dpc-4021	228	1	j	j	PROPN
dpc-4021	228	2	dermatolog	dermatolog	PROPN
dpc-4021	228	3	treat	treat	NOUN
dpc-4021	228	4	.	.	PUNCT
dpc-4021	229	1	2023	2023	NUM
dpc-4021	229	2	dec;34(1):2215354	dec;34(1):2215354	PROPN
dpc-4021	229	3	.	.	PROPN
dpc-4021	229	4	doi	doi	PROPN
dpc-4021	229	5	:	:	PUNCT
dpc-4021	229	6	10.1080	10.1080	NUM
dpc-4021	229	7	/09546634.2023.2215354	/09546634.2023.2215354	PRON
dpc-4021	229	8	.	.	PUNCT
dpc-4021	230	1	pmid	pmid	NOUN
dpc-4021	230	2	:	:	PUNCT
dpc-4021	230	3	37246910	37246910	NUM
dpc-4021	230	4	.	.	PUNCT
dpc-4021	231	1	4	4	X
dpc-4021	231	2	.	.	X
dpc-4021	231	3	yamanaka	yamanaka	PROPN
dpc-4021	231	4	k	k	PROPN
dpc-4021	231	5	,	,	PUNCT
dpc-4021	231	6	yamamoto	yamamoto	PROPN
dpc-4021	231	7	o	o	PROPN
dpc-4021	231	8	,	,	PUNCT
dpc-4021	231	9	honda	honda	PROPN
dpc-4021	231	10	t.	t.	PROPN
dpc-4021	231	11	pathophysiology	pathophysiology	NOUN
dpc-4021	231	12	of	of	ADP
dpc-4021	231	13	psoriasis	psoriasis	NOUN
dpc-4021	231	14	:	:	PUNCT
dpc-4021	231	15	a	a	DET
dpc-4021	231	16	review	review	NOUN
dpc-4021	231	17	.	.	PUNCT
dpc-4021	232	1	j	j	PROPN
dpc-4021	232	2	dermatol	dermatol	NOUN
dpc-4021	232	3	.	.	PUNCT
dpc-4021	233	1	2021	2021	NUM
dpc-4021	233	2	jun;48(6):722	jun;48(6):722	NOUN
dpc-4021	233	3	-	-	NOUN
dpc-4021	233	4	731	731	NUM
dpc-4021	233	5	.	.	PUNCT
dpc-4021	234	1	doi	doi	NOUN
dpc-4021	234	2	:	:	PUNCT
dpc-4021	234	3	10.1111/1346	10.1111/1346	NUM
dpc-4021	234	4	-	-	SYM
dpc-4021	234	5	8138.15913	8138.15913	NUM
dpc-4021	234	6	.	.	PUNCT
dpc-4021	235	1	epub	epub	NOUN
dpc-4021	235	2	2021	2021	NUM
dpc-4021	235	3	apr	apr	NOUN
dpc-4021	235	4	22	22	NUM
dpc-4021	235	5	.	.	PUNCT
dpc-4021	236	1	pmid	pmid	NOUN
dpc-4021	236	2	:	:	PUNCT
dpc-4021	236	3	33886133	33886133	NUM
dpc-4021	236	4	.	.	PUNCT
dpc-4021	237	1	5	5	X
dpc-4021	237	2	.	.	X
dpc-4021	237	3	dhabale	dhabale	NOUN
dpc-4021	237	4	a	a	DET
dpc-4021	237	5	,	,	PUNCT
dpc-4021	237	6	nagpure	nagpure	ADJ
dpc-4021	237	7	s.	s.	PROPN
dpc-4021	237	8	types	type	NOUN
dpc-4021	237	9	of	of	ADP
dpc-4021	237	10	psoriasis	psoriasis	NOUN
dpc-4021	237	11	and	and	CCONJ
dpc-4021	237	12	their	their	PRON
dpc-4021	237	13	effects	effect	NOUN
dpc-4021	237	14	on	on	ADP
dpc-4021	237	15	the	the	DET
dpc-4021	237	16	immune	immune	ADJ
dpc-4021	237	17	system	system	NOUN
dpc-4021	237	18	.	.	PUNCT
dpc-4021	238	1	cureus	cureus	NOUN
dpc-4021	238	2	.	.	PUNCT
dpc-4021	239	1	2022	2022	NUM
dpc-4021	239	2	sep	sep	PROPN
dpc-4021	239	3	24;14(9):e29536	24;14(9):e29536	NUM
dpc-4021	239	4	.	.	PUNCT
dpc-4021	240	1	doi	doi	NOUN
dpc-4021	240	2	:	:	PUNCT
dpc-4021	240	3	10.7759	10.7759	NUM
dpc-4021	240	4	/cureus.29536	/cureus.29536	SYM
dpc-4021	240	5	.	.	PUNCT
dpc-4021	241	1	pmid	pmid	NOUN
dpc-4021	241	2	:	:	PUNCT
dpc-4021	241	3	36312680	36312680	NUM
dpc-4021	241	4	;	;	PUNCT
dpc-4021	241	5	pmcid	pmcid	ADJ
dpc-4021	241	6	:	:	PUNCT
dpc-4021	241	7	pmc9592057	pmc9592057	VERB
dpc-4021	241	8	.	.	PUNCT
dpc-4021	242	1	6	6	X
dpc-4021	242	2	.	.	X
dpc-4021	242	3	yang	yang	PROPN
dpc-4021	242	4	ej	ej	PROPN
dpc-4021	242	5	,	,	PUNCT
dpc-4021	242	6	beck	beck	PROPN
dpc-4021	242	7	km	km	PROPN
dpc-4021	242	8	,	,	PUNCT
dpc-4021	242	9	sanchez	sanchez	PROPN
dpc-4021	243	1	i	i	PRON
dpc-4021	243	2	m	m	PROPN
dpc-4021	243	3	,	,	PUNCT
dpc-4021	243	4	koo	koo	PROPN
dpc-4021	243	5	j	j	PROPN
dpc-4021	243	6	,	,	PUNCT
dpc-4021	243	7	liao	liao	PROPN
dpc-4021	243	8	w.	w.	PROPN
dpc-4021	244	1	the	the	DET
dpc-4021	244	2	impact	impact	NOUN
dpc-4021	244	3	of	of	ADP
dpc-4021	244	4	genital	genital	ADJ
dpc-4021	244	5	psoriasis	psoriasis	NOUN
dpc-4021	244	6	on	on	ADP
dpc-4021	244	7	quality	quality	NOUN
dpc-4021	244	8	of	of	ADP
dpc-4021	244	9	life	life	NOUN
dpc-4021	244	10	:	:	PUNCT
dpc-4021	244	11	a	a	DET
dpc-4021	244	12	systematic	systematic	ADJ
dpc-4021	244	13	review	review	NOUN
dpc-4021	244	14	.	.	PUNCT
dpc-4021	245	1	psoriasis	psoriasis	NOUN
dpc-4021	245	2	(	(	PUNCT
dpc-4021	245	3	auckl	auckl	NOUN
dpc-4021	245	4	)	)	PUNCT
dpc-4021	245	5	.	.	PUNCT
dpc-4021	246	1	2018	2018	NUM
dpc-4021	246	2	aug	aug	PROPN
dpc-4021	246	3	28;8:41	28;8:41	NUM
dpc-4021	246	4	-	-	SYM
dpc-4021	246	5	47	47	NUM
dpc-4021	246	6	.	.	PUNCT
dpc-4021	247	1	doi	doi	NOUN
dpc-4021	247	2	:	:	PUNCT
dpc-4021	247	3	10.2147	10.2147	NUM
dpc-4021	247	4	/	/	SYM
dpc-4021	247	5	ptt.s169389	ptt.s169389	NOUN
dpc-4021	247	6	.	.	PUNCT
dpc-4021	248	1	pmid	pmid	NOUN
dpc-4021	248	2	:	:	PUNCT
dpc-4021	248	3	30214891	30214891	NUM
dpc-4021	248	4	;	;	PUNCT
dpc-4021	248	5	pmcid	pmcid	ADJ
dpc-4021	248	6	:	:	PUNCT
dpc-4021	248	7	pmc6118254	pmc6118254	NOUN
dpc-4021	248	8	.	.	PUNCT
dpc-4021	249	1	7	7	X
dpc-4021	249	2	.	.	X
dpc-4021	249	3	burden	burden	NOUN
dpc-4021	249	4	ad	ad	NOUN
dpc-4021	249	5	,	,	PUNCT
dpc-4021	249	6	choon	choon	PROPN
dpc-4021	249	7	se	se	PROPN
dpc-4021	249	8	,	,	PUNCT
dpc-4021	249	9	gottlieb	gottlieb	PROPN
dpc-4021	249	10	ab	ab	PROPN
dpc-4021	249	11	,	,	PUNCT
dpc-4021	249	12	navarini	navarini	ADJ
dpc-4021	249	13	aa	aa	PROPN
dpc-4021	249	14	,	,	PUNCT
dpc-4021	249	15	warren	warren	PROPN
dpc-4021	249	16	rb	rb	PROPN
dpc-4021	249	17	.	.	PUNCT
dpc-4021	249	18	clinical	clinical	ADJ
dpc-4021	249	19	disease	disease	NOUN
dpc-4021	249	20	measures	measure	NOUN
dpc-4021	249	21	in	in	ADP
dpc-4021	249	22	generalized	generalized	ADJ
dpc-4021	249	23	pustular	pustular	ADJ
dpc-4021	249	24	psoriasis	psoriasis	NOUN
dpc-4021	249	25	.	.	PUNCT
dpc-4021	250	1	am	be	AUX
dpc-4021	250	2	j	j	PROPN
dpc-4021	250	3	clin	clin	PROPN
dpc-4021	250	4	dermatol	dermatol	NOUN
dpc-4021	250	5	.	.	PUNCT
dpc-4021	251	1	2022	2022	NUM
dpc-4021	251	2	jan;23(suppl	jan;23(suppl	PROPN
dpc-4021	251	3	1):39	1):39	PROPN
dpc-4021	251	4	-	-	PUNCT
dpc-4021	251	5	50	50	NUM
dpc-4021	251	6	.	.	PUNCT
dpc-4021	252	1	doi	doi	NOUN
dpc-4021	252	2	:	:	PUNCT
dpc-4021	252	3	10.1007	10.1007	NUM
dpc-4021	252	4	/	/	SYM
dpc-4021	252	5	s40257	s40257	NOUN
dpc-4021	252	6	-	-	PUNCT
dpc-4021	252	7	021	021	NUM
dpc-4021	252	8	-	-	PUNCT
dpc-4021	252	9	00653	00653	NUM
dpc-4021	252	10	-	-	PUNCT
dpc-4021	252	11	0	0	NUM
dpc-4021	252	12	.	.	PUNCT
dpc-4021	253	1	epub	epub	NOUN
dpc-4021	253	2	2022	2022	NUM
dpc-4021	253	3	jan	jan	PROPN
dpc-4021	253	4	21	21	NUM
dpc-4021	253	5	.	.	PUNCT
dpc-4021	254	1	pmid	pmid	NOUN
dpc-4021	254	2	:	:	PUNCT
dpc-4021	254	3	35061231	35061231	NUM
dpc-4021	254	4	;	;	PUNCT
dpc-4021	254	5	pmcid	pmcid	PROPN
dpc-4021	254	6	:	:	PUNCT
dpc-4021	254	7	pmc8801406	pmc8801406	ADJ
dpc-4021	254	8	.	.	PUNCT
dpc-4021	255	1	7	7	X
dpc-4021	255	2	.	.	X
dpc-4021	255	3	perez	perez	PROPN
dpc-4021	255	4	-	-	PUNCT
dpc-4021	255	5	chada	chada	PROPN
dpc-4021	255	6	lm	lm	PROPN
dpc-4021	255	7	,	,	PUNCT
dpc-4021	255	8	cohen	cohen	PROPN
dpc-4021	255	9	jm	jm	PROPN
dpc-4021	255	10	,	,	PUNCT
dpc-4021	255	11	gottlieb	gottlieb	PROPN
dpc-4021	255	12	ab	ab	PROPN
dpc-4021	255	13	,	,	PUNCT
dpc-4021	255	14	et	et	PROPN
dpc-4021	255	15	al	al	PROPN
dpc-4021	255	16	.	.	PUNCT
dpc-4021	255	17	achieving	achieve	VERB
dpc-4021	255	18	international	international	ADJ
dpc-4021	255	19	consensus	consensus	NOUN
dpc-4021	255	20	on	on	ADP
dpc-4021	255	21	the	the	DET
dpc-4021	255	22	assessment	assessment	NOUN
dpc-4021	255	23	of	of	ADP
dpc-4021	255	24	psoriatic	psoriatic	ADJ
dpc-4021	255	25	arthritis	arthritis	NOUN
dpc-4021	255	26	in	in	ADP
dpc-4021	255	27	psoriasis	psoriasis	NOUN
dpc-4021	255	28	clinical	clinical	ADJ
dpc-4021	255	29	trials	trial	NOUN
dpc-4021	255	30	:	:	PUNCT
dpc-4021	255	31	an	an	DET
dpc-4021	255	32	international	international	ADJ
dpc-4021	255	33	dermatology	dermatology	NOUN
dpc-4021	255	34	outcome	outcome	NOUN
dpc-4021	255	35	measures	measure	NOUN
dpc-4021	255	36	(	(	PUNCT
dpc-4021	255	37	ideom	ideom	NOUN
dpc-4021	255	38	)	)	PUNCT
dpc-4021	255	39	initiative	initiative	NOUN
dpc-4021	255	40	.	.	PUNCT
dpc-4021	256	1	arch	arch	ADJ
dpc-4021	256	2	dermatol	dermatol	NOUN
dpc-4021	256	3	res	re	NOUN
dpc-4021	256	4	.	.	PROPN
dpc-4021	256	5	2018	2018	NUM
dpc-4021	256	6	nov;310(9):701	nov;310(9):701	X
dpc-4021	256	7	-	-	PUNCT
dpc-4021	256	8	710	710	NUM
dpc-4021	256	9	.	.	PUNCT
dpc-4021	257	1	doi	doi	NOUN
dpc-4021	257	2	:	:	PUNCT
dpc-4021	257	3	10.1007	10.1007	NUM
dpc-4021	257	4	/	/	SYM
dpc-4021	257	5	s00403	s00403	NOUN
dpc-4021	257	6	-	-	PUNCT
dpc-4021	257	7	018	018	NUM
dpc-4021	257	8	-	-	PUNCT
dpc-4021	257	9	1855	1855	NUM
dpc-4021	257	10	-	-	PUNCT
dpc-4021	257	11	3	3	NUM
dpc-4021	257	12	.	.	PUNCT
dpc-4021	258	1	epub	epub	PROPN
dpc-4021	258	2	2018	2018	NUM
dpc-4021	258	3	aug	aug	PROPN
dpc-4021	258	4	25	25	NUM
dpc-4021	258	5	.	.	PUNCT
dpc-4021	259	1	pmid	pmid	NOUN
dpc-4021	259	2	:	:	PUNCT
dpc-4021	259	3	30167814	30167814	NUM
dpc-4021	259	4	.	.	PUNCT
dpc-4021	260	1	8	8	X
dpc-4021	260	2	.	.	X
dpc-4021	260	3	schadler	schadler	PROPN
dpc-4021	260	4	ed	ed	PROPN
dpc-4021	260	5	,	,	PUNCT
dpc-4021	260	6	ortel	ortel	VERB
dpc-4021	260	7	b	b	NUM
dpc-4021	260	8	,	,	PUNCT
dpc-4021	260	9	mehlis	mehlis	PROPN
dpc-4021	260	10	sl	sl	PROPN
dpc-4021	260	11	.	.	PUNCT
dpc-4021	260	12	biologics	biologic	NOUN
dpc-4021	260	13	for	for	ADP
dpc-4021	260	14	the	the	DET
dpc-4021	260	15	primary	primary	ADJ
dpc-4021	260	16	care	care	NOUN
dpc-4021	260	17	physician	physician	NOUN
dpc-4021	260	18	:	:	PUNCT
dpc-4021	260	19	review	review	NOUN
dpc-4021	260	20	and	and	CCONJ
dpc-4021	260	21	treatment	treatment	NOUN
dpc-4021	260	22	of	of	ADP
dpc-4021	260	23	psoriasis	psoriasis	NOUN
dpc-4021	260	24	.	.	PUNCT
dpc-4021	261	1	dis	dis	PROPN
dpc-4021	261	2	mon	mon	PROPN
dpc-4021	261	3	.	.	PROPN
dpc-4021	262	1	2019	2019	NUM
dpc-4021	262	2	mar;65(3):51	mar;65(3):51	PROPN
dpc-4021	262	3	-	-	SYM
dpc-4021	262	4	90	90	NUM
dpc-4021	262	5	.	.	PUNCT
dpc-4021	263	1	doi	doi	NOUN
dpc-4021	263	2	:	:	PUNCT
dpc-4021	263	3	10.1016	10.1016	NUM
dpc-4021	263	4	/	/	SYM
dpc-4021	263	5	j.disamonth.2018.06.001	j.disamonth.2018.06.001	PROPN
dpc-4021	263	6	.	.	PUNCT
dpc-4021	264	1	epub	epub	PROPN
dpc-4021	264	2	2018	2018	NUM
dpc-4021	264	3	jul	jul	PROPN
dpc-4021	264	4	20	20	NUM
dpc-4021	264	5	.	.	PUNCT
dpc-4021	265	1	pmid	pmid	NOUN
dpc-4021	265	2	:	:	PUNCT
dpc-4021	265	3	30037762	30037762	NUM
dpc-4021	265	4	.	.	PUNCT
dpc-4021	265	5	.	.	PUNCT
dpc-4021	266	1	9	9	X
dpc-4021	266	2	.	.	X
dpc-4021	266	3	van	van	PROPN
dpc-4021	266	4	huizen	huizen	PROPN
dpc-4021	266	5	am	am	PROPN
dpc-4021	266	6	,	,	PUNCT
dpc-4021	266	7	sikkel	sikkel	ADJ
dpc-4021	266	8	r	r	NOUN
dpc-4021	266	9	,	,	PUNCT
dpc-4021	266	10	caron	caron	PROPN
dpc-4021	266	11	agm	agm	PROPN
dpc-4021	266	12	,	,	PUNCT
dpc-4021	266	13	menting	menting	NOUN
dpc-4021	266	14	sp	sp	NOUN
dpc-4021	266	15	,	,	PUNCT
dpc-4021	266	16	spuls	spuls	PROPN
dpc-4021	266	17	pi	pi	PROPN
dpc-4021	266	18	.	.	PUNCT
dpc-4021	267	1	methotrexate	methotrexate	VERB
dpc-4021	267	2	dosing	dose	VERB
dpc-4021	267	3	regimen	regiman	NOUN
dpc-4021	267	4	for	for	ADP
dpc-4021	267	5	plaque	plaque	NOUN
dpc-4021	267	6	-	-	PUNCT
dpc-4021	267	7	type	type	NOUN
dpc-4021	267	8	psoriasis	psoriasis	NOUN
dpc-4021	267	9	:	:	PUNCT
dpc-4021	267	10	an	an	DET
dpc-4021	267	11	update	update	NOUN
dpc-4021	267	12	of	of	ADP
dpc-4021	267	13	a	a	DET
dpc-4021	267	14	systematic	systematic	ADJ
dpc-4021	267	15	review	review	NOUN
dpc-4021	267	16	.	.	PUNCT
dpc-4021	268	1	j	j	PROPN
dpc-4021	268	2	dermatolog	dermatolog	PROPN
dpc-4021	268	3	treat	treat	NOUN
dpc-4021	268	4	.	.	PUNCT
dpc-4021	269	1	2022	2022	NUM
dpc-4021	269	2	dec;33(8):3104	dec;33(8):3104	PROPN
dpc-4021	269	3	-	-	PUNCT
dpc-4021	269	4	3118	3118	NUM
dpc-4021	269	5	.	.	PUNCT
dpc-4021	270	1	doi	doi	NOUN
dpc-4021	270	2	:	:	PUNCT
dpc-4021	270	3	10.1080/09546634.2022.2117539	10.1080/09546634.2022.2117539	NUM
dpc-4021	270	4	.	.	PUNCT
dpc-4021	271	1	epub	epub	VERB
dpc-4021	271	2	2022	2022	NUM
dpc-4021	271	3	sep	sep	PROPN
dpc-4021	271	4	9	9	NUM
dpc-4021	271	5	.	.	PUNCT
dpc-4021	272	1	pmid	pmid	NOUN
dpc-4021	272	2	:	:	PUNCT
dpc-4021	272	3	36043844	36043844	NUM
dpc-4021	272	4	.	.	PUNCT
dpc-4021	273	1	10	10	NUM
dpc-4021	273	2	.	.	PUNCT
dpc-4021	274	1	puig	puig	PROPN
dpc-4021	274	2	l.	l.	PROPN
dpc-4021	274	3	methotrexate	methotrexate	PROPN
dpc-4021	274	4	:	:	PUNCT
dpc-4021	274	5	new	new	ADJ
dpc-4021	274	6	therapeutic	therapeutic	ADJ
dpc-4021	274	7	approaches	approach	NOUN
dpc-4021	274	8	.	.	PUNCT
dpc-4021	275	1	actas	actas	PROPN
dpc-4021	275	2	dermosifiliogr	dermosifiliogr	NOUN
dpc-4021	275	3	.	.	PUNCT
dpc-4021	276	1	2014	2014	NUM
dpc-4021	276	2	jul	jul	PROPN
dpc-4021	276	3	-	-	PUNCT
dpc-4021	276	4	aug;105(6):583	aug;105(6):583	NOUN
dpc-4021	276	5	-	-	PUNCT
dpc-4021	276	6	9	9	NUM
dpc-4021	276	7	.	.	PUNCT
dpc-4021	277	1	english	english	PROPN
dpc-4021	277	2	,	,	PUNCT
dpc-4021	277	3	spanish	spanish	PROPN
dpc-4021	277	4	.	.	PUNCT
dpc-4021	278	1	doi	doi	NOUN
dpc-4021	278	2	:	:	PUNCT
dpc-4021	278	3	10.1016	10.1016	NUM
dpc-4021	278	4	/	/	SYM
dpc-4021	278	5	j.ad.2012.11.017	j.ad.2012.11.017	PROPN
dpc-4021	278	6	.	.	PUNCT
dpc-4021	279	1	epub	epub	PROPN
dpc-4021	279	2	2013	2013	NUM
dpc-4021	279	3	feb	feb	NOUN
dpc-4021	279	4	22	22	NUM
dpc-4021	279	5	.	.	PUNCT
dpc-4021	280	1	pmid	pmid	NOUN
dpc-4021	280	2	:	:	PUNCT
dpc-4021	280	3	23434058	23434058	NUM
dpc-4021	280	4	.	.	PUNCT
dpc-4021	281	1	11	11	NUM
dpc-4021	281	2	.	.	X
dpc-4021	281	3	weidmann	weidmann	PROPN
dpc-4021	281	4	a	a	PROPN
dpc-4021	281	5	,	,	PUNCT
dpc-4021	281	6	foulkes	foulkes	PROPN
dpc-4021	281	7	ac	ac	PROPN
dpc-4021	281	8	,	,	PUNCT
dpc-4021	281	9	kirkham	kirkham	PROPN
dpc-4021	281	10	n	n	NUM
dpc-4021	281	11	,	,	PUNCT
dpc-4021	281	12	reynolds	reynolds	PROPN
dpc-4021	281	13	nj	nj	PROPN
dpc-4021	281	14	.	.	PROPN
dpc-4021	281	15	methotrexate	methotrexate	VERB
dpc-4021	281	16	toxicity	toxicity	NOUN
dpc-4021	281	17	during	during	ADP
dpc-4021	281	18	treatment	treatment	NOUN
dpc-4021	281	19	of	of	ADP
dpc-4021	281	20	chronic	chronic	ADJ
dpc-4021	281	21	plaque	plaque	NOUN
dpc-4021	281	22	psoriasis	psoriasis	NOUN
dpc-4021	281	23	:	:	PUNCT
dpc-4021	281	24	a	a	DET
dpc-4021	281	25	case	case	NOUN
dpc-4021	281	26	report	report	NOUN
dpc-4021	281	27	and	and	CCONJ
dpc-4021	281	28	review	review	NOUN
dpc-4021	281	29	of	of	ADP
dpc-4021	281	30	the	the	DET
dpc-4021	281	31	literature	literature	NOUN
dpc-4021	281	32	.	.	PUNCT
dpc-4021	282	1	dermatol	dermatol	NOUN
dpc-4021	282	2	ther	ther	ADV
dpc-4021	282	3	(	(	PUNCT
dpc-4021	282	4	heidelb	heidelb	NOUN
dpc-4021	282	5	)	)	PUNCT
dpc-4021	282	6	.	.	PUNCT
dpc-4021	283	1	2014	2014	NUM
dpc-4021	283	2	dec;4(2):145	dec;4(2):145	NOUN
dpc-4021	283	3	-	-	PUNCT
dpc-4021	283	4	56	56	PROPN
dpc-4021	283	5	.	.	PUNCT
dpc-4021	284	1	doi	doi	NOUN
dpc-4021	284	2	:	:	PUNCT
dpc-4021	284	3	10.1007	10.1007	NUM
dpc-4021	284	4	/	/	SYM
dpc-4021	284	5	s13555	s13555	PROPN
dpc-4021	284	6	-	-	PUNCT
dpc-4021	284	7	014	014	NUM
dpc-4021	284	8	-	-	PUNCT
dpc-4021	284	9	0056	0056	NUM
dpc-4021	284	10	-	-	PUNCT
dpc-4021	284	11	z.	z.	PROPN
dpc-4021	284	12	epub	epub	PROPN
dpc-4021	284	13	2014	2014	NUM
dpc-4021	284	14	jun	jun	PROPN
dpc-4021	284	15	19	19	NUM
dpc-4021	284	16	.	.	PUNCT
dpc-4021	285	1	pmid	pmid	NOUN
dpc-4021	285	2	:	:	PUNCT
dpc-4021	285	3	24942326	24942326	NUM
dpc-4021	285	4	;	;	PUNCT
dpc-4021	285	5	pmcid	pmcid	ADJ
dpc-4021	285	6	:	:	PUNCT
dpc-4021	285	7	pmc4257944	pmc4257944	PROPN
dpc-4021	285	8	.	.	PUNCT
dpc-4021	286	1	12	12	NUM
dpc-4021	286	2	.	.	PUNCT
dpc-4021	287	1	xue	xue	PROPN
dpc-4021	287	2	h	h	PROPN
dpc-4021	287	3	,	,	PUNCT
dpc-4021	287	4	ci	ci	PROPN
dpc-4021	287	5	x	x	PROPN
dpc-4021	287	6	,	,	PUNCT
dpc-4021	287	7	luo	luo	PROPN
dpc-4021	287	8	m	m	PROPN
dpc-4021	287	9	,	,	PUNCT
dpc-4021	287	10	et	et	PROPN
dpc-4021	287	11	al	al	PROPN
dpc-4021	287	12	.	.	PROPN
dpc-4021	287	13	tofacitinib	tofacitinib	PROPN
dpc-4021	287	14	combined	combine	VERB
dpc-4021	287	15	with	with	ADP
dpc-4021	287	16	leflunomide	leflunomide	NOUN
dpc-4021	287	17	for	for	ADP
dpc-4021	287	18	treatment	treatment	NOUN
dpc-4021	287	19	of	of	ADP
dpc-4021	287	20	psoriatic	psoriatic	ADJ
dpc-4021	287	21	arthritis	arthritis	NOUN
dpc-4021	287	22	with	with	ADP
dpc-4021	287	23	iga	iga	PROPN
dpc-4021	287	24	nephropathy	nephropathy	NOUN
dpc-4021	287	25	:	:	PUNCT
dpc-4021	287	26	a	a	DET
dpc-4021	287	27	case	case	NOUN
dpc-4021	287	28	report	report	NOUN
dpc-4021	287	29	with	with	ADP
dpc-4021	287	30	literature	literature	PROPN
dpc-4021	287	31	review	review	PROPN
dpc-4021	287	32	.	.	PUNCT
dpc-4021	288	1	clin	clin	PROPN
dpc-4021	288	2	rheumatol	rheumatol	PROPN
dpc-4021	288	3	.	.	PUNCT
dpc-4021	289	1	2022	2022	NUM
dpc-4021	289	2	jul;41(7):2225	jul;41(7):2225	PROPN
dpc-4021	289	3	-	-	PUNCT
dpc-4021	289	4	2231	2231	NUM
dpc-4021	289	5	.	.	PUNCT
dpc-4021	290	1	doi	doi	NOUN
dpc-4021	290	2	:	:	PUNCT
dpc-4021	290	3	10.1007	10.1007	NUM
dpc-4021	290	4	/	/	SYM
dpc-4021	290	5	s10067	s10067	NOUN
dpc-4021	290	6	-	-	PUNCT
dpc-4021	290	7	022	022	NUM
dpc-4021	290	8	-	-	PUNCT
dpc-4021	290	9	06113	06113	NUM
dpc-4021	290	10	-	-	PUNCT
dpc-4021	290	11	2	2	NUM
dpc-4021	290	12	.	.	PUNCT
dpc-4021	291	1	epub	epub	NOUN
dpc-4021	291	2	2022	2022	NUM
dpc-4021	291	3	feb	feb	PROPN
dpc-4021	291	4	21	21	NUM
dpc-4021	291	5	.	.	PUNCT
dpc-4021	292	1	pmid	pmid	NOUN
dpc-4021	292	2	:	:	PUNCT
dpc-4021	292	3	35192086	35192086	NUM
dpc-4021	292	4	.	.	PUNCT
dpc-4021	293	1	13	13	NUM
dpc-4021	293	2	.	.	PUNCT
dpc-4021	294	1	haroon	haroon	PROPN
dpc-4021	294	2	m	m	PROPN
dpc-4021	294	3	,	,	PUNCT
dpc-4021	294	4	batool	batool	PROPN
dpc-4021	294	5	s	s	PROPN
dpc-4021	294	6	,	,	PUNCT
dpc-4021	294	7	asif	asif	PROPN
dpc-4021	294	8	s	s	PROPN
dpc-4021	294	9	,	,	PUNCT
dpc-4021	294	10	hashmi	hashmi	PROPN
dpc-4021	294	11	f	f	PROPN
dpc-4021	294	12	,	,	PUNCT
dpc-4021	294	13	ullah	ullah	PROPN
dpc-4021	294	14	s.	s.	PROPN
dpc-4021	294	15	combination	combination	NOUN
dpc-4021	294	16	of	of	ADP
dpc-4021	294	17	methotrexate	methotrexate	NOUN
dpc-4021	294	18	and	and	CCONJ
dpc-4021	294	19	leflunomide	leflunomide	ADJ
dpc-4021	294	20	is	be	AUX
dpc-4021	294	21	safe	safe	ADJ
dpc-4021	294	22	and	and	CCONJ
dpc-4021	294	23	has	have	VERB
dpc-4021	294	24	good	good	ADJ
dpc-4021	294	25	drug	drug	NOUN
dpc-4021	294	26	retention	retention	NOUN
dpc-4021	294	27	among	among	ADP
dpc-4021	294	28	patients	patient	NOUN
dpc-4021	294	29	with	with	ADP
dpc-4021	294	30	psoriatic	psoriatic	ADJ
dpc-4021	294	31	arthritis	arthritis	NOUN
dpc-4021	294	32	.	.	PUNCT
dpc-4021	295	1	j	j	PROPN
dpc-4021	295	2	rheumatol	rheumatol	NOUN
dpc-4021	295	3	.	.	PUNCT
dpc-4021	296	1	2021	2021	NUM
dpc-4021	296	2	oct;48(10):1624	oct;48(10):1624	NOUN
dpc-4021	296	3	-	-	SYM
dpc-4021	296	4	1626	1626	NUM
dpc-4021	296	5	.	.	PUNCT
dpc-4021	297	1	doi	doi	NOUN
dpc-4021	297	2	:	:	PUNCT
dpc-4021	297	3	10.3899	10.3899	NUM
dpc-4021	297	4	/	/	SYM
dpc-4021	297	5	jrheum.201408	jrheum.201408	PROPN
dpc-4021	297	6	.	.	PUNCT
dpc-4021	298	1	epub	epub	NOUN
dpc-4021	298	2	2021	2021	NUM
dpc-4021	298	3	may	may	AUX
dpc-4021	298	4	15	15	NUM
dpc-4021	298	5	.	.	PUNCT
dpc-4021	299	1	pmid	pmid	NOUN
dpc-4021	299	2	:	:	PUNCT
dpc-4021	299	3	33993112	33993112	NUM
dpc-4021	299	4	.	.	PUNCT
dpc-4021	300	1	14	14	NUM
dpc-4021	300	2	.	.	PUNCT
dpc-4021	300	3	mulder	mulder	PROPN
dpc-4021	300	4	mlm	mlm	PROPN
dpc-4021	300	5	,	,	PUNCT
dpc-4021	300	6	vriezekolk	vriezekolk	PROPN
dpc-4021	300	7	je	je	PROPN
dpc-4021	300	8	,	,	PUNCT
dpc-4021	300	9	den	den	PROPN
dpc-4021	300	10	broeder	broeder	NOUN
dpc-4021	300	11	n	n	CCONJ
dpc-4021	300	12	,	,	PUNCT
dpc-4021	300	13	et	et	PROPN
dpc-4021	300	14	al	al	PROPN
dpc-4021	300	15	.	.	PROPN
dpc-4021	300	16	comparing	compare	VERB
dpc-4021	300	17	methotrexate	methotrexate	NOUN
dpc-4021	300	18	monotherapy	monotherapy	NOUN
dpc-4021	300	19	with	with	ADP
dpc-4021	300	20	methotrexate	methotrexate	NOUN
dpc-4021	300	21	plus	plus	CCONJ
dpc-4021	300	22	leflunomide	leflunomide	ADJ
dpc-4021	300	23	combination	combination	NOUN
dpc-4021	300	24	therapy	therapy	NOUN
dpc-4021	300	25	in	in	ADP
dpc-4021	300	26	psoriatic	psoriatic	ADJ
dpc-4021	300	27	arthritis	arthritis	NOUN
dpc-4021	300	28	:	:	PUNCT
dpc-4021	300	29	protocol	protocol	NOUN
dpc-4021	300	30	of	of	ADP